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Figure 3A 
ATGGTTTTTCCCATAGAAGCCiTTGTAGGACTAGTAACCTT---CACATTTCTCTTATAC 
ATGGTTTTTCCCATAGAAGCCATTGTAGGA~AGTAACC~T~~ACATTTCTCTTATAC 
~'"' ~;.,,,,> ''"" '.\n:::s·J~;\,\:\': 
ATGGTTTTTCCCATAGAAGCC~TTGTAGGACTAGTAACCTT---CACATTTCTCTTATAC 
ATG~TTT~TCCCATAGAAGCCATTGTAGGACTAGTAACCTT---CACATTTCTCTT~T~C 
ATGGTTTTTCCCATAGAAGCCATTGTAGGACTAGTAACCTT---CACATTTCTCTT~T~C 
ATGGTTTTTCC~TAGAAGCCATTGTAGGSCTAGT@ACCTT---CACATTTCTCTT~TAC 
"~' ><>l ··v l\~"1 :).,; 
***-***-***--********-*******---***-***-*----***********-*-* 
TTCCTATGGACAAAAAAATCTCAAAAAC~TGCAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGiflACAAAAAAATCTCAAAAACii.TT'cAAAGCCCTTACC~CGAAAATCCCCGGA 
•. ~~ ftd ····! ~iii-1 ;: •• 
TTCCTATGGACAAAAAAATCTCAAAAAC~T~CAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGA 
TTCCTATGGACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCC~GGA 
********-*******************-*-****-*********-**********-*** 
GGATGGCCGGTAATCGGCCATCTTTT~CACTTCAATAACGACGGCGACGACCGTCCATT~ 
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAATAACGACGGCGACGACCGTCCATT~ 
GGATGGCCGGTAATCGGCCATCTTTTT:CACTTCAATAACGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAAT~CGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTCCACTTCAAT~ACGACGGCGACGACCGTCCATTA 
GGATGGCCGGTAATCGGCCATCTTTTC~~CTTC~AT~ACGACGGCGACGACCGTCCATTA 
**************************--*****-**-**********************-
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT 
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT 
GCTCGAAAACTCGGAGACTTAGCTGATAAATACGGCCCCGTTTTCACTTTTCGGCTAGGT 
GCTCGAAAACTCGGAGACTTAGCTGA~TACGGCCCCGTTTTCACTTTTCGGCTAG~ 
GCTCGAAAACTCGGAGACTTAGCTGA,~TACGGCCCCGTTTTCACTTTTCGGCTAGG~ 
GCTCGAAAACTCGGAGACTTAGCTGA~AAATACGG~CCCGTTTTCACTTTTCGGCTAGG~ 
**************************-********-***********************-
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Figure 3B 
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCTTGTGCTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGCTTCTCTACAAAT 
CTTCCCCTTGT~~TAGTTGTAAGCAGTTACGAAGCT~TAAAAGA~TG~TTCTCTACAAAT 
CTTCCCCTTGTdWTAGTTGTAAGCAGTTACGAAGCT~TAAAAGA~TG~TTCTCTACAAAT 
CTTCCCCTTGTGfTAGTTGTAAGCAGTTACGAAGCTATAAAAGATTGITTCTCTACAAAT 
***********--***********************-*******-**-************ 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTACAATAAT 
GAi!!GCCATTTTCTCCAATCGTCCAGCTTTTCTTTAii'!GGCGAATACCTTGGCTACAGTAAT 
GACGCCATTTTWTCCAATCGTCCAGCTTTTCTTTACGGCGA\VTACCTTGGCTACAATAAT - ~ GACGCCATTTTITCCAATCGTCCAGCTTTTCTTTACGGCGAWTACCTTGGCTACAATAAT 
GACGCCATTTTCTCCAATCGTCCAGCTTTTCTTTACGGCGAATACCTTGGCTAC~T 
**-********-***********************-*****-*************--*** 
~c®ATGCT~TT~TJGCAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGTCATT 
~C~TGCT~TT~T~GCAAATTACGGACCTTACTGGCGAAAAAATCGTAAATTAGTCATT 
GCCATGCTATTT-TGicAAAiTACGGACCTTACTGGCGAAAAAAT~G~TTAGTCATT 
GCCATGCTATTTTTGGC~AATTACGGACCTTACTGGCGAAAAAATCG~TTAGT~ATT 
GCCATGCTATTTTTGGC~AATTACGGA~CTTACTGGCGAAAAAATCGAAAATTA~T~ATT 
GCCATGCTATTTTTGGCAAATTACGGAlCTTACTGGCGAAAAAATCGTAAATT~T~ATT 
-*-*****-***-*--*-**-******-*****************-*-******-*-*** 
CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACAAGTGAGATTC~CCAGAATT 
CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACAAGTGAGATTC~CCAGAATT 
CAGGAAGTTCTCT~TGCTAGTCGTCTCGAAAAATT~AA~CACGTGAGATT~GGT:G;2\:AATT 
CAGGAAGTTCTCTC~GCTAGTCGTCTCGAAAAATTCAAACACGTGAGATT~G<::j.AGAATT 
CAGGAAGTTCTCTC~GCTAGTCGTCTCGAAAAATTCAAACACGTGAGATT~GC~GAATT 
CAGGAAGTTCTCTCTGCTAGTCGTCTCGAAAAATTCAAACACGTGAGATTCGCCAGAATT 
*************--********************-**-**-********------**** 
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Figure 3C 
CAAACGAGCATTAAGAATTTATACACTCGAATT~TGGAAATTCGAGTACGATAAATCTA 
CAAACGAGCATTAAGAATTTATACACTCGAATTAATGGAAATTCGAGTACGATAAATCTA 
CA~ACGAGCATTAAGAATTTATACACTCGAATTGATGGAAATTCGAGTACGATAAATCTA 
CAA~CGAGCATTAAGAATTTAT~~ACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA 
CAA§CGAGCATTAAGAATTTAT~~ACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA 
CAAACGAGCATTAAGAATTTATACACTCGAATTGATGGAAATTCGAGTACGATAAAT~TA 
**--*******************-*********-***********************-** 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAATGATCGCTGGGAAAAAT 
~~TGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAAATGATCGCTGGGAAAAAT 
AC~ 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGG~T 
~ 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAGATGATCGCTGG~T 
ACTGATTGGTTAGAAGAATTGAATTTTGGTCTGATCGTGAAiATGATCGCTGGGAAAAAT 
*--**************************************-***********-****** 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAiAGATTTAAGAAWGCGTTTAAGGATTTT 
TATGAATCCGGTAAAGGAGATGAACAAGTGG~GATTTAAGAA~GCGTTTAAGGATTTT - -TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT 
TATGAATCCGGTAAAGGAGATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTT 
********************************-***********-*************** 
ATGGTTTTATCAATGGAATTTGTATTATGGGATGCATTTCCAATTCCATTATTTAAATGG 
~~IT ~ 
ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG 
ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG 
ATGATTTTATCAATGGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGG 
***-*************-*****-************************************ 
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Figure 3D 
GTGGATTTTCAAGG~CATiTTAAGGCIATGAAAAGGAC~TTTAA~GATATAGATTCTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT 
GTGGATTTTCAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTT 
**************-***-*******-***********-*****-*************** 
TTTCAGAA~TGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT- - - GGAGGTT~,~TGCA 
TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT---GGAGGTT~TGCA 
>:;T~!i 
TTTCAGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAAT---GGAGGTT~TGCA 
TTTCAGAATTGGTTAGAGGAACATATTAA~~GAGAAAAAAT~~GGAGGTTGGT~CA 
********-********************-**************---*******--*-** 
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAITGAGTAAlGAATATCTT 
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT 
GAAGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT 
GAAGGGAATGAACAAGATTTIDATAGATGTGGTGCTTTCAAAAATGAGTAATGAATATCTT 
~ -
********************-**-******************-*******-********* 
GiTGAAGGTTACTCTCGTGATACTGTCATTAAAGCAACAGT~TTTAGTTTGGTCTTGGAT 
GGTGAAGGTTACTCTCGTGATACTGTCATTAAAGCAACSGTGTTTAGTTTGGTCTTGGAT 
GGTGAAGGTTACTCTCGTGATACTGTCATT~GCAAC~GTGTTTAGTTTGGTCTTGGAT 
GGOOAAGGTTACTCTC~GATACTGTCATMA.iGCAACAGTIJTTTAGTTTGGTCTTGGAT 
;~ .:c :..iF ,\,,1 <,')~ 
*--**************-***********-**-*****-**-****************** 
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATG~CATTATTGATAAACAATCAA 
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAA 
GCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATTGATAAACAATCAA 
GCAGCAGACACAGTTGCTCTTCACATAAATTG~GGAATGGCATTATTGATAAACAATCAA 
********************************-******-******************** 
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Figure 3E 
AATGCCTTGAmGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGATAGATGGGTA 
~~·· ' '<" : " " 
~GCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGACAGATGGGTA 
AA~GCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGA~AGATGGGTA 
AATGCCTTG~GAAAGCACAAGAAGAGATAGACACAAAAGTTGGTAAGGATAGATGGGTA 
~ 
**-*******-***************************************-********* 
GAAGAGAGTGATATTAAGGATTT~GTATACCTCCAAGCTATTGTTAAAfiA~GTGTTACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA 
GAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAGCTATTGTTAAAGAAGTGTTACGA 
***********************-************************-*-********* 
TTATATCCACCAGGACCTTTGTTAGTACCACAWGAAAATGT~~GATTGTGTTGTTAGT 
TTATATCCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT 
TTATATCCACCAGGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT 
TTATATCCACC~GGACCTTTGTTAGTACCACACGAAAATGTAGAAGATTGTGTTGTTAGT 
~ 
***********-********************-*********-*-*************** 
GGATATCACATTCCTAAAGAGACTAGATTATTCGCAAACGTCATGAAACTGCAijC~GAT 
GGATATCACATTCCTAAAGGGAC~GATTATTCGCAAACGTCATGAAACTGCAACGTGAT 
GGATATCACATTCCTAAAGGGAC~GATTATTCGCAAACGTCATGAAACTGCAACGTGAT 
GGATATCACATTCCTAAAGGAACTAGA~TATTCGCAAAIDGTiA.TGAAACTiCAACGTGAT 
n-'~ •; '' ·~\i~ mi1 ;i'~; 
*******************--**-***-**********-**-********-**-**-*** 
CCTAAACTCTreGTCAAATCCTGATAAGTTCGATCCAGAGAGATTCATCGCT~GTGATATT 
ccTAAACTCTGGTc~;~ATCCTGAT~~~TTCGATCCAGAGAGATTCAT~GCT~TGATATT 
CCTAAACTCTGGTCm~ATCCTGATA~~TTC~ATCCAGAGAGATTCATW:GCTA~TGATATT 
CCTAAACTCTGGTCAAATCCTGATAAGTTC~TCCAGAGAGATTCATCGCT~GTGATATT 
**********-***--*********--***-****************-***--******* 
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Figure 3F 
GACTT~CGTGGTCA~~CTAT~AGTmTATCCC~TTTGGTTCTGGAAGACGATCTTGTCC~ 
GACTTTCGTGGTCAGTACTAT~GTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCC~ 
GACTTTCGTGGTCAGTACTAT~GTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCC~ 
GACTTTCiTGGTCAGqACTATGAGTATATCCCGTTTGGTTCTGGAAGACG~TCTTGTCCG 
*****-*-******--*****-***-******-*****************-********-
GGGATGACTTATGCATTGCAAGTGGAACACCTAACAATGGCACATTT~TCCAGGGTTTC 
~ 
GGGATGACTTATGCATTGCAAGTGGAACAC~TAACAATGGCACATTTGATCCA!GGTTTC 
GGGATGACTTATGCATTGCAAGTGGAACAC~TAACAATGGCACATTTGATCCAAGGTTTC 
~ a 
GGGATGACTTATGCATTGCAAGTGGAACACCTAACAATGGCACATTTGATCCAGGGTTTC 
******************************-****************-*****-****** 
AATTACAiAACTCCAAATGACGAG~CCTTGGATATGAAGGAAGGTGCAGGCATAAC~TA 
AATTACAGAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATA 
AATTACAGAACTCCAAATGACGAGCCCTTGGAEATGAAGGAAGGTGCAGGCATAACTATA 
AATTACAGAACTCCAAgTG~~GAGCCCTTGGATATG~GAAGGTGCAGGCATAACTATA 
*******-********-***-***-*******-*****-*****************-*** 
CGTAAGGTAAATCC~GTGGAA~TGATAATAACGCCTCGCTTGGCACCTGAGCTTTAjTAA 
CGTAAGGTAAATCCTGTGGAACTGATAATA~CGCCTCGC~TGGCACCTGAGCTTTATTAA 
CGTAAGGTAAATCCTGTGGAACTGATAATAGCGCCTCGCGTGGCACCTGAGCTTTATTAA 
CGTAAGGTAAATCCTGTG~GTGATAATroACGCCTCGCTTGGCACCTGAGCTTTATTAA 
~ ~ -**************-***-**-*******--********-****************-*** 
AACCTAAGATCTTTCATCTTGGTTGATCATTGTTTAATACTCCTAGATGGGTATTCATTT 
AACCTAAGATCTTTCATCTTGGTTGATCATTGT~TAATACTCCTA!ATGGATATTCATTT 
AACCTAAGATCTTTCATCTTGGTTGATCATTGT~TAATACTCCTAiATGJ~TATTCATTT 
J~:~l ~h' ~:--.t• i:ii' ··.".< .·c:~ 
AA~CTAAGAT~TTTCATCTTGGTTGATCATTGTTTAATACTCCTAGATGGGTATTCAT~T 
**-*******-**********************-***********-****-*******-* 
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Figure 3G 
ACCTTTTTTCAATTAATT~~~GTACGAG~TTTTTTAATTTGGTA~ATTTGTAA~AATAA 
ACCTTTTiTCAATTAATTGTCAGTACGAGTTTTT~TAATTTGGTACATTTGTAATAATAA 
~ = 
ACCTTTTITCAATTAATTGTCAGTACGAGTTTTT€TAATTTGGTACATTTGTAATAATAA 
ACCTTTTTTCAATTA~TTGTC~GTACGI~TTTTTTTAATTTGGTAI~TTTGTAATAATAA 
*******-*******-***---*****---****-**********--*******-***** 
GTAAAGAATGATTGTGCTAATATATAAAG~TTTGCAGAAGATAATTGACTGATTGTCCC 
GTAAAGAAT~TTGTGCTAATATATAAAGGTTTG~AGAAGATAATTGACTGATTGTCCC 
GTAAAGAATiATTGTGCTAATATATAAAGGTTTGiAGAAGAT~ATTGACTGATTGTCCC 
'W'm:, ,>UY ''-""~ e:n ;;:'; :<~"\<> J~':;!;~~~lr~:O:tr·. 
GTAAAGAA~GATTGTGCTAATATATAAIGGT--GCAI~TAATTG~W~ 
********--*****************-*-*--*-*-**-**-*****----******* 
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Figure 4 
MVFPIE~GLVTFTFL~-g:FLWTKKSQK~~;KPLPPKIPGGWPVIGHLFHF~GDDRPLA 60 
MVFPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60 
MLSPIEAIVGLVTFTFLFFFLWTKKSQKPSKPLPPKIPGGWPVIGHLFHFNDDGDDRPLA 60 
MVFP!EAIVGLVTFTFLF~FLWTKKSQKPSKPLPPKIPGGWPVIGHLF~F~DDGDDRPLA 60 
*: *:**!*********::********* ******************:*::******** 
3D C12 RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAlKDCFSTNDAIFSNRPAFLYG11;YLGYNNW 120 
3D C12-7 RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120 
3D C12-10 RKLGDLADKYGPVFTFRLGLPLVLVVSSYEAVKDCFSTNDAIFSNRPAFLYGDYLGYNNA 120 
7D A06 RKLGDLADKYGPVFTFRLGLPLVLVVSSYE~KDCFSTNDAIFSNRPAFLYG§YLGY~NA 120 
3D C12 
3D C12-7 
3D C12-10 
7D A06 
*******************************~********************;****;*: 
MLFLANYGPYWRKNRKLVIQEVLSASRLEKFK~VRFWRIQ~SIKNLYTRI~GNSSTINLT 
MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 
MLFLANYGPYWRKNRKLVIQEVLSASRLEKFKHVRFARIQASIKNLYTRIDGNSSTINLT 
MLFLANYG?YWRKNRKL~IQEVLSASRLEKFKHVRFARIQmsrKNLYTRIDGNSSTINLT 
********·********:**************;***:***:*********:********* 
180 
180 
180 
180 
3D C12 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFK~AFKDFMYLSMEFVLWDAFPIPLFKWV 240 
3D C12-7 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240 
3D C12-10 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240 
7D A06 DWLEELNFGLIVKMIAGKNYESGKGDEQVERFKKAFKDFMILSMEFVLWDAFPIPLFKWV 240 
3D C12 
3D C12-7 
3D C12-10 
7D A06 
3D C12 
3D C12-7 
3D C12-10 
7D A06 
*********************************:******;******************* 
DFQGH~KAMKRTFKDIDSVFQNWLEEHINKREK-MEV~AEGNEQDFIDVVLSK~S~EYLg 299 
DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREK-MEVNAEGNEQDFIDVVLSKMSNEYLG 299 
DFQGHVKAMKRTFKDIDSVFQNWLEEHINKREK-MEVNAEGNEQDFIDVVLSKMSNEYLG 299 
DFQGHVKAMKRTFKDIDSVFQNWLEEHI~REK:i;,MEV~-;eEGNEQDFIDVVLSKMSNEYLG 3 0 0 
*****;**********************:**** ***.:**************:*;***· 
EGYSRDTVIKATVFSLVLDAADTVALHINWGMWLLINNQ~A~KAQEEIDTKVGKDRWVE 
EGYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVE 
EGYSRDTVIKATVFSLVLDAADTVALHINWGMALLINNQKALTKAQEEIDTKVGKDRWVE 
EGYSRDTVIKATVFSLVLDAADTVALHIN~GMALLINNQ~AL~KAQEEIDTKVGKDRWVE 
***************************** **;******!******************** 
359 
359 
359 
360 
3D C12 ESDIKDLVYLQAIVK~LRLYPPGPLLVPH~DCVVSGYHIPK!TRLFANVMKLQRDP 419 
3D C12-7 ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 419 
3D C12-10 ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 419 
7D A06 ESDIKDLVYLQAIVKEVLRLYPPGPLLVPHENVEDCVVSGYHIPKGTRLFANVMKLQRDP 420 
***************;*****************;*********** ************** 
3D C12 KL~S~PD~FDPERFIA~DIDFRGn~y~~IPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 479 
3D C12-7 KLWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 479 
3D C12-10 KLWSDPDTFDPERFIATDIDFRGQYYKYIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 479 
7D A06 KLWS~PD~F~PERFIA~IDF~GQijY1YIPFGSGRRSCPGMTYALQVEHLTMAHLIQGFN 480 
3D C12 
3D C12-7 
3D C12-10 
7D A06 
** *:**.*:****** ****:*::*::******************************** 
Y~TPNDE~LDMKEGAGITIRKVNPVELII~PRLAPELY 517 
YRTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517 
YRTPNDEPLDMKEGAGITIRKVNPVELIIAPRLAPELY 517 
YRTP~DEPLDMKEGAGITIRKVNPV~II~PRLAPELY 518 
*:**·**·*****************: :**:******** 
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Figure 7 
CTGTCATTAAAGCAACGGTGTTTGTAAGTTCATCTGTCATTTTTCATTTATTCACTTTT 
ATTTTGAGGAGCAGACATGTTAATAATAATTTGGAGCAACTGTAAAGTTATCTATGTGT 
AC1 GGTTCGAGCCTCAGGTGCAACCACTMTGCTTGTATTA GATTATGTTGTCTGCAT 
CATACCCCTAA TTGGA GTGTGGCTCTTCCCGAACCCTGCAA TGCTGGATGCTGGATGC 
TTTATGTATCAGACTGACCTTTTTGTTAAACTATCTAAATACTAAGGATGATTTAATAA 
AAA TATA GAATGGTAAACAGAAAAAGATGA GATTATTTTTGGGGCTATATGGATTCGC 
CCGGGCTTTGGGAGGTAAAACGGTATCTACCAGTTGAGACTTTACTCCAGMCTTTAT 
CTCGAGAGCTCTGAATAAAAATGAAATAGTATTTACCACTCCAAAATCTTTGATGGTAA 
AAAGATGAGATATAACCTCTTATAATTGATTGAACCACGTTGATAGAATAAAACTTCTT 
TACTCCCATTCAGC1TAAGAAAAATGAAACCAAACGGAATTCTTCTCTTTTTTAGGGGG 
AAATTCCTTAATTGCTTGTTGAATATAGATTCATGTCGTTATTCTATTTTTAATAATGAT 
GAAAATCAATATAGTCAAAGTTAATACTTATGTCATTTGGTTTGCGGACAAGTTATATT 
GGAA C1:A1:41:4ATACGTC1:4 T1:41:4 GAA1:4 GTGATTATTTA GA GGATATA CA TTTTTTT 
TGGATAAATATTTGATTTATTGGATTAAAAATAGAATATACAGGTAAGGTCTAAAACGT 
GTGTTTGCTTTTACACTAAATAAACTTGACCTCGTACAATTCTAAGAAAATATTTGAAA 
TAAA TGAA TTATTTTATTGTTAATCAA T1:4AAAAAA TCATA GTATAGATGAGATGTGTG 
CATACTTGGCAATAACTATACTAACTAAAACAAGGTATGTGAATAATTGATATTCCTTT 
TTTAA TTATTCTTTTTTCCA GAGTTTGGTCTTGGATGCAGCAGACACAG'lTGCTCTTCA 
CATAAATTGGGGAATGGCATTATTGATAAACAATCAAAAGGCCTTGACGAAAGCAC 
AAG 
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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation of U.S. application Ser. 
2 
tion of curing conditions while maintammg acceptable 
quality standards have not proven to be successful for the 
air-cured tobaccos. 
In Burley tobaccos, a positive correlation has been found 
5 between the nornicotine content of the leaf and the amount of 
NNN that accumulates in the cured product (Bush et a!. 
(2001) Rec. Adv. Tab. Sci. 27:23-46; Shi eta!. (2000) Tab. 
Chern. Res. Conf 54:Abstract 27). However, keeping norni-
cotine levels at a minimum has been difficult because of the No. 11/580,765, filed Oct. 13, 2006, which is a continuation-
in-part of International Application No. PCTIUS2005/ 10 
005665, filed Feb. 23, 2005, the contents of which are herein 
conversion phenomenon that results in a continual introduc-
tion of high nornicotine-producing plants within commer-
cially grown Burley populations. Minimizing the number of 
Burley plants that accumulate high levels of nornicotine has 
traditionally been the responsibility of plant breeders and 
incorporated by reference in their entirety. 
FIELD OF THE INVENTION 
15 seed producers. Though the percentage of converter plants 
that are ultimately grown in farmers' fields can be reduced 
through the roguing of converter plants during the propaga-
tion of seed stocks, this process is costly, time-consuming, 
The invention relates to compositions and methods for 
reducing the level of nornicotine and its metabolite, N'-ni-
trosonornicotine, in a plant that is a member of the genus 
Nicotiana, particularly compositions and methods for inhib- 20 
iting expression or function of a cytochrome P450 polypep-
tide involved in the metabolic conversion of nicotine to nor-
and imperfect. 
Previous studies have shown that once a plant has con-
verted, the high nornicotine trait is inherited as a single domi-
nant gene (Griffith eta!. (1955) Science 121:343-344; Burk 
and Jeffrey (1958) Tab. Sci. 2:139-141; Mann eta!. (1964) 
Crop Sci. 4:349-353). The nature of this gene, however, is 
nicotine. 
BACKGROUND OF THE INVENTION 
The predominant alkaloid found in commercial tobacco 
varieties is nicotine, typically accounting for 90-95% of the 
total alkaloid pool. The remaining alkaloid fraction is com-
prised primarily of three additional pyridine alkaloids: nor-
nicotine, anabasine, and anatabine. Nornicotine is generated 
directly from nicotine through the activity of the enzyme 
nicotine N-demethylase (FIG. 1). Nornicotine usually repre-
sents less than 5% of the total pyridine alkaloid pool, but 
through a process termed "conversion," tobacco plants that 
initially produce very low amounts of nornicotine give rise to 
progeny that metabolically "convert" a large percentage of 
leaf nicotine to nornicotine. In tobacco plants that have 
genetically converted (termed "converters"), the great major-
ity of nornicotine production occurs during the senescence 
and curing of the mature leaf (Wernsman and Matzinger 
(1968) Tab. Sci. 12:226-228). Burley tobaccos are particu-
larly prone to genetic conversion, with rates as high as 20% 
per generation observed in some cultivars. 
During the curing and processing of the tobacco leaf, a 
portion of the nornicotine is metabolized to the compound 
N'-nitrosonornicotine (NNN; FIG. 1), a tobacco-specific nit-
rosamine (TSNA) that has been shown to be carcinogenic in 
laboratory animals (Hecht and Hoffmann (1990) Cancer Sur-
veys 8:273-294; Hoffmann eta!. (1994) J. Toxicol. Environ. 
Health 41:1-52; Hecht (1998) Chern. Res. Toxicol. 11:559-
603). In flue-cured tobaccos, TSNAs were found to be pre-
dominantly formed through the reaction of alkaloids with the 
minute amounts of nitrogen oxides present in combustion 
gases formed by the direct-fired heating systems found in 
traditional curing barns (Peele and Gentry (1999) "Formation 
of Tobacco-specific Nitrosamines in Flue-cured Tobacco," 
CORESTA Meeting, Agro-Phyto Groups, Suzhou, China). 
Retrofitting these curing barns with heat-exchangers virtually 
eliminated the mixing of combustion gases with the curing air 
and dramatically reduced the formation ofTSNAs in tobac-
cos cured in this marmer (Boyette and Hamm (2001) Rec. Adv. 
25 currently unknown. In the most simple of scenarios, the con-
version locus may represent a nonfunctional nicotine N -dem-
ethylase gene that regains its function in converter plants, 
possibly through the mobilization of a mutation-inducing 
transposable element. Alternatively, the converter locus may 
30 encode a protein that initiates a cascade of events that ulti-
mately enables the plant to metabolize nicotine to nornico-
tine, which would mean that multiple genes may be involved. 
Regardless of whether there are one or many genes asso-
ciated with the conversion process, it is clear that the gene(s) 
35 encoding polypeptides having nicotine demethylase activity 
play a pivotal role in this process. Although the inability to 
purify active nicotine N-demethylase from crude extracts has 
impeded the isolation and identification of this enzyme, there 
is some evidence that a member of the cytochrome P450 
40 superfamily of monooxygenases may be involved (Hao and 
Yeoman (1996) Phytochern. 41:477-482; Hao and Yeoman 
(1996) Phytochern. 42:325-329; Chelvarajan eta!. (1993) J. 
Agric. Food Chern. 41:858-862; Hao and Yeoman (1998) J. 
Plant Physiol. 152:420-426). However, these studies are not 
45 conclusive, as the classic P450 inhibitors carbon monoxide 
and tetcylasis have failed to lower enzyme activity at rates 
comparable to other reported P450-mediated reactions (Chel-
varajan eta!. (1993) J. Agric. Food Chern. 41:858-862). 
Furthermore, the cytochrome P450s are ubiquitous, trans-
50 membrane proteins that participate in the metabolism of a 
wide range of compounds (reviewed by Schuler (1996) Crit. 
Rev. Plant Sci. 15:235-284; Schuler and Werck-Reichhart 
(2003) Annu. Rev. Plant Biol. 54:629-667). Examples ofbio-
chemical reactions mediated by cytochrome P450s include 
55 hydroxy lations, demethylations, and epoxidations. In plants, 
the cytochrome P450 gene families are very large. For 
example, total genome sequence examination has revealed 
272 predicted cytochrome P450 genes in Arabidopsis and at 
least 455 unique cytochrome P450 genes in rice (see, for 
60 example, Nelson et a!. (2004) Plant Physiol. 135(2):756-
772). Even though cytochrome P450 has been implicated as 
having a role in the metabolic conversion of nicotine to nor-
nicotine, identification of key participating members of this To b. Sci. 27:17-22.). In contrast, in theair-curedBurleytobac-
cos, TSNA formation proceeds primarily through reaction of 
tobacco alkaloids with nitrite, a process catalyzed by leaf- 65 
borne microbes (Bush eta!. (2001) Rec. Adv. To b. Sci. 27:23-
46). Thus far, attempts to reduce TNSAs through modifica-
protein family remains a challenge. 
Aside from serving as a precursor for NNN, recent studies 
suggest that the nornicotine found in tobacco products may 
have additional undesirable health consequences. Dickerson 
US 9,187,759 B2 
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and Janda demonstrated that nornicotine causes aberrant pro-
tein glycation within the cell (Dickerson and Janda (2002) 
Proc. Nat!. Acad. Sci. USA 99: 15084-15088). Concentrations 
of nornicotine-modified proteins were found to be much 
higher in the plasma of smokers compared to nonsmokers. 
Furthermore, this same study showed that nornicotine can 
covalently modify commonly prescribed steroid drugs such 
as prednisone. Such modifications have the potential of alter-
ing both the efficacy and toxicity of these drugs. 
In view of the difficulties associated with conversion and 
the undesirable health effects of nornicotine accumulation, 
improved methods for reducing the nornicotine content in 
tobacco varieties, particularly Burley tobacco, are therefore 
desirable. Such methods would not only help ameliorate the 
potential negative health consequences of the nornicotine per 
se as described above, but should also concomitantly reduce 
NNNlevels. 
The methods of the invention find use in the production of 
Nicotiana plants that have decreased levels of nornicotine and 
its metabolite, the nitrosamine N'-nitrosonornicotine, within 
the leaf and stem tissues. When harvested, the leaf and stem 
tissues of these plants can be utilized to produce tobacco 
products having reduced levels of nornicotine and this 
tobacco-specific nitrosamine, and thus reduced carcinogenic 
potential for individuals consuming these products or 
exposed to secondary smoke derived from these products. 
10 Also provided are transgenic Nicotiana plants having a 
nicotine to nornicotine conversion rate ofless than about 2%, 
where the plants comprise a heterologous nucleic acid con-
struct comprising a promoter capable of functioning in a plant 
15 
cell operably linked to a nucleic acid sequence having a first 
nucleotide sequence comprising a fragment ofbetween about 
100 nucleotides and about 400 nucleotides of a Nicotiana 
nicotine demethylase polynucleotide and a second nucleotide 
sequence capable of forming a double-stranded RNA with the 
SUMMARY OF THE INVENTION 
Compositions and methods for reducing the nornicotine 
content in plants that are members of the genus Nicotiana are 
provided. Compositions include isolated cytochrome P450 
polynucleotides and polypeptides that are involved in the 
metabolic conversion of nicotine to nornicotine in plants, 
particularly Nicotiana species. The isolated polynucleotides 
comprise the nucleotide sequence set forth in SEQ ID NO: 1, 
20 first nucleotide sequence, where the transgenic Nicotiana 
plants are transgenic converter lines of Nicotiana. In some 
embodiments, the Nicotiana nicotine demethylase poly-
nucleotide is a tobacco nicotine demethylase polynucleotide. 
The present invention also provides a recombinant nucleic 
25 acid construct comprising a promoter capable of functioning 
in a plant cell operably linked to a nucleic acid sequence 
having a first nucleotide sequence comprising a fragment of 
between about 100 nucleotides and about 400 nucleotides of 
3, 5, 7, 9, or 11, a nucleotide sequence encoding a polypeptide 
as set forth in SEQ ID N0:2, 4, 6, 8, 10, or 12, and fragments 30 
and variants thereof. Isolated polypeptides of the invention 
comprise an amino acid sequence set forth in SEQ ID N0:2, 
a tobacco nicotine demethylase polynucleotide and a second 
nucleotide sequence capable of forming a double-stranded 
RNA with the first nucleotide sequence. 
Also provided are methods of reducing the conversion of 
nicotine to nornicotine in a Nicotiana plant comprising trans-
4, 6, 8, 10, or 12, an amino acid sequence encoded by the 
nucleotide sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, or 
11, and fragments and variants thereof. 35 forming a Nicotiana plant with a recombinant nucleic acid 
construct comprising a promoter capable of functioning in a 
plant cell operably linked to a nucleic acid sequence having a 
first nucleotide sequence comprising a fragment of between 
about 100 nucleotides and about 400 nucleotides of a Nicoti-
The polynucleotides of the invention find use in suppress-
ing expression of a cytochrome P450 that is involved in the 
metabolic conversion of nicotine to nornicotine in a plant, 
including the cytochrome P450s of the present invention. In 
this manner, compositions further include expression cas- 40 
settes comprising an inhibitory sequence that is capable of 
inhibiting expression or function of a cytochrome P450 
polypeptide of the invention, where the inhibitory sequence is 
operably linked to a promoter that is functional in a plant cell. 
In some embodiments, the inhibitory sequence comprises the 45 
sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 14, 15, 
or 16, or a complement or fragment thereof. Compositions 
also include transformed plants and plant parts that comprise 
an expression cassette of the present invention, optionally 
stably incorporated into the genome of the plant. Further 50 
provided are tobacco products, including chewing tobacco, 
snuff, cigarettes, pipe tobacco, and cigars, having a reduced 
level of nornicotine, and its related nitrosamine, N'-nitroso-
nornicotine. 
ana nicotine demethylase polynucleotide and a second nucle-
otide sequence capable of forming a double-stranded RNA 
with the first nucleotide sequence; and regenerating a trans-
genic Nicotiana plant. In some embodiments, the Nicotiana 
nicotine demethylase polynucleotide is a tobacco nicotine 
demethylase polynucleotide. 
The present invention also provides seed obtained from the 
transgenic Nicotiana plant having a nicotine to nornicotine 
conversion rate of less than about 2%, where the seed com-
prises a heterologous nucleic acid construct comprising a 
promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence having a first nucleotide 
sequence comprising a fragment ofbetween about 100 nucle-
otides and about 400 nucleotides of a Nicotiana nicotine 
demethylase polynucleotide and a second nucleotide 
55 sequence capable of forming a double-stranded RNA with the 
first nucleotide sequence, where the transgenic Nicotiana 
plants are transgenic converter lines of Nicotiana. In some 
embodiments, the Nicotiana nicotine demethylase poly-
The methods of the invention comprise inhibiting the 
expression or function of a cytochrome P450 polypeptide of 
the present invention. In some embodiments, an expression 
cassette comprising an inhibitory sequence that targets 
expression or function of a cytochrome P450 polypeptide of 
the present invention is introduced into the plant or plant part 60 
of interest, wherein expression of the inhibitory sequence 
produces a polynucleotide or polypeptide that inhibits 
expression or function of a cytochrome P450 polypeptide of 
the invention. In one such embodiment, the inhibitory 
sequence comprises a sequence set forth in SEQ ID NO: 1, 3, 65 
5, 7, 9, 11, 13, 14, 15, or 16, or a complement or fragment 
thereof. 
nucleotide is a tobacco nicotine demethylase polynucleotide. 
The present invention also provides transgenic plant cells 
comprising a nucleic acid molecule having a promoter func-
tional in a plant cell and a nucleic acid sequence encoding a 
nicotine demethylase having an isoleucine residue at position 
274 and a tryptophan residue at position 329. 
The present invention also provides methods of screening 
for a nicotine demethylase sequence comprising: obtaining a 
nucleic acid sequence that has greater than about 90% 
US 9,187,759 B2 
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sequence identity with SEQ ID N0:5 and identifYing a codon 
sequence encoding for a tryptophan residue at position 329 of 
the encoded polypeptide. 
Further provided are methods for screening for a nicotine 
demethylase having an isoleucine at position 274 or a tryp- 5 
tophan at position 329 comprising obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 
with SEQ ID N0:5 and identifYing a first codon sequence 
encoding for an isoleucine residue at position 27 4 or a second 
codon sequence encoding a tryptophan residue at position 10 
329 of the encoded polypeptide. 
6 
FIG. 7 shows a genomic sequence of a fragment of the 
3D_C12-10 gene possessing an intron. Intron sequences are 
indicated in bold, italicized type. Exon sequences are shown 
in plain type. The sequences corresponding to the PCR prim-
ers used to amplifY the fragment from the tobacco genomic 
DNA are underlined. 
FIG. 8 shows a diagram of the RNAi constructs used to 
silence expression of members of the 3D_CD12 gene family. 
DETAILED DESCRIPTION OF THE INVENTION 
Background and Definitions 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the structures of nicotine, nornicotine, and 
N'-nitrosonornicotine (NNN). 
Before describing the present invention in detail, it is to be 
understood that many modifications and other embodiments 
15 of the inventions set forth herein will come to mind to one 
FIG. 2 shows Northern blot analysis of converter and non-
converter RNAs using 7D_A06 as a hybridization probe. 
Lanes 1 and 2 show RNAs isolated from sodium bicarbonate- 20 
treated leaves of genotypes DH 98-325-5 (nonconverter) and 
DH 98-325-6 (converter), respectively. Lanes 3 and 4 show 
RNAs isolated from ethephon-treated leaves of genotypes 
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), 
respectively. Estimated size of the hybridizing band is indi- 25 
cated in kilo bases (kb). 
FIGS. 3A-3G shows a nucleotide sequence aligument of 
members of the 3D_C12 gene family. Asterisks denote posi-
tions where sequence identity is conserved among all 
sequences compared. Positions where differences are found 30 
are indicated with dashes and the corresponding residues are 
shaded grey. The nucleotide sequences present in the align-
ment include 3D_C12 (SEQ ID N0:1), 3D_C12-10 (SEQ ID 
N0:3); 3D_C12-7 (SEQIDN0:5); 7D_A06 (SEQIDN0:7); 
3D_C12-15 (SEQ ID N0:9); and 131A_A02 (SEQ ID 35 
NO:ll). The 3D_C12-15 and 131A_A02 entries are partial-
length eDNA sequences. The 99 bp region of 3D_C12 that 
was used to make the RNAi-based construct is underlined. 
FIG. 4 shows an alignment of predicted amino acid 
sequences for full-length members of the 3D_C12 family of 40 
P450 genes. The amino acid sequences present in the align-
ment include 3D_C12 (SEQ ID N0:2), 3D_C12-10 (SEQ ID 
N0:4); 3D_C12-7 (SEQ ID N0:6); and 7D_A06 (SEQ ID 
NO: 8). Asterisks denote positions conserved among all four 
sequences. Residues that differ among the members are 45 
shaded in grey. 
FIG. 5 shows a Northern blot analysis of transgenic plants 
possessing the 3D_C12/RNAi construct. (A) Hybridization 
of the 3D_C12-7 probe to RNAs isolated from ethephon-
treated, cured leaves of transgenic plants displaying low nor- 50 
nicotine phenotypes (3D_C12/RNAi-1, 3, and 4) and high 
nornicotine phenotypes (3D_C12/RNAi-6, 7, and vector-
only control plant 11). Estimated size of hybridizing band is 
indicated in kilo bases (kb ). (B) Ethidium bromide staining of 
the portion of the gel used in (A) that contains the 28S ribo- 55 
somal RNA to show the relative equivalence of RNA loading 
among the lanes. 
FIG. 6 shows a Northern blot analysis of transgenic plants 
possessing sense-orientation constructs of members of the 
3D_C12 gene family. (A) Hybridization of the 3D_C12-7 60 
probe to RNAs isolated from nontreated leaves of indepen-
dent transgenic lines expressing 3D_C12-7, 3D_C12, and 
7D_A06 constructs and a vector-only control (control 8). 
Estimated size of hybridizing band is indicated in kilobases 
(kb ). (B) Ethidium bromide staining of the portion of the gel 65 
used in (A) that contains the 28S ribosomal RNA to show the 
relative equivalence of RNA loading among the lanes. 
skilled in the art to which this invention pertains having the 
benefit of the teachings presented in the foregoing descrip-
tions and the associated drawings. Therefore, it is to be under-
stood that the invention is not to be limited to the specific 
embodiments disclosed and that modifications and other 
embodiments are intended to be included within the scope of 
the appended claims. Rather, these embodiments are pro-
vided so that this disclosure will satisfY applicable legal 
requirements. 
Although specific terms are employed herein, they are used 
in a generic and descriptive sense only and not for purposes of 
limitation. Like numbers refer to like elements throughout. 
Further, the article "a" and "an" are used herein to refer to one 
or more than one (i.e., to at least one) of the grammatical 
object of the article. By way of example, "an element" means 
one or more element. Throughout the specification the word 
"comprising," or variations such as "comprises" or "compris-
ing," will be understood to imply the inclusion of a stated 
element, integer or step, or group of elements, integers or 
steps, but not the exclusion of any other element, integer or 
step, or group of elements, integers or steps. 
The present invention is drawn to compositions and meth-
ods for inhibiting the expression or function of cytochrome 
P450 polypeptides that are involved in the metabolic conver-
sion of nicotine to nornicotine in a plant, particularly plants of 
the Nicotiana genus, including tobacco plants of the various 
commercial varieties. As used herein, the terms "inhibit," 
"inhibition," and "inhibiting" are defined as any method 
known in the art or described herein that decreases the expres-
sion or function of a gene product of interest (i.e., the target 
gene product). "Inhibition" can be in the context of a com-
parison between two plants, for example, a genetically altered 
plant versus a wild-type plant. Alternatively, inhibition of 
expression or function of a target gene product can be in the 
context of a comparison between plant cells, organelles, 
organs, tissues, or plant parts within the same plant or 
between different plants, and includes comparisons between 
developmental or temporal stages within the same plant or 
plant part or between plants or plant parts. "Inhibition" 
includes any relative decrement of function or production of 
a gene product of interest, up to and including complete 
elimination of function or production of that gene product. 
The term "inhibition" encompasses any method or composi-
tion that down-regulates translation and/or transcription of 
the target gene product or functional activity of the target gene 
product. 
The term "inhibitory sequence" encompasses any poly-
nucleotide or polypeptide sequence capable of inhibiting the 
expression or function of a cytochrome P450 polypeptide 
involved in the metabolic conversion of nicotine to nornico-
tine in a plant, such as full-length polynucleotide or polypep-
tide sequences, truncated polynucleotide or polypeptide 
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sequences, fragments of polynucleotide or polypeptide 
sequences, variants of polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense-
oriented nucleotide sequences, the complement of a sense- or 
antisense-oriented nucleotide sequence, inverted regions of 
nucleotide sequences, hairpins of nucleotide sequences, 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. The 
term "polynucleotide sequence" includes sequences of RNA, 
DNA, chemically modified nucleic acids, nucleic acid ana- 10 
logs, combinations thereof, and the like. 
8 
within the scope of the invention, provided that these com-
prise the introduced nucleic acid sequences of the invention. 
By "phenotypic change" is intended a measurable change 
in one or more cell functions. For example, plants having a 
genetic modification at the genomic locus encoding a cyto-
chrome P450 polypeptide of the invention can show reduced 
or eliminated expression or activity of that cytochrome P450 
polypeptide. 
The term "introducing" is intended to mean presenting to 
the plant the polynucleotide or polypeptide in such a manner 
that the sequence gains access to the interior of a cell of the 
plant. 
The term "operably linked" is intended to mean a func-
tional linkage between two or more elements. For example, 
an operable linkage between a polynucleotide of interest and 
a regulatory sequence (i.e., a promoter) is a functional link 
that allows for expression of the polynucleotide of interest. 
Operably linked elements may be contiguous or non-contigu-
Inhibitory sequences are designated herein by the name of 
the target gene product. Thus, a "cytochrome P450 inhibitory 
sequence" refers to an inhibitory sequence that is capable of 
15 
inhibiting the expression of a cytochrome P450 polypeptide 
that is involved in the metabolic conversion of nicotine to 
nomicotine in a plant, for example, at the level of transcrip-
tion and/or translation, or which is capable of inhibiting the 
function of such a cytochrome P450 polypeptide. When the 
phrase "capable of inhibiting" is used in the context of a 
polynucleotide inhibitory sequence, it is intended to mean 
that the inhibitory sequence itself exerts the inhibitory effect; 
20 ous. When used to refer to the joining of two protein coding 
regions, by operably linked is intended that the coding regions 
are in the same reading frame. 
The term "heterologous" according to the present inven-
tion when used in reference to a sequence is intended to mean or, where the inhibitory sequence encodes an inhibitory 
nucleotide molecule (for example, hairpin RNA, miRNA, or 
double-stranded RNA polynucleotides ), or encodes an inhibi-
tory polypeptide (i.e., a polypeptide that inhibits expression 
or function of the target gene product), following its transcrip-
tion (for example, in the case of an inhibitory sequence encod-
ing a hairpin RNA, miRNA, or double-stranded RNA poly-
nucleotide) or its transcription and translation (in the case of 
an inhibitory sequence encoding an inhibitory polypeptide), 
the transcribed or translated product, respectively, exerts the 
inhibitory effect on the target gene product (i.e, inhibits 
expression or function of the target gene product). 
25 a sequence that originates from a foreign species, or, if from 
the same species, is substantially modified from its native 
form in composition and/or genomic locus by deliberate 
human intervention. The term also is applicable to nucleic 
acid constructs, also referred to herein as "polynucleotide 
30 constructs" or "nucleotide constructs." In this manner, a "het-
erologous" nucleic acid construct is intended to mean a con-
struct that originates from a foreign species, or, if from the 
same species, is substantially modified from its native form in 
By "host cell" is meant a cell that comprises a heterologous 
nucleic acid sequence of the invention. Though the nucleic 
acid sequences of the invention, and fragments and variants 
thereof, can be introduced into any cell of interest, of particu-
lar interest are plant cells, more particularly cells of a Nicoti-
ana plant species, for example, the tobacco plant species and 
varieties described herein below. 
35 
composition and/or genomic locus by deliberate human inter-
vention. Heterologous nucleic acid constructs include, but are 
not limited to, recombinant nucleotide constructs that have 
been introduced into a plant or plant part thereof, for example, 
via transformation methods or subsequent breeding of a 
40 transgenic plant with another plant of interest. 
For example, a promoter operably linked to a heterologous 
polynucleotide is from a species different from the species 
from which the polynucleotide was derived, or, if from the 
same/analogous species, one or both are substantially modi-
45 fied from their original form and/or genomic locus, or the 
promoter is not the native promoter for the operably linked 
polynucleotide. Furthermore, as used herein a chimeric gene 
comprises a coding sequence operably linked to a transcrip-
The use of the term "polynucleotide" is not intended to 
limit the present invention to polynucleotides comprising 
DNA. Those of ordinary skill in the art will recognize that 
polynucleotides can comprise ribonucleotides and combina-
tions of ribonucleotides and deoxyribonucleotides. Such 
deoxyribonucleotides and ribonucleotides include both natu-
rally occurring molecules and synthetic analogues. The poly-
nucleotides of the invention also encompass all forms of 50 
sequences including, but not limited to, single-stranded 
forms, double-stranded forms, hairpins, stem-and-loop struc-
tures, and the like. 
tion initiation region that is heterologous to the coding 
sequence. 
The term "expression" as used herein refers to the biosyn-
thesis of a gene product, including the transcription and/or 
translation of said gene product. For example, for the pur-
poses of the present invention, an expression cassette, as 
described elsewhere herein, capable of expressing a poly-
nucleotide that inhibits the expression of at least one cyto-
chrome P450 polypeptide of the invention is an expression 
cassette capable of producing an RNA molecule that inhibits 
The term "variant" as used herein is intended to mean a 
substantially similar sequence, and the term "native" poly- 55 
nucleotide or polypeptide is intended to mean a naturally 
occurring nucleotide sequence or amino acid sequence, 
respectively. By "fragment" is intended a portion of a poly-
nucleotide or a portion of an amino acid sequence and hence 
protein encoded thereby. 
As used herein, the term "plant part" includes plant cells, 
plant protoplasts, plant cell tissue cultures from which a 
whole plant can be regenerated, plant calli, plant clumps, and 
plant cells that are intact in plants or parts of plants such as 
embryos, pollen, anthers, ovules, seeds, leaves, flowers, 65 
stems, branches, fruit, roots, root tips, and the like. Progeny, 
variants, and mutants of regenerated plants are also included 
60 the transcription and/or translation of at least one cytochrome 
P450 polypeptide. The "expression" or "production" of a 
protein or polypeptide from a DNA molecule refers to the 
transcription and translation of the coding sequence to pro-
duce the protein or polypeptide, while the "expression" or 
"production" of a protein or polypeptide from an RNA mol-
ecule refers to the translation of the RNA coding sequence to 
produce the protein or polypeptide. 
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Cytochrome 450 Polynucleotides and Polypeptides, and Vari-
ants and Fragments Thereof 
Compositions of the present invention include isolated 
cytochrome P450 polynucleotides and polypeptides that are 
involved in the metabolic conversion of nicotine to nomico-
tine in plants, including commercial varieties of tobacco 
plants. In particular, compositions of the invention include 
isolated polypeptides comprising the amino acid sequences 
10 
corresponding to nt 1-1551 of the eDNA sequence set forth in 
SEQ ID N0:3, which codes for the full-length 517-residue 
polypeptide set forth in SEQ ID N0:4. The third of these 
cytochrome P450 genes, designated 3D_C12-7, encodes an 
mRNA transcript corresponding to nt 1-1551 of the eDNA 
sequence set forth in SEQ ID N0:5, which codes for the 
full-length 517 residue polypeptide set forth in SEQ ID N0:6. 
The fourth member of the novel cytochrome P450 family, 
designated 7D_A06, encodes an mRNA transcript corre-as shown in SEQ ID NOS:2, 4, 6, 8, 10, and 12, and isolated 
polynucleotides comprising the nucleotide sequences as 
shown in SEQ ID NOS: 1, 3, 5, 7, 9, and 11. The polynucle-
otides of the invention find use in inhibiting expression of 
these cytochrome P450 polypeptides or variants thereof that 
are involved in the metabolic conversion of nicotine to nor-
nicotine in plants, particularly tobacco plants. 
10 sponding to nt 1-1554 of the eDNA sequence set forth in SEQ 
ID N0:7, which codes for the full-length 518-residue 
polypeptide set forth in SEQ ID N0:8. 
Two partial-length P450 gene sequences sharing high 
sequence identity to the full-length members of the 3D_C12 
In this manner, the invention further provides expression 
cassettes comprising all or a portion of the polynucleotide 
sequence set forth in SEQ ID N0:1, 3, 5, 7, 9, or 11, a 
complement or fragment thereof, or a sequence having sub-
stantial sequence identity to SEQIDN0:1, 3, 5, 7, 9, or 11, or 
15 cytochrome P450 gene family were also isolated from these 
Burley tobacco lines. The first of these, designated 3D_C12-
15, encodes an mRNA transcript corresponding to the eDNA 
sequence set forth in SEQ ID N0:9, which encodes the par-
tial-length polypeptide set forth in SEQ ID NO: 10. The sec-
20 ond partial-length P450 gene sequence, designated 
131A_A02, encodes an mRNA transcript corresponding to 
the eDNA sequence set forth in SEQ ID NO: 11, which 
encodes the partial-length polypeptide set forth in SEQ ID 
N0:12. 
a complement or fragment thereof, operably linked to a pro-
moter that is functional in a plant cell for use in expressing an 
inhibitory RNA transcript that interferes with expression (i.e., 
transcription and/or translation) of cytochrome P450 
polypeptides described herein. In some embodiments, the 25 
expression cassettes comprise the nucleotide sequence as 
shown in SEQ ID N0:13, 14, 15, or 16, a complement or 
fragment thereof, or a sequence having substantial sequence 
identity to SEQ ID N0:13, 14, 15, or 16, or a complement or 
fragment thereof. Introduction of these expression cassettes 30 
into a Nicotiana plant of interest, particularly a tobacco plant 
of varieties commonly known as flue or bright varieties, Bur-
ley varieties, dark varieties, and oriental/Turkish varieties, 
results in the production of tobacco plants having reduced 
amounts of nomicotine and the nitrosamine, N'-nitrosonorni- 35 
cotine (NNN). Leaf and stem material from these transgenic 
plants can be used to produce a variety of tobacco products 
having reduced levels of nornicotine, and a concomitant 
reduction in this carcinogenic nitrosamine metabolite. 
The cytochrome P450 polynucleotides and encoded 40 
polypeptides of the present invention represent a novel cyto-
chrome P450 gene family, designated the 3D_C12 cyto-
chrome 450 gene family, that is newly identified as having a 
role in the metabolic conversion of nicotine to nomicotine in 
tobacco plants. Suppression of the expression of their 45 
encoded gene products in transgenic tobacco plants results in 
a significant reduction in the accumulation of nomicotine in 
the leaves of these transgenic plants. While not being bound 
by theory, the metabolic role of these polypeptides may be a 
direct one, i.e., directly catalyzing the N-demethylation reac- 50 
tion, or an indirect one, i.e., in the form of production of a 
product that leads to the up-regulation of the nicotine dem-
ethylase activity of the leaf. Regardless of the mechanism, 
any means by which expression and/or function of the 
polypeptides encoded by members of this cytochrome P450 55 
gene family are targeted for inhibition within a Nicotiana 
plant will be effective in reducing nomicotine levels, and 
levels of its carcinogenic metabolite, NNN, within leaves and 
stems of these plants. 
The cytochrome P450 genes of the invention were isolated 60 
from tobacco lines of a Burley variety. The first of these 
cytochrome P450 genes, designated 3D_C12, encodes an 
mRNA transcript corresponding to nucleotides (nt) 1-1551 of 
the eDNA sequence set forth in SEQ ID NO: 1, which codes 
for the full-length 517-residue polypeptide set forth in SEQ 65 
ID N0:2. The second member of this novel cytochrome P450 
family, designated 3D_ C12-1 0, encodes an mRNA transcript 
In one aspect, the cytochrome P450 genes of the present 
invention are involved in the conversion of nicotine to norni-
cotine in a plant. In one aspect, the cytochrome P450 genes of 
the present invention have nicotine demethylase activity. 
An alignment of the members of the 3D_C12 cytochrome 
P450 gene family is shown in FIGS. 3A-3G. The predicted 
amino acid sequences for the four full-length clones are 
aligned in FIG. 4. These sequences share high sequence iden-
tity with each other (at least 90% at both the nucleotide and 
amino acid level (see Tables 2 and 3, Example 4 herein 
below). 
The invention encompasses isolated or substantially puri-
fied polynucleotide or protein compositions. An "isolated" or 
"purified" polynucleotide or protein, or biologically active 
portion thereof, is substantially or essentially free from com-
ponents that normally accompany or interact with the poly-
nucleotide or protein as fonnd in its naturally occurring en vi-
ronment. Thus, an isolated or purified polynucleotide or 
protein is substantially free of other cellular material, or cul-
ture medium when produced by recombinant techniques, or 
substantially free of chemical precursors or other chemicals 
when chemically synthesized. Optimally, an "isolated" poly-
nucleotide is free of sequences (optimally protein encoding 
sequences) that naturally flank the polynucleotide (i.e., 
sequences located at the 5' and 3' ends of the polynucleotide) 
in the genomic DNA of the organism from which the poly-
nucleotide is derived. For example, in various embodiments, 
the isolated polynucleotide can contain less than about 5 kb, 
4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or0.1 kb of nucleotide sequence 
that naturally flank the polynucleotide in genomic DNA of the 
cell from which the polynucleotide is derived. A protein that 
is substantially free of cellular material includes preparations 
of protein having less than about 30%, 20%, 10%, 5%, or 1% 
(by dry weight) of contaminating protein. When the protein of 
the invention or biologically active portion thereof is recom-
binantly produced, optimally culture medium represents less 
than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of 
chemical precursors or non-protein-of-interest chemicals. 
Fragments of the disclosed cytochrome P450 polynucle-
otides and polypeptides encoded thereby are also encom-
passed by the present invention. Fragments of a polynucle-
otide may encode protein fragments that retain the biological 
activity of the native protein and hence are involved in the 
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metabolic conversion of nicotine to nornicotine in a plant. 
Alternatively, fragments of a polynucleotide that are useful as 
hybridization probes or PCR primers using methods 
described below generally do not encode fragment proteins 
retaining biological activity. Furthermore, fragments of the 5 
disclosed nucleotide sequences include those that can be 
assembled within recombinant constructs for use in gene 
silencing with any method known in the art, including, but not 
limited to, sense suppression/cosuppression, antisense sup-
pression, double-stranded RNA (dsRNA) interference, hair- 10 
pin RNA interference and intron-containing hairpin RNA 
interference, amplicon-mediated interference, ribozymes, 
and small interfering RNA or micro RNA, as described herein 
below. Thus, fragments of a cytochrome P450 polynucleotide 
sequence may range from at least about 20 nucleotides, about 15 
50 nucleotides, about 70 nucleotides, about 100 nucleotides, 
about 150 nucleotides, about 200 nucleotides, about 250 
nucleotides, about 300 nucleotides, about 350 nucleotides, 
about 400 nucleotides, and up to the full-length polynucle-
otide encoding the proteins of the invention, depending upon 20 
the desired outcome. In one aspect, the fragments of a cyto-
chrome P450 polynucleotide sequence can be a fragment of 
between about 50 and about 400 nucleotides, between about 
70 and about 350 nucleotides, between about 90 and about 
325 nucleotides, between about 90 and about 300 nucle- 25 
otides, between about 90 and about 27 5 nucleotides, between 
about 100 and about 400 nucleotides, between about 100 and 
about 350 nucleotides, between about 100 and about 325 
nucleotides, between about 100 and about 300 nucleotides, 
between about 125 and about 300 nucleotides, or between 30 
about 125 and about 275 nucleotides in length. In some 
embodiments, a fragment of a cytochrome P450 polynucle-
otide is about 50, about 60, about 70, about 80, about 90, 
about100,about125,about150,about175,about200,about 
225,about250,about275,about300,about325,about350, 35 
about 400 nucleotides in length, and other such values 
between about 70 and about 400 nucleotides. In one such 
embodiment, a fragment of a cytochrome P450 polynucle-
otide of the invention is about 90 bp to about 110 bp in length, 
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 40 
103, 104, 105, 106, 107, 108, 109, and 110 bp in length. In 
another such embodiment, a fragment of a cytochrome P450 
polynucleotide of the invention is about 290 to about 310 bp 
in length, including 290, 291, 292, 293, 294, 295, 296, 297, 
298,299,300,301,302,303,304,305,306,307,308,309, 45 
and 310 bp in length. 
A fragment of a cytochrome P450 polynucleotide of the 
present invention that encodes a biologically active portion of 
a cytochrome P450 polypeptide of the present invention will 
encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 200, 50 
250,300,350,400,450, or 500 contiguous amino acids, or up 
to the total number of amino acids present in a full-length 
cytochrome P450 polypeptide of the invention (e.g., 517 for 
SEQ ID NOS: 2, 4, and 6; and 518 for SEQ ID N0:8), or will 
encode at least 15, 25, 30, 50, 75, 100, 125, 150, or up to the 55 
total number of amino acids present in a partial-length cyto-
chrome P450 polypeptide of the invention (e.g., 173 for SEQ 
ID N0:10; and 222 for SEQ ID N0:12). In one aspect, a 
fragment of a cytochrome P450 polynucleotide of the inven-
tion encodes a polypeptide that comprises position 329 of the 60 
encoded polypeptide sequence. In another aspect, the poly-
nucleotide fragment encodes a fragment of a cytochrome 
P450 polypeptide, where the polypeptide fragment comprises 
the amino acids from position 225 through the amino acid at 
about position 600 of SEQ ID N0:6. In one such embodi- 65 
ment, the polynucleotide fragment encodes a fragment of a 
cytochrome P450 polypeptide, where the polypeptide frag-
12 
ment comprises the amino acids from about position 239 
through the amino acid at about position 402 of SEQ ID 
N0:6. A biologically active portion of a cytochrome P450 
polypeptide can be prepared by isolating a portion of one of 
the cytochrome P450 polynucleotides of the present inven-
tion, expressing the encoded portion of the cytochrome P450 
polypeptide (e.g., by recombinant expression in vitro), and 
assessing the activity of the encoded portion of the cyto-
chrome P450 polypeptide, i.e., the ability to promote conver-
sion of nicotine to nomicotine, using assays known in the art 
and those provided herein below. 
Polynucleotides that are fragments of a cytochrome P450 
nucleotide sequence of the present invention comprise at least 
16, 20, 50, 75,100,150,200,250,300,350,400,450,500, 
550, 600,650,700, 800, 900, 950, 1000, 1050, 1100, 1150, 
1200,1250,1300,1350,1400,1450,1500,1550,1600,1650, 
or 1700 contiguous nucleotides, or up to the number of nucle-
otides present in a full-length cytochrome P450 polynucle-
otide as disclosed herein (e.g., 539 for SEQ ID NO: 9; 666 for 
SEQ ID NO: 11; 1733 for SEQ ID NOS: 1, 3, and 5; and 1727 
for SEQ ID N0:7). Polynucleotides that are fragments of a 
cytochrome P450 nucleotide sequence of the present inven-
tion comprise fragments from about 20 to about 1700 con-
tiguous nucleotides, from about 50 to about 1600 contiguous 
nucleotides, from about 75 to about 1500 contiguous nucle-
otides, from about 100 to about 1400 nucleotides, from about 
150 to about 1300 contiguous nucleotides, from about 150 to 
about 1200 contiguous nucleotides, from about 17 5 to about 
1100 contiguous nucleotides, or from about 200 to about 
1000 contiguous nucleotides from a cytochrome P450 poly-
nucleotide as disclosed herein. 
In one aspect, fragments of a cytochrome P450 polynucle-
otide comprise a polynucleotide sequence containing the 
nucleotides from about position 700 to about position 1250 of 
a cytochrome P450 coding sequence. In another aspect, frag-
ments of a cytochrome P450 polynucleotide comprise a poly-
nucleotide sequence containing the nucleotides from about 
position 715 to about position 1210, or from about position 
717 to about position 1207 of a cytochrome P450 coding 
sequence disclosed herein. 
In other embodiments of the invention, fragments of a 
cytochrome P450 polynucleotide comprise a polynucleotide 
sequence containing the nucleotides from about position 265 
to about position 625 of a cytochrome P450 coding sequence 
disclosed herein, or a complement thereof. In some of these 
embodiments, the fragments of a cytochrome P450 coding 
sequence disclosed herein comprise the nucleotides corre-
sponding to about position 297 to about position 594 of the 
P450 coding sequence set forth in SEQ ID N0:3 or SEQ ID 
N0:5, or a complement thereof. 
In yet other embodiments of the invention, fragments of a 
cytochrome P450 polynucleotide comprise a polynucleotide 
sequence containing the nucleotides from about position 
1420 to about position 1580 of a cytochrome P450 coding 
sequence disclosed herein, or a complement thereof. In some 
of these embodiments, the fragments of a cytochrome P450 
coding sequence disclosed herein comprise the nucleotides 
corresponding to about position 1453 to about position 1551 
of the P450 coding sequence set forth in SEQ ID NO: 1, or a 
complement thereof. 
Variants of the disclosed polynucleotides and polypeptides 
encoded thereby are also encompassed by the present inven-
tion. Such naturally occurring variants include those variants 
that share substantial sequence identity to the disclosed cyto-
chrome P450 polynucleotides and polypeptides disclosed 
herein as defined herein below. The compositions and meth-
ods of the invention can be used to target expression or func-
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tion of any naturally occurring cytochrome P450 that shares 
substantial sequence identity to the disclosed cytochrome 
P450 polypeptides and which possesses the relevant cyto-
chrome P450 activity, i.e., involvement in the metabolic con-
version of nicotine to nornicotine in plants. Such variants may 
result from, for example, genetic polymorphism or from 
human manipulation as occurs with breeding and selection. 
Biologically active variants of a cytochrome P450 protein of 
the invention, for example, variants of the polypeptide set 
forth in SEQ ID N0:2, 4, 6, 8, 10, or 12, will have at least 
about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 
99% or more sequence identity to the amino acid sequence for 
the native protein as determined by sequence alignment pro-
grams and parameters described elsewhere herein, and are 
characterized by their functional involvement in the meta-
bolic conversion of nicotine to nornicotine in plants. A bio-
logically active variant of a protein of the invention may differ 
from that protein by as few as 1-15 amino acid residues, as 
few as 10, as few as 9, as few as 8, as few as 7, as few as 6, as 
few as 5, as few as 4, as few as 3, as few as 2, or as few as 1 
amino acid residue. 
chrome P450 polypeptides involved in the metabolic conver-
sion of nicotine to nornicotine in plants, particularly tobacco 
plants, thereby inhibiting accumulation of nornicotine and its 
metabolite N'-nitrosonornicotine in the stems and leaves of 
the genetically modified plant. Percent sequence identity 
between any two polypeptides can be calculated using 
sequence alignment programs and parameters described else-
where herein. Where any given pair of polynucleotides of the 
invention is evaluated by comparison of the percent sequence 
10 identity shared by the two polypeptides they encode, the 
percent sequence identity between the two encoded polypep-
tides is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 
15 
97%, 98%, 99% or more sequence identity. In one aspect, a 
variant polypeptide of the present invention includes a 
polypeptide having a tryptophan at position 329 or an isoleu-
cine at position 274 of the cytochrome P450 polypeptide, or 
both a tryptophan at position 329 and an isoleucine at position 
20 274. 
Variants of a particular polynucleotide of the present inven-
tion include those naturally occurring polynucleotides that 
encode a cytochrome P450 polypeptide that is involved in the 25 
metabolic conversion of nicotine to nornicotine in plants. 
Such polynucleotide variants can comprise a deletion and/or 
addition of one or more nucleotides at one or more sites 
within the native polynucleotide disclosed herein and/or a 
substitution of one or more nucleotides at one or more sites in 30 
the native polynucleotide. Because of the degeneracy of the 
genetic code, conservative variants for polynucleotides 
include those sequences that encode the amino acid sequence 
of one of the cytochrome P450 polypeptides of the invention. 
Naturally occurring variants such as these can be identified 35 
with the use ofwell-knownmolecularbiology techniques, as, 
for example, with polymerase chain reaction (PCR) and 
hybridization techniques as outlined below. Variant poly-
nucleotides also include synthetically derived polynucle-
otides, such as those generated, for example, by using site- 40 
directed mutagenesis but which still share substantial 
sequence identity to the naturally occurring sequences dis-
closed herein, and thus can be used in the methods of the 
invention to inhibit the expression or function of a cyto-
chrome P450 that is involved in the metabolic conversion of 45 
Furthermore, the polynucleotides of the invention can be 
used to isolate corresponding cytochrome P450 sequences 
from other organisms, particularly other plants, more particu-
larly other members of the Nicotiana genus. PCR, hybridiza-
tion, and other like methods can be used to identifY such 
sequences based on their sequence homology to the 
sequences set forth herein. Sequences isolated based on their 
sequence identity to the nucleotide sequences set forth herein 
or to variants and fragments thereof are encompassed by the 
present invention. Such sequences include sequences that are 
orthologs of the disclosed sequences. 
According to the present invention, "orthologs" are genes 
derived from a common ancestral gene and which are found 
in different species as a result of speciation. Genes found in 
different species are considered orthologs when their nucle-
otide sequences and/or their encoded protein sequences share 
at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 
94%, 95%, 96%, 97%, 98%, 99%, or greater sequence iden-
tity. Functions of orthologs are often highly conserved among 
species. Thus, isolated polynucleotides that encode for a cyto-
chrome P450 polypeptide that is involved in the nicotine-to-
nornicotine metabolic conversion and which hybridize under 
stringent conditions to the cytochrome P450 sequences dis-
closed herein, or to variants or fragments thereof, are encom-
passed by the present invention. Such sequences can be used 
in the methods of the present invention to inhibit expression 
of cytochrome P450 polypeptides that are involved in the 
metabolic conversion of nicotine to nornicotine in plants. 
Using PCR, oligonucleotide primers can be designed for 
nicotine to nornicotine, including the cytochrome P450 
polypeptides set forth in SEQ ID NOS:2, 4, 6, and 8, and 
polypeptides comprising the sequence set forth in SEQ ID 
NO: 10 or 12. Generally, variants of a particular polynucle-
otide of the invention, for example, the sequence set forth in 
SEQ ID N0:1, 3, 5, 7, 9, or 11, will have at least about 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
sequence identity to that particular polynucleotide as deter-
mined by sequence alignment programs and parameters 
described elsewhere herein. 
50 use in PCR reactions to amplify corresponding DNA 
sequences from eDNA or genomic DNA extracted from any 
plant of interest. Methods for designing PCR primers and 
PCR cloning are generally known in the art and are disclosed 
in Sambrook eta!. (1989) Molecular Cloning: A Laboratory 
Variants of a particular polynucleotide of the present inven-
tion (also referred to as the reference polynucleotide) can also 
55 Manual (2d ed., Cold Spring Harbor Laboratory Press, Pla-
inview, N.Y.). Innis et a!., eds. (1990) PCR Protocols: A 
Guide to Methods and Applications (Academic Press, New 
York); Innis and Gelfand, eds. (1995) PCR Strategies (Aca-
demic Press, New York); and Innis and Gelfand, eds. (1999) be evaluated by comparison of the percent sequence identity 
between the polypeptide encoded by the reference polynucle-
otide and the polypeptide encoded by a variant polynucle-
otide. For example, isolated polynucleotides encoding a 
polypeptide with a particular percent sequence identity to the 
full-length polypeptide of SEQ ID N0:2, 4, 6, or 8, or the 
partial-length polypeptide encoded by SEQ ID N0:9 or 11 65 
are disclosed. Such polynucleotides can be used in the meth-
ods of the present invention to target expression of cyto-
60 PCR Methods Manual (Academic Press, New York). Known 
methods ofPCR include, but are not limited to, methods using 
paired primers, nested primers, single specific primers, 
degenerate primers, gene-specific primers, vector-specific 
primers, partially mismatched primers, and the like. 
Hybridization techniques involve the use of all or part of a 
known polynucleotide as a probe that selectively hybridizes 
to other corresponding polynucleotides present in a popula-
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tion of cloned genomic DNA fragments or eDNA fragments 
(i.e., genomic or eDNA libraries) from a chosen organism. 
Hybridization may be carried out under stringent condi-
tions. By "stringent conditions" or "stringent hybridization 
conditions" is intended conditions under which a probe will 5 
hybridize to its target sequence to a detectably greater degree 
than to other sequences (e.g., at least 2-fold over back-
ground). Stringent conditions are sequence-dependent and 
will be different in different circumstances. By controlling 
the stringency of the hybridization and/or washing condi- 10 
tions, target sequences that are 100% complementary to the 
probe can be identified (homologous probing). Alternatively, 
stringency conditions can be adjusted to allow some mis-
matching in sequences so that lower degrees of similarity are 
detected (heterologous probing). Generally, a probe is less 15 
than about 1000 nucleotides in length, optimally less than 500 
nucleotides in length. 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 20 
7.0 to 8.3 and the temperature is at least about 30° C. Stringent 
conditions may also be achieved with the addition of desta-
bilizing agents such as formamide. Exemplary low stringency 
conditions include hybridization with a buffer solution of30 
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl 25 
sulphate) at 37° C., and a wash in 1x to 2xSSC (20xSSC=3.0 
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary 
moderate stringency conditions include hybridization in 40 to 
45% formamide, 1.0 MNaCl, 1% SDS at 37° C., and a wash 
in 0.5x to 1xSSC at 55 to 60° C. Exemplary high stringency 30 
conditions include hybridization in 50% formamide, 1 M 
NaCl, 1% SDS at 37° C., and a washin0.1xSSC at 60 to 65° 
C. Optionally, wash buffers may comprise about 0.1% to 
about 1% SDS. Duration of hybridization is generally less 
than about 24 hours, usually about 4 to about 12 hours. The 35 
duration of the wash time will be at least a length of time 
sufficient to reach equilibrium. 
In a specific embodiment, stringency conditions include 
hybridization in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 flg/fll Poly ARNA, 0.45 flg/fll calf thymus 40 
DNA and 50% formamide at 42° C., and at least one post-
hybridization wash in a solution comprising from about 0.01 x 
SSC to about 1xSSC. The duration of hybridization is from 
about 14 to about 16 hours. 
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tion and/or wash at 6, 7, 8, 9, or 10° C. lower than the thermal 
melting point (T m); low stringency conditions can utilize a 
hybridization and/or wash at 11, 12, 13, 14, 15, or 20° C. 
lower than the thermal melting point (Tm). Using the equa-
tion, hybridization and wash compositions, and desired T m' 
those of ordinary skill will understand that variations in the 
stringency of hybridization and/or wash solutions are inher-
ently described. If the desired degree of mismatching results 
in a T m of less than 45° C. (aqueous solution) or 32° C. 
(formamide solution), it is optimal to increase the sse con-
centration so that a higher temperature can be used. An exten-
sive guide to the hybridization of nucleic acids is found in 
Tijssen (1993) Laboratory Techniques in Biochemistry and 
Molecular Biology-Hybridization with Nucleic Acid 
Probes, Part I, Chapter 2 (Elsevier, N.Y.); andAusubel eta!., 
eds. (1995) Current Protocols in Molecular Biology, Chapter 
2 (Greene Publishing and Wiley-Interscience, New York). 
See Sambrook eta!. (1989) Molecular Cloning: A Laboratory 
Manual (2d ed., Cold Spring Harbor Laboratory Press, Pla-
inview, N.Y.). 
Hybridization probes may be genomic DNA fragments, 
eDNA fragments, RNA fragments, or other oligonucleotides, 
and may be labeled with a detectable group such as 32P, or any 
other detectable marker. For example, probes for hybridiza-
tion can be made by labeling synthetic oligonucleotides based 
on the cytochrome P450 polynucleotides sequences of the 
present invention. Methods for preparation of probes for 
hybridization and for construction of eDNA and genomic 
libraries are generally known in the art and are disclosed in 
Sambrook et a!. (1989) Molecular Cloning: A Laboratory 
Manual (2d ed., Cold Spring Harbor Laboratory Press, Pla-
inview, N.Y.). 
For example, the cytochrome P450 polynucleotide 
sequences disclosed herein, or one or more portions thereof, 
may be used as probes capable of specifically hybridizing to 
corresponding cytochrome P450 polynucleotides and mes-
senger RNAs. To achieve specific hybridization under a vari-
ety of conditions, such probes include sequences that are 
unique among cytochrome P450 polynucleotide sequences, 
including upstream regions 5' to the coding sequence and 
downstream regions 3' to the coding sequence, and are opti-
mally at least about 10 nucleotides in length, and most opti-
mally at least about 20 nucleotides in length. Such probes 
may be used to amplifY corresponding cytochrome P450 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and tem-
perature of the final wash solution. For DNA-DNA hybrids, 
the T m can be approximated from the equation of Meinkoth 
and Wahl (1984) Anal. Biochem. 138:267-284: Tm=81.5° 
C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-500/L; where 
45 polynucleotides. This technique may be used to isolate addi-
tional coding sequences from a desired plant or as a diagnos-
tic assay to determine the presence of coding sequences in a 
plant. Hybridization techniques include hybridization screen-
ing of plated DNA libraries (either plaques or colonies; see, 
M is the molarity of monovalent cations, % GC is the per-
centage of guanosine and cytosine nucleotides in the DNA, % 
form is the percentage of formamide in the hybridization 
solution, and Lis the length of the hybrid in base pairs. The T m 
is the temperature (under defined ionic strength and pH) at 
which 50% of a complementary target sequence hybridizes to 
50 for example, Sambrook eta!. (1989) Molecular Cloning: A 
Laboratory Manual (2d ed., Cold Spring Harbor Laboratory 
Press, Plainview, N.Y.). 
As used herein, with respect to the sequence relationships 
between two or more polynucleotides or polypeptides, the 
55 term "reference sequence" is a defined sequence used as a 
basis for sequence comparison. A reference sequence may be 
a subset or the entirety of a specified sequence; for example, 
as a segment of a full-length eDNA or gene sequence, or the 
a perfectly matched probe. T m is reduced by about 1 o C. for 
each 1% of mismatching; thus, T m' hybridization, and/or 
wash conditions can be adjusted to hybridize to sequences of 
the desired identity. For example, if sequences with ;;:90% 60 
identity are sought, the T m can be decreased 10° C. Generally, 
stringent conditions are selected to be about so C. lower than 
the thermal melting point (T m) for the specific sequence and 
complete eDNA or gene sequence. 
As used herein, the term "comparison window" makes 
reference to a contiguous and specified segment of a poly-
nucleotide sequence, wherein the polynucleotide sequence in 
the comparison window may comprise additions or deletions 
(i.e., gaps) compared to the reference sequence (which does its complement at a defined ionic strength and pH. However, 
severely stringent conditions can utilize a hybridization and/ 
or wash at 1, 2, 3, or4° C. lower than thethermalmeltingpoint 
(T m); moderately stringent conditions can utilize a hybridiza-
65 not comprise additions or deletions) for optimal alignment of 
the two polynucleotides. Generally, the comparison window 
is at least 20 contiguous nucleotides in length, and optionally 
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can be 30, 40, 50, 100, or longer. Those of skill in the art 
understand that to avoid a high similarity to a reference 
sequence due to inclusion of gaps in the polynucleotide 
sequence a gap penalty is typically introduced and is sub-
tracted from the number of matches. 
18 
the percent sequence identity may be adjusted upwards to 
correct for the conservative nature of the substitution. 
Sequences that differ by such conservative substitutions are 
said to have "sequence similarity" or "similarity." Means for 
making this adjustment are well known to those of skill in the 
art. Typically this involves scoring a conservative substitution 
as a partial rather than a full mismatch, thereby increasing the 
percentage sequence identity. Thus, for example, where an 
identical amino acid is given a score of 1 and a non-conser-
10 vative substitution is given a score of zero, a conservative 
substitution is given a score between zero and 1. The scoring 
of conservative substitutions is calculated, e.g., as imple-
mented in the program PC/GENE (Intelligenetics, Mountain 
Methods of alignment of sequences for comparison are 
well known in the art. Thus, the determination of percent 
sequence identity between any two sequences can be accom-
plished using a mathematical algorithm. Non-limiting 
examples of such mathematical algorithms are the algorithm 
ofMyers and Miller (1988) CABIOS 4: 11-17; the local align-
ment algorithm of Smith eta!. (1981 )Adv. Appl. Math. 2:482; 
the global alignment algorithm of Needleman and Wunsch 
(1970) J. Mol. Biol. 48:443-453; the search-for-local align-
ment method ofPearson and Lipman (1988) Proc. Nat!. A cad. 15 
Sci. 85:2444-2448; the algorithm of Karlin and Altschul 
(1990) Proc. Nat!. Acad. Sci. USA 872264, modified as in 
Karlin and Altschul (1993) Proc. Nat!. Acad. Sci. USA 
90:5873-5877. 
View, Calif.). 
The term "percentage of sequence identity" as used herein 
means the value determined by comparing two optimally 
aligned sequences over a comparison window, wherein the 
portion of the polynucleotide sequence in the comparison 
window may comprise additions or deletions (i.e., gaps) as 
The BLAST programs of Altschul eta!. (1990) J. Mol. Biol. 
215:403 are based on the algorithm of Karlin and Altschul 
(1990) supra. BLAST nucleotide searches can be performed 
with the BLASTN program, score=100, wordlength=12, to 
obtain nucleotide sequences homologous to a nucleotide 
sequence encoding a protein of the invention. BLAST protein 
searches can be performed with the BLASTX program, 
score=50, wordlength=3, to obtain amino acid sequences 
homologous to a protein or polypeptide of the invention. To 
obtain gapped alignments for comparison purposes, Gapped 
BLAST (in BLAST 2.0) can be utilized as described in Alts-
chul eta!. (1997) Nucleic Acids Res. 25:3389. Alternatively, 
PSI-BLAST (in BLAST 2.0) can be used to perform an iter-
ated search that detects distant relationships between mol-
ecules. See Altschul et a!. (1997) supra. When utilizing 
BLAST, Gapped BLAST, PSI-BLAST, the default param-
eters of the respective programs (e.g., BLASTN for nucle-
otide sequences, BLASTX for proteins) can be used (See 
www.ncbi.nlm.nih.gov). Alignment may also be performed 
manually by inspection. 
The sequence identity/similarity values provided herein 
were calculated using the BLASTX (Altschul et a!. (1997) 
supra), Clustal W (Higgins eta!. (1994) Nucleic Acids Res. 
22: 4673-4680), and GAP (University of Wisconsin Genetic 
Computing Group software package) algorithms using 
default parameters. The present invention also encompasses 
the use of any equivalent program thereof for the analysis and 
comparison of nucleic acid and protein sequences. By 
"equivalent program" is intended any sequence comparison 
program that, for any two sequences in question, generates an 
aligrm1ent having identical nucleotide or amino acid residue 
matches and an identical percent sequence identity when 
compared to the corresponding alignment generated by 
BLASTX, Clustal W, or GAP. 
For purposes of the foregoing discussion of variant nucle-
otide and polypeptide sequences encompassed by the present 
invention, the term "sequence identity" or "identity" in the 
context of two polynucleotides or polypeptide sequences 
makes reference to the residues in the two sequences that are 
the same when aligned for maximum correspondence over a 
specified comparison window. When percentage of sequence 
identity is used in reference to proteins it is recognized that 
residue positions which are not identical often differ by con-
servative amino acid substitutions, where amino acid residues 
are substituted for other amino acid residues with similar 
chemical properties (e.g., charge or hydrophobicity) and 
therefore do not change the functional properties of the mol-
ecule. When sequences differ in conservative substitutions, 
20 compared to the reference sequence (which does not com-
prise additions or deletions) for optimal alignment of the two 
sequences. The percentage is calculated by determining the 
number of positions at which the identical nucleic acid base or 
amino acid residue occurs in both sequences to yield the 
25 number of matched positions, dividing the number of 
matched positions by the total number of positions in the 
window of comparison, and multiplying the result by 100 to 
yield the percentage of sequence identity. 
When any two polypeptide sequences are optimally 
30 aligned for comparison, it is recognized that residues appear-
ing opposite of one another within the alignment occupy 
positions within their respective polypeptides that correspond 
to one another. Such positions are referred to herein as "cor-
responding positions" and the residues residing at corre-
35 sponding positions are referred to as "corresponding resi-
dues" or residues that "correspond" to one another. Thus, for 
example, where a polypeptide of interest is optimally aligned 
to a reference polypeptide sequence having, for example, 10 
residues, the residue within the polypeptide of interest 
40 appearing opposite residue 5 of the reference sequence is 
referred to as the "residue at the position corresponding to 
residue 5" of the reference sequence. 
In like mauner, when any two polynucleotide sequences 
are optimally aligned for comparison, it is recognized that the 
45 nucleotides appearing opposite of one another within the 
alignment occupy positions within their respective poly-
nucleotide positions that correspond to one another. Such 
positions are referred to herein as "corresponding positions" 
and the nucleotides residing at corresponding positions are 
50 referred to as "corresponding nucleotides" or nucleotides that 
"correspond" to one another. Thus, for example, where a 
polynucleotide of interest is optimally aligned to a reference 
polynucleotide sequence having, for example, 300 nucle-
otides, the nucleotide within the polynucleotide of interest 
55 appearing opposite nucleotide 275 of the reference sequence 
is referred to as the "nucleotide at the position corresponding 
to nucleotide 275" of the reference sequence. 
Where a region of nucleotides is being compared between 
a polynucleotide of interest and a reference polynucleotide, 
60 the nucleotides within these regions are said to "correspond" 
to one another. Thus, for example, where a region of a refer-
ence polynucleotide sequence, for example, the polynucle-
otide sequence set forth in SEQ ID N0:5, resides from nucle-
otide position 265 to nucleotide position 625 of the reference 
65 polynucleotide, and this region ofnucleotides is being com-
pared to the corresponding region of nucleotides within an 
optimally aligned polynucleotide sequence of interest, the 
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nucleotides within the corresponding region of the polynucle-
otide of interest are referred to herein as "a region" of the 
polynucleotide of interest that "corresponds to nucleotide 
position 265 to nucleotide position 625" of the reference 
sequence, in this case, SEQ ID N0:5. 
Cytochrome P450 polynucleotide and polypeptide 
sequences can be identified using the sequences provided 
herein. Such methods include obtaining a polynucleotide or 
polypeptide sequence at least 80%, 85%, 90%, 95%, 98%, 
99% sequence identity with the polynucleotide sequence of 10 
SEQ ID NO 1, 3, 5, 7, 9, or 11 or a complement or fragment 
thereof, or a polypeptide sequence of SEQ ID N0:2, 4, 6, 7, 
20 
promoter functional in a plant cell and a nucleic acid sequence 
encoding a nicotine demethylase having an isoleucine residue 
at position 274 and a tryptophan residue at position 329. In 
some embodiments, the nucleic acid sequence encoding this 
nicotine demethylase is derived from a sequence selected 
from the group consisting of SEQ ID N0:3, SEQ ID N0:5, 
and SEQ ID N0:7. These transgenic plant cells, plants, and 
seed include, but are not limited to, Nicotiana plant cells, 
Nicotiana plants, and seed of Nicotiana plants. In some 
embodiments, theNicotiana plant cells, Nicotiana plants, and 
seed of Nicotiana plants are from converter Nicotiana plants. 
Expression Cassettes for Use in the Methods of the Invention 
Compositions of the present invention further include 
expression cassettes comprising inhibitory sequences 
10, or 12. In one embodiment, the identified sequence con-
tains or encodes for a tryptophan residue at position 329 and 
an isoleucine residue at position 274. 15 capable of inhibiting expression or function of a cytochrome 
P450 polypeptide involved in the conversion of nicotine to 
nornicotine in a Nicotiana plant or plant part thereof, where 
the inhibitory sequences are operably linked to a promoter 
In this manner, one aspect of the present invention is 
directed to a method of screening for a nicotine demethylase 
sequence. This method comprises obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 
with SEQ ID N0:3 or SEQ ID N0:5; and identifYing within 20 
this nucleic acid sequence a codon sequence encoding for a 
tryptophan residue at position 329 of the polypeptide encoded 
by the nucleic acid sequence. In some embodiments, this 
nucleic acid sequence also encodes an isoleucine at position 
27 4 of the encoded polypeptide. Any suitable method known 25 
in the art can be used to identify the codon sequence encoding 
the tryptophan or isoleucine residue. In one embodiment, the 
codon sequence is identified by a method selected from the 
group consisting of identifYing a single nucleotide polymor-
phism and RT-PCR. In some embodiments of this aspect of 30 
the invention, the screening method identifies a nicotine dem-
ethylase that converts nicotine to nomicotine at a rate that is at 
least about 5-fold greater than the conversion rate of the 
nicotine demethylase encoded by SEQ ID N0:3 (polypeptide 
set forth in SEQ ID N0:4) or SEQ ID N0:5 (polypeptide set 35 
forth in SEQ ID N0:6). In particular embodiments, the nico-
tine demethylase identified with this screening method has a 
conversion rate that is at least about 8-fold greater than the 
conversion rate of the nicotine demethylase encoded by SEQ 
that is functional in a plant cell. In this manner, expression 
cassettes comprising all or part of the sequence set forth in 
SEQ ID N0:1, 3, 5, 7, 9, or 11, a complement or fragment 
thereof, or sequences sharing substantial sequence identity to 
SEQ ID N0:1, 3, 5, 7, 9, 11, or a complement or fragment 
thereof, operably linked to a promoter that is functional in a 
plant cell are constructed for use in the gene-silencing meth-
ods of the present invention described herein below. Such 
sequences are referred to herein as "inhibitory sequences" or 
"inhibitory polynucleotide sequences" as they are capable of 
being expressed as an RNA molecule that inhibits expression 
(i.e, transcription and/or translation) of the target cytochrome 
P450 polypeptide, for example, the polypeptide set forth in 
SEQ ID N0:2, 4, 6, or 8 and variants thereof, or a polypeptide 
comprising the sequence set forth in SEQ ID NO: 10 or 12 and 
variants thereof, where the variant polypeptides have substan-
tial sequence identity to these disclosed cytochrome P450 
polypeptides and are involved in the metabolic conversion of 
nicotine to nomicotine in a plant. 
As noted above, such inhibitory sequences include frag-
ment sequences of the target cytochrome P450 polynucle-
ID N0:3 or SEQ ID N0:5. 
In another aspect, the present invention provides a method 
for screening for a nicotine demethylase having an isoleucine 
40 otides. For example, a fragment sequence can include any 
portion of the cytochrome P450 sequence, including coding 
and non-coding sequence (e.g., 5' UTR, intron, and 3' UTR 
sequences), and can include fragments of between about 20 at position 274 or a tryptophan at position 329 of the polypep-
tide. This method comprises obtaining a nucleic acid 
sequence that has greater than about 90% sequence identity 45 
with SEQ ID N0:3 or SEQ ID N0:5; and identifying a first 
codon sequence encoding for an isoleucine residue at position 
274 of the encoded polypeptide or a second codon sequence 
encoding a tryptophan residue at position 329 of the encoded 
polypeptide. As noted above, any suitable method known to 50 
those of skill in the art can be used to identify these codons. In 
one embodiment, either or both of the first and second codons 
are identified by a method selected from the group consisting 
and about 400 nucleotides, between about 50 and about 400 
nucleotides, between about 100 and about 400 nucleotides, 
between about 125 and about 325 nucleotides, between about 
125 and about 300 nucleotides, or between about 125 and 
about 275 nucleotides. 
In this marmer, such inhibitory sequences include, but are 
not limited, sequences that comprise a fragment of a cyto-
chrome P450 polynucleotide sequence ranging from at least 
about 20 nucleotides, about 50 nucleotides, about 70 nucle-
otides, about 100 nucleotides, about 150 nucleotides, about 
200 nucleotides, about 250 nucleotides, about 300 nucle-
otides, about 350 nucleotides, and up to the full-length poly-
nucleotide encoding the proteins of the invention, depending 
upon the desired outcome. In one aspect, the inhibitory 
sequences comprise a fragment of a cytochrome P450 poly-
nucleotide sequence that is between about 50 and about 400 
nucleotides, between about 50 and about 350 nucleotides, 
between about 70 and about 350 nucleotides, between about 
90 and about 325 nucleotides, between about 90 and about 
300 nucleotides, between about 90 and about 275 nucle-
otides, between about 100 and about 400 nucleotides, 
of identifYing a single nucleotide polymorphism and RT-
PCR. In some embodiments of this aspect of the invention, the 55 
screening method identifies a nicotine demethylase that con-
verts nicotine to nornicotine at a rate that is at least about 
5-fold greater than the conversion rate of the nicotine dem-
ethylase encoded by SEQ ID N0:3 (polypeptide set forth in 
SEQ ID N0:4) or SEQ ID NO: 5 (polypeptide set forth in SEQ 60 
ID N0:6). In particular embodiments, the nicotine demethy-
lase identified with this screening method has a conversion 
rate that is at least about 8-fold greater than the conversion 
rate of the nicotine demethylase encoded by SEQ ID N0:3 or 
SEQIDN0:5. 65 between about 100 and about 350 nucleotides, between about 
100 and about 325 nucleotides, between about 100 and about 
300 nucleotides, between about 125 and about 300 nucle-
The present invention also provides transgenic plant cells, 
plants, and seed comprising a nucleic acid molecule having a 
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otides, or between about 125 and about 275 nucleotides in 
length. In some embodiments, the inhibitory sequences com-
prise a fragment of a cytochrome P450 polynucleotide 
sequencethatisabout50,about60,about70,about80,about 
90, about 100, about 125, about 150, about 175, about 200, 5 
about225,about250,about275,about300,about325,about 
350, about 400 nucleotides in length, and other such values 
between about 50 and about 400 nucleotides. It is recognized 
that the inhibitory sequence can also comprise a sequence that 
is complementary to all or a part of the fragment of the 10 
cytochrome P450 polynucleotide sequence. 
In one such embodiment, the inhibitory sequences com-
prise a fragment of a cytochrome P450 polynucleotide of the 
invention that is about 90 bp to about 110 bp in length, 
including 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 15 
103, 104, 105, 106, 107, 108, 109, and 110 bp in length, and 
can also comprise a sequence that is complementary to all or 
a part of the fragment sequence. In another such embodiment, 
a fragment of a cytochrome P450 polynucleotide of the inven-
tion is about 290 to about 310 bp in length, including 290, 20 
291,292,293,294,295,296,297,298,299,300,301,302, 
303, 304, 305, 306, 307, 308, 309, and 310 bp in length, and 
can also comprise a sequence that is complementary to all or 
a part of the fragment sequence. 
In other embodiments of the invention, the inhibitory 25 
sequence within an expression cassette of the invention com-
prises a polynucleotide sequence containing the nucleotides 
from about position 265 to about position 625 of a cyto-
chrome P450 coding sequence disclosed herein and sequence 
that is fully or partially complementary thereto. In some of 30 
these embodiments, the inhibitory sequence comprises the 
nucleotides corresponding to about position 297 to about 
position 594 of the P450 coding sequence set forth in SEQ ID 
N0:3 or SEQ ID N0:5 and a sequence that is fully or partially 
complementary thereto. In preferred embodiments, such 35 
inhibitory sequences are expressed as a hairpin RNA as 
described herein below. 
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"functional" is intended the promoter, when operably linked 
to an inhibitory sequence encoding an inhibitory nucleotide 
molecule (for example, a hairpin RNA, double-stranded 
RNA, miRNA polynucleotide, and the like), the promoter is 
capable of initiating transcription of the operably linked 
inhibitory sequence such that the inhibitory nucleotide mol-
ecule is expressed. The promoters can be selected based on 
the desired outcome. The nucleic acids can be combined with 
constitutive, tissue-preferred, or other promoters for expres-
sion in plants. 
An expression cassette of the present invention may also 
contain at least one additional gene to be cotransformed into 
the plant. Alternatively, the additional gene(s) can be pro-
vided on multiple expression cassettes. Such an expression 
cassette is provided with a plurality of restriction sites and/or 
recombination sites for insertion of the cytochrome P450 
inhibitory polynucleotide sequence to be under the transcrip-
tional regulation of the regulatory regions. The expression 
cassette may additionally contain selectable marker genes. 
In this manner, an expression cassette of the present inven-
tion includes a transcriptional and translational initiation 
region (i.e., a promoter) in the 5'-3' direction of transcription, 
an inhibitory sequence as described elsewhere herein, and a 
transcriptional and translational termination region (i.e., ter-
mination region) functional in a plant cell. The regulatory 
regions (i.e., promoters, transcriptional regulatory regions, 
and translational termination regions) and/or the inhibitory 
sequence of the invention may be native/analogous to the host 
cell or to each other. Alternatively, the regulatory regions 
and/or the inhibitory sequence of the invention may be het-
erologous to the host cell or to each other. While heterologous 
promoters can be used to express the inhibitory sequences of 
the invention, native promoter sequences may also be used. 
The termination region may be native with the transcrip-
tional initiation region, may be native with the operably 
linked inhibitory sequence of the invention, may be native 
with the plant host, or may be derived from another source 
(i.e., foreign or heterologous to the promoter, the inhibitory 
sequence of interest, the plant host, or any combination 
In yet other embodiments of the invention, the inhibitory 
sequence within an expression cassette of the invention com-
prises a polynucleotide sequence containing the nucleotides 
from about position 1420 to about position 1580 of a cyto-
chrome P450 coding sequence disclosed herein and a 
sequence that is fully or partially complementary thereto. In 
some of these embodiments, the inhibitory sequence com-
prises the nucleotides corresponding to about position 1453 
to about position 1551 of the P450 coding sequence set forth 
in SEQ ID NO: 1 and a sequence that is fully or partially 
complementary thereto. In preferred embodiments, such 
inhibitory sequences are expressed as a hairpin RNA as 
described herein below. 
40 thereof). Convenient termination regions are available from 
the Ti-plasmid of A. tumefaciens, such as the octopine syn-
thase and nopaline synthase termination regions. See also 
Guerineau et a!. (1991) Mol. Gen. Genet. 262:141-144; 
Proudfoot (1991) Cell 64:671-674; Sanfacon et a!. (1991) 
45 Genes Dev. 5:141-149; Mogen et a!. (1990) Plant Cell 
2:1261-1272; Munroe eta!. (1990) Gene 91:151-158; Ballas 
eta!. (1989)NucleicAcids Res. 17:7891-7903; and Joshi eta!. 
(1987) Nucleic Acids Res. 15:9627-9639. 
Expression cassettes of the present invention may addition-
50 ally contain 5' leader sequences that can act to enhance trans-
lation. Translation leaders are known in the art and include: It is recognized that expression cassettes of the present 
invention encompass constructs in which a desired nucleic 
acid sequence is operably linked to a promoter that is func-
tional in a plant cell, particularly in the cell of a Nicotiana 
plant. By "promoter" is intended a regulatory region of DNA 55 
usually comprising a TATA box capable of directing RNA 
polymerase II to initiate RNA synthesis at the appropriate 
transcription initiation site for a particular polynucleotide 
sequence. A promoter may additionally comprise other rec-
ognition sequences generally positioned upstream or 5' to the 60 
TATA box, referred to as upstream promoter elements, which 
influence the transcription initiation rate. It is also recognized 
that expression cassettes of the present invention encompass 
additional domains that modulate the level of expression, the 
developmental timing of expression, or tissue type that 65 
expression occurs in (e.g., Australian Patent No. AU-A-
77751/94 and U.S. Pat. Nos. 5,466,785 and 5,635,618). By 
picornavirus leaders, for example, EMCV leader (Encepha-
lomyocarditis 5' noncoding region) (Elroy-Stein eta!. (1989) 
Proc. Nat!. A cad. Sci. USA 86:6126-6130); potyvirus leaders, 
for example, TEV leader (Tobacco Etch Virus) (Gallie eta!. 
(1995) Gene 165(2):233-238), MDMV leader (Maize Dwarf 
Mosaic Virus) (Virology 154:9-20), and human immunoglo-
bulin heavy-chain binding protein (BiP) (Macejak et a!. 
(1991) Nature 353:90-94); untranslated leader from the coat 
protein mRNA of alfalfa mosaic virus (AMY RNA 4) 
(Jobling eta!. (1987) Nature 325:622-625); tobacco mosaic 
virus leader (TMV) (Gallie eta!. (1989) in Molecular Biology 
of RNA, ed. Cech (Liss, New York), pp. 237 -256); and maize 
chlorotic mottle virus leader (MCMV) (Lamme! eta!. (1991) 
Virology 81:382-385). See also, Della-Cioppa eta!. (1987) 
Plant Physiol. 84:965-968. Other methods known to enhance 
translation can also be utilized. 
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In preparing the expression cassette, DNA fragments of the 
invention may be manipulated so as to provide for the DNA 
sequences in the proper orientation and, as appropriate, in the 
proper reading frame. Adapters or linkers may be employed 
to join the DNA fragments or other manipulations may be 5 
involved to provide for convenient restriction sites, removal 
24 
activated by salicylic acid. Other chemical-inducible promot-
ers of interest include steroid-responsive promoters (see, for 
example, the glucocorticoid-inducible promoter in Schena et 
a!. (1991) Proc. Nat!. Acad. Sci. USA 88:10421-10425 and 
McNellis eta!. (1998) Plant J. 14(2):247-257) and tetracy-
cline-inducible promoters (see, for example, Gatz et a!. 
(1991) Mol. Gen. Genet. 227:229-237, and U.S. Pat. Nos. 
5,814,618 and 5,789,156), herein incorporated by reference. 
Constitutive promoters include, for example, the core pro-
of superfluous DNA, removal of restriction sites, or the like. 
For this purpose, in vitro mutagenesis, primer repair, restric-
tion, annealing, resubstitutions, e.g., transitions and transver-
sions, may be involved. 1 o mater of the Rsyn 7 promoter and other constitutive promoters 
disclosed in U.S. Pat. No. 6,072,050; the core CaMV 35S 
promoter (Odell eta!. (1985) Nature 313:810-812); ubiquitin 
(Christensen eta!. (1989) Plant Mol. Biol. 12:619-632 and 
The expression cassettes of the present invention can also 
comprise a selectable marker gene for the selection of trans-
formed cells. Selectable marker genes are utilized for the 
selection of transformed cells or tissues. Marker genes 
include genes encoding antibiotic resistance, such as those 15 
encoding neomycin phosphotransferase II (NEO) and hygro-
mycin phosphotransferase (HPT), as well as genes conferring 
resistance to herbicidal compounds, such as glufosinate 
ammonium, bromoxynil, imidazolinones, and 2,4-dichlo-
rophenoxyacetate (2,4-D). Additional selectable markers 20 
include phenotypic markers such as ~-galactosidase and fluo-
rescent proteins such as green fluorescent protein (GFP) 
(Rouwendal eta!. (1997) Plant Mo. Biol. 33:989-999; Suet 
a!. (2004)BiotechnolBioeng 85:610-9 and Fetter eta!. (2004) 
Plant Cell16:215-28), cyan florescent protein (CYP) (Bolte 25 
eta!. (2004).1. Cell Science 117:943-54 andKato eta!. (2002) 
Plant Physiol 129:913-42), and yellow fluorescent protein 
(PhiYFP™ from Evrogen, see, Bolte et a!. (2004) J. Cell 
Science 117:943-954). For additional selectable markers, see 
generally, Yarranton (1992) Curr. Opin. Biotech. 3:506-511; 30 
Christopherson et a!. (1992) Proc. Nat!. Acad. Sci. USA 
89:6314-6318; Yao et a!. (1992) Cell 71:63-72; Reznikoff 
(1992) Mol. Microbial. 6:2419-2422; Barkley eta!. (1980) in 
The Operon, pp. 177 -220; Hu eta!. (1987) Cell 48:555-566; 
Brown eta!. (1987) Cell49:603-612; Figge eta!. (1988) Cell 35 
52:713-722; Deuschle eta!. (1989) Proc. Nat!. Acad. Aci. 
USA 86:5400-5404; Fuerst eta!. (1989) Proc. Nat!. A cad. Sci. 
USA 86:2549-2553; Deuschle eta!. (1990) Science 248:480-
483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; 
Reines eta!. (1993) Proc. Nat!. Acad. Sci. USA 90:1917- 40 
1921; La bow et a!. (1990) Mol. Cell. Biol. 1 0:3343-3356; 
Zambretti eta!. (1992) Proc. Nat!. Acad. Sci. USA 89:3952-
3956; Baimetal. (1991)Proc. Nat!. Acad. Sci. USA 88:5072-
5076; Wyborski et a!. (1991) Nucleic Acids Res. 19:4647-
4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 45 
10:143-162; Degenkolb et a!. (1991) Antimicrob. Agents 
Chemother. 35:1591-1595; Kleinschnidt et a!. (1988) Bio-
chemistry 27: 1094-1104; Bonin (1993) Ph.D. Thesis, Univer-
sity ofHeidelberg; Gossen eta!. (1992) Proc. Nat!. A cad. Sci. 
USA 89:5547-5551; Oliva eta!. (1992) Antimicrob. Agents 50 
Chemother. 36:913-919; Hlavka eta!. (1985) Handbook of 
Experimental Pharmacology, Vol. 78 (Springer-Verlag, Ber-
lin); Gillet a!. (1988) Nature 334:721-724. Such disclosures 
are herein incorporated by reference. The above list of select-
able marker genes is not meant to be limiting. Any selectable 55 
marker gene can be used in the present invention. 
A number of promoters can be used in the practice of the 
invention. Of particular interest are constitutive promoters, 
inducible promoters, particularly chemical-inducible pro-
moters, and tissue-preferred promoters, particularly leaf-pre- 60 
ferred promoters. 
Chemical-inducible promoters can be used to inhibit the 
expression of a cytochrome P450 that is involved in the meta-
bolic conversion of nicotine to nomicotine in a plant through 
the application of an exogenous chemical regulator. Chemi- 65 
cal-inducible promoters are known in the art and include, but 
are not limited to, the tobacco PR-1a promoter, which is 
Christensen et a!. (1992) Plant Mol. Biol. 18:675-689); 
pEMU (Last eta!. (1991) Theon. Appl. Genet. 81:581-588); 
MAS (Velten et a!. (1984) EMBO J. 3:2723-2730); ALS 
promoter (U.S. Pat. No. 5,659,026), and the like. Other con-
stitutive promoters include, for example, U.S. Pat. Nos. 
5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 
5,399,680; 5,268,463; 5,608,142; and 6,177,611. 
Tissue-preferred promoters can be utilized to target expres-
sion of an inhibitory polynucleotide sequence of the present 
invention within a particular plant tissue. Tissue-preferred 
promoters include Yamamoto eta!. (1997)PlantJ. 12(2):255-
265; Kawamata eta!. (1997) Plant Cell Physiol. 38(7):792-
803; Hansen eta!. (1997) Mol. Gen Genet. 254(3):337-343; 
Russell eta!. (1997) Transgenic Res. 6(2): 157-168; Rinehart 
eta!. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et 
a!. (1996) Plant Physiol. 112(2):525-535; Canevascini eta!. 
(1996) Plant Physiol. 112(2):513-524; Yamamoto et a!. 
(1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) 
Results Probl. Cell Differ. 20:181-196; Orozco eta!. (1993) 
Plant Mol Biol. 23(6):1129-1138; Matsuoka eta!. (1993) 
Proc Nat!. Acad. Sci. USA 90(20):9586-9590; and Guevara-
Garcia eta!. (1993) Plant J. 4(3):495-505. 
Of particular interest are leaf-preferred promoters that pro-
vide for expression predominately in leaf tissues. See, for 
example, Yamamoto et a!. (1997) Plant J. 12(2):255-265; 
Kwon eta!. (1994) Plant Physiol. 105:357-67; Yamamoto et 
a!. (1994) Plant Cell Physiol. 35(5):773-778; Gator et a!. 
(1993) Plant J. 3:509-18; Orozco eta!. (1993) Plant Mol. 
Biol. 23(6):1129-1138; Baszczynski eta!. (1988) Nucl. Acid 
Res. 16:4732; Mitra eta!. (1994) Plant Molecular Biology 
26:35-93; Kayaya et a!. (1995) Molecular and General 
Genetics 248:668-674; and Matsuoka eta!. (1993)Proc. Nat!. 
A cad. Sci. USA 90(20):9586-9590. Senecence-regulated pro-
moters are also of use, such as SAM22 (Crowell eta!. (1992) 
Plant Mol. Biol. 18:459-466); SAG12 (Lohman eta!. (1994) 
Physiol. Plant. 92:322-328; Wingler et a!. (1998) Plant 
Physiol. 116:329-335); SAG 13 (Gan and Amasino (1997) 
PlantPhysiol. 113:313-319; SAG15 (Gan (1995) "Molecular 
Characterization and Genetic Manipulation of Plant Senes-
cence," Ph.D. Thesis, University of Wisconsin, Madison); 
SENT (Oh eta!. (1996) Plant Mol. Biol. 30:739-754; pro-
moter of a senescence-specific gene for expression of IPT 
(Gan and Amasino 91995) Science 270: 1986-1988); and the 
like (see, for example, Or: eta!. (1999) Plant Cell11:1073-
1080 and McCabe eta!. (2001) Plant Physiol. 127:505-516). 
Methods for Inhibiting Expression or Function of a Cyto-
chrome P450 Involved in the Conversion of Nicotine to Nor-
nicotine 
Methods of reducing the concentration, content, and/or 
activity of a cytochrome P450 polypeptide of the present 
invention in a Nicotiana plant or plant part, particularly the 
leaf tissue, are provided. Many methods may be used, alone or 
in combination, to reduce or eliminate the activity of a cyto-
chrome P450 polypeptide of the present invention. In addi-
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tion, combinations of methods may be employed to reduce or 
eliminate the activity of two or more different cytochrome 
P450 polypeptides. 
In accordance with the present invention, the expression of 
a cytochrome P450 polypeptide of the present invention is 
inhibited if the protein level of the cytochrome P450 polypep-
tide is statistically lower than the protein level of the same 
cytochrome P450 polypeptide in a plant that has not been 
genetically modified or mutagenized to inhibit the expression 
of that cytochrome P450 polypeptide, and where these plants 10 
have been cultured and harvested using the same protocols. In 
particular embodiments of the invention, the protein level of 
the cytochrome P450 polypeptide in a modified plant accord-
ing to the invention is less than 95%, less than 90%, less than 
80%, less than 70%, less than 60%, less than 50%, less than 15 
40%, less than 30%, less than 20%, less than 10%, less than 
5%, less than 4%, less than 3%, less than 2%, or less than 1% 
of the protein level of the same cytochrome P450 polypeptide 
in a plant that is not a mutant or that has not been genetically 
modified to inhibit the expression of that cytochrome P450 20 
polypeptide and which has been cultured and harvested using 
the same protocols. The expression level of the cytochrome 
P450 polypeptide may be measured directly, for example, by 
assaying for the level of the cytochrome P450 transcript or 
cytochrome P450 polypeptide expressed in the Nicotiana 25 
plant or plant part, or indirectly, for example, by measuring 
the conversion of nicotine to nornicotine in the Nicotiana 
plant or plant part. Methods for monitoring the expression 
level of a protein are known in the art, and include, but are not 
limited to, Northern blot analysis as discussed in the 30 
examples herein below. Methods for determining the activity 
of the targeted cytochrome P450 polypeptide in converting 
nicotine to nornicotine are described elsewhere herein below, 
and include, but are not limited to, alkaloid analysis using gas 
chromatography, for example the procedures described in the 35 
examples herein below. 
In other embodiments of the invention, the activity of one 
or more cytochrome P450 polypeptides is reduced or elimi-
nated by transforming a plant or plant part with an expression 
cassette comprising a polynucleotide encoding a polypeptide 40 
that inhibits the activity of one or more cytochrome P450 
polypeptides of the present invention. The activity of a cyto-
chrome P450 polypeptide in converting nicotine to nornico-
tine in a Nicotiana plant or plant part is inhibited according to 
the present invention if this conversion activity is statistically 45 
lower than conversion activity of the same cytochrome P450 
polypeptide in aNicotiana plant or plant part that has not been 
genetically modified to inhibit the conversion activity of that 
cytochrome P450 polypeptide and which has been cultured 
and harvested using the same protocols. In particular embodi- 50 
ments, activity of a cytochrome P450 polypeptide in convert-
ing nicotine to nornicotine in a modified Nicotiana plant or 
plant part according to the invention is inhibited if the activity 
is less than 95%, less than 90%, less than 80%, less than 70%, 
less than 60%, less than 50%, less than 40%, less than 30%, 55 
less than 20%, less than 10%, less than 5%, less than 4%, less 
than 3%, less than 2%, or less than 1% of the conversion 
activity of the same cytochrome P450 polypeptide in a Nic-
otiana plant that that has not been genetically modified to 
inhibit the expression of that cytochrome P450 polypeptide 60 
and which has been cultured and harvested using the same 
protocols. The activity of a cytochrome P450 polypeptide in 
converting nicotine to nornicotine in a Nicotiana plant or 
plant part is eliminated according to the invention when it is 
not detectable by the assay methods described elsewhere 65 
herein. Methods of determining the activity of a cytochrome 
P450 polypeptide in converting nicotine to nornicotine in a 
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Nicotiana plant or plant part are described elsewhere herein, 
and include the alkaloid analyses using gas chromatography 
disclosed in the examples herein below. 
In specific embodiments, a cytochrome P450 inhibitory 
polynucleotide sequence described herein is introduced into a 
Nicotiana plant or plant part. Subsequently, a Nicotiana plant 
or plant part having the introduced inhibitory polynucleotide 
sequence of the invention is selected using methods known to 
those of skill in the art such as, but not limited to, Southern 
blot analysis, DNA sequencing, PCR analysis, or phenotypic 
analysis. A plant or plant part altered or modified by the 
foregoing embodiments is grown under plant forming condi-
tions for a time sufficient to modulate the concentration and/ 
or activity of polypeptides of the present invention in the 
plant. Plant forming conditions are well known in the art and 
discussed briefly elsewhere herein. 
In some embodiments, a transformed tobacco plant con-
taining a cytochrome P450 inhibitory polynucleotide 
sequence described herein has a reduced level of conversion 
of nicotine to nornicotine. In particular embodiments, con-
version of nicotine to nornicotine in a transformed tobacco 
plant or plant part according to the invention is less than 95%, 
less than 90%, less than 80% less than 70%, less than 60%, 
less than 50%, less than 40%, less than 30%, less than 20% 
less than 10%, less than 5%, less than 4%, less than 3%, less 
than 2%, or less than 1% of the conversion in a tobacco plant 
that that has not been genetically modified to inhibit the 
expression of that cytochrome P450 polypeptide and which 
has been cultured and harvested using the same protocols. In 
some embodiments, the transformed tobacco plant is a con-
verter tobacco plant. In some embodiments, the transformed 
tobacco plant has a conversion rate lower than the rate 
observed in commercial nonconverter tobacco plants. 
It is also recognized that the level and/or activity of the 
polypeptide may be modulated by employing a polynucle-
otide that is not capable of directing, in a transformed plant, 
the expression of a protein or an RNA. For example, the 
polynucleotides of the invention may be used to design poly-
nucleotide constructs that can be employed in methods for 
altering or mutating a genomic nucleotide sequence in an 
organism. Such polynucleotide constructs include, but are not 
limited to, RNA:DNA vectors, RNA:DNA mutational vec-
tors, RNA:DNA repair vectors, mixed-duplex oligonucle-
otides, self-complementary RNA:DNA oligonucleotides, 
and recombinogenic oligonucleobases. Such nucleotide con-
structs and methods of use are known in the art. See, U.S. Pat. 
Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 5,795,972; 
and 5,871,984; all of which are herein incorporated by refer-
ence. See also, WO 98/49350, WO 99/07865, WO 99/25821, 
and Beetham et a!. (1999) Proc. Nat!. Acad. Sci. USA 
96:8774-8778; herein incorporated by reference. 
It is therefore recognized that methods of the present inven-
tion do not depend on the incorporation of the entire cyto-
chrome P450 inhibitory polynucleotide into the genome, only 
that the Nicotiana plant or plant part thereof is altered as a 
result of the introduction of this inhibitory polynucleotide 
into a cell. In one embodiment of the invention, the genome 
may be altered following the introduction of the cytochrome 
P450 inhibitory polynucleotide into a cell. For example, the 
inhibitory polynucleotide, or any part thereof, may incorpo-
rate into the genome of the plant. Alterations to the genome 
include, but are not limited to, additions, deletions, and sub-
stitutions of nucleotides into the genome. While the methods 
of the present invention do not depend on additions, deletions, 
and substitutions of any particular number of nucleotides, it is 
recognized that such additions, deletions, or substitutions 
comprise at least one nucleotide. 
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It is further recognized that reducing the level and/or activ-
ity of a cytochrome P450 sequence of the present invention 
can be performed to elicit the effects of the sequence only 
during certain developmental stages and to switch the effect 
off in other stages where expression is no longer desirable. 
Control of cytochrome P450 expression can be obtained via 
the use of inducible or tissue-preferred promoters. Alterna-
tively, the gene could be inverted or deleted using site-specific 
recombinases, transposons or recombination systems, which 
would also turn on or off expression of the cytochrome P450 
sequence. 
According to the present invention, changes in levels, 
ratios, activity, or distribution of cytochrome P450 polypep-
tides of the present invention, or changes inNicotiana plant or 
plant part phenotype, particularly reduced accumulation of 
nornicotine and its carcinogenic metabolite, NNN, could be 
measured by comparing a subject plant or plant part to a 
control plant or plant part, where the subject plant or plant part 
and the control plant or plant part have been cultured and/or 
harvested using the same protocols. As used herein, a subject 
plant or plant part is one in which genetic alteration, such as 
transformation, has been affected as to the cytochrome P450 
polypeptide of interest, or is a Nicotiana plant or plant part 
that is descended from a Nicotiana plant or plant part so 
altered and which comprises the alteration. A control plant or 
plant part provides a reference point for measuring changes in 
phenotype of the subject plant or plant part. 
The measurement of changes in phenotype can be mea-
sured at any time in a plant or plant part, including during 
plant development, senescence, or after curing. In other 
embodiments, the measurement of changes in phenotype can 
be measured in plants grown under any conditions, including 
from plants grown in a growth chamber, greenhouse, or in a 
field. In one embodiment, changes in phenotype can be mea-
sured by determining the nicotine to nornicotine conversion 
rate. In a preferred embodiment, conversion can be measured 
by dividing the percentage of nornicotine (as a percentage of 
the total tissue weight) by the sum of the percentage nicotine 
and nornicotine (as percentages of the total tissue weight) and 
multiplying by 100. 
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polypeptide that is involved in the metabolic conversion of 
nicotine to nornicotine. In some embodiments, the inhibitory 
sequence is introduced by transformation of the plant or plant 
part, such as a plant cell, with an expression cassette that 
expresses a polynucleotide that inhibits the expression of the 
cytochrome P450 polypeptide. The polynucleotide may 
inhibit the expression of a cytochrome P450 polypeptide 
directly, by preventing translation of the cytochrome P450 
polypeptide messenger RNA, or indirectly, by encoding a 
10 polypeptide that inhibits the transcription or translation of an 
cytochrome P450 polypeptide gene encoding a cytochrome 
P450 polypeptide. Methods for inhibiting or eliminating the 
expression of a gene product in a plant are well known in the 
art, and any such method may be used in the present invention 
15 to inhibit the expression of cytochrome P450 polypeptides. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention may be reduced or elimi-
nated by disrupting the gene encoding the cytochrome P450 
polypeptide. The invention encompasses mutagenized plants 
20 that carry mutations in cytochrome P450 genes, where the 
mutations reduce expression of the cytochrome P450 gene or 
inhibit the activity of an encoded cytochrome P450 polypep-
tide of the present invention. 
In some embodiments of the present invention, a Nicotiana 
25 plant or plant part is transformed with an expression cassette 
that is capable of expressing a polynucleotide that inhibits the 
expression of a cytochrome P450 sequence. Such methods 
may include the use of sense suppression/cosuppression, 
antisense suppression, double-stranded RNA ( dsRNA) inter-
30 ference, hairpin RNA interference and intron-containing 
hairpin RNA interference, amplicon-mediated interference, 
ribozymes, and small interfering RNA or micro RNA. 
For cosuppression, an expression cassette is designed to 
express an RNA molecule corresponding to all or part of a 
35 messenger RNA encoding a cytochrome P450 polypeptide of 
interest (for example, a cytochrome P450 polypeptide com-
prising the sequence set forth in SEQ ID N0:2, 4, 6, 8, 10, or 
12 or a sequence having substantial sequence identity to SEQ 
ID N0:2, 4, 6, 8, 10, or 12) in the "sense" orientation. Over 
40 expression of the RNA molecule can result in reduced expres-
sion of the native gene. Multiple plant lines transformed with 
the cosuppression expression cassette are then screened to 
identify those that show the greatest inhibition of cytochrome 
According to the present invention, a control plant or plant 
part may comprise a wild-type Nicotiana plant or plant part, 
i.e., of the same genotype as the starting material for the 
genetic alteration that resulted in the subject plant or plant 
part. A control plant or plant part may also comprise a Nic- 45 
otiana plant or plant part of the same genotype as the starting 
material but that has been transformed with a null construct 
(i.e., with a construct that has no known effect on the trait of 
interest, such as a construct comprising a selectable marker 
gene). Alternatively, a control plant or plant part may com-
prise a Nicotiana plant or plant part that is a non-transformed 
segregant among progeny of a subject plant or plant part, or a 
Nicotiana plant or plant part genetically identical to the sub-
ject plant or plant part but that is not exposed to conditions or 
stimuli that would induce suppression of the cytochrome 
P450 gene of interest. Finally, a control plant or plant part 
may comprise the subject plant or plant part itself under 
conditions in which the cytochrome P450 inhibitory 
sequence is not expressed. In all such cases, the subject plant 
P450 polypeptide expression. 
The polynucleotide used for cosuppression may corre-
spond to all or part of the sequence encoding a cytochrome 
P450 polypeptide or the present invention, all or part of the 5' 
and/or 3' untranslated region of a cytochrome P450 polypep-
tide transcript, or all or part of both the coding sequence and 
50 the untranslated regions of a transcript encoding a cyto-
chrome P450 polypeptide. In some embodiments where the 
polynucleotide comprises all or part of the coding region for 
a cytochrome P450 polypeptide of the present invention, the 
expression cassette is designed to eliminate the start codon of 
55 the polynucleotide so that no protein product will be tran-
scribed. 
Cosuppression may be used to inhibit the expression of 
plant genes to produce plants having undetectable protein 
levels for the proteins encoded by these genes or may also be 
used to inhibit the expression of multiple proteins in the same 
plant (e.g., Brain eta!. (2002) Plant Cell14:1417-1432; U.S. 
Pat. No. 5,942,657). Methods for using cosuppression to 
inhibit the expression of endogenous genes in plants are 
described in Flavell eta!. (1994) Proc. Nat!. Acad. Sci. USA 
91:3490-3496; Jorgensen et a!. (1996) Plant Mol. Biol. 
31:957-973; Johansen and Carrington (2001) Plant Physiol. 
126:930-938; Brain eta!. (2002) Plant Cell 14: 1417-1432; 
or plant part and the control plant or plant part are cultured 60 
and harvested using the same protocols. 
As described elsewhere herein, methods are provided to 
reduce or eliminate the activity and/or concentration of a 
cytochrome P450 polypeptide of the present invention by 
introducing into a Nicotiana plant or plant part a cytochrome 65 
P450 inhibitory polynucleotide sequence that is capable of 
inhibiting expression or function of a cytochrome P450 
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Stoutjesdijk eta!. (2002) Plant Physiol. 129:1723-1731; Yu et 
a!. (2003) Phytochemistry 63:753-763; and U.S. Pat. Nos. 
5,034,323, 5,283,184, and 5,942,657; each of which is herein 
incorporated by reference. The efficiency of cosuppression 
may be increased by including a poly-dT region in the expres-
sion cassette at a position 3' to the sense sequence and 5' of the 
polyadenylation signal. See, U.S. Patent Publication No. 
20020048814, herein incorporated by reference. Typically, 
such a nucleotide sequence has substantial sequence identity 
30 
then screened to identify plant lines that show the greatest 
inhibition of expression of the targeted cytochrome P450 
polypeptide. Methods for using dsRNA interference to inhibit 
the expression of endogenous plant genes are described in 
Waterhouse et a!. (1998) Proc. Nat!. Acad. Sci. USA 
95:13959-13964, Liu eta!. (2002) Plant Physiol. 129:1732-
1743, and WO 99/49029, WO 99/53050, WO 99/61631, and 
WO 00/49035; each of which is herein incorporated by ref-
erence. 
to the sequence of the transcript of the endogenous gene, 10 
optimally greater than about 65% sequence identity, more 
optimally greater than about 85% sequence identity, most 
optimally greater than about 95% sequence identity (e.g., 
U.S. Pat. Nos. 5,283,184 and 5,034,323; herein incorporated 
Amplicon expression cassettes comprise a plant virus-de-
rived sequence that contains all or part of the target gene but 
generally not all of the genes of the native virus. The viral 
sequences present in the transcription product of the expres-
sion cassette allow the transcription product to direct its own 
by reference). 15 replication. The transcripts produced by the amplicon may be 
either sense or antisense relative to the target sequence (i.e., 
the messenger RNA for a cytochrome P450 polypeptide that 
is involved in the metabolic conversion of nicotine to norni-
In some embodiments of the invention, inhibition of the 
expression of the cytochrome P450 polypeptide of the present 
invention may be obtained by antisense suppression. For anti-
sense suppression, the expression cassette is designed to 
express an RNA molecule complementary to all or part of a 20 
messenger RNA encoding the cytochrome P450 polypeptide. 
Over expression of the antisense RNA molecule can result in 
reduced expression of the native gene. Accordingly, multiple 
plant lines transformed with the antisense suppression 
expression cassette are screened to identify those that show 25 
the greatest inhibition of cytochrome P450 polypeptide 
cotine ). Methods of using amplicons to inhibit the expression 
of endogenous plant genes are described, for example, in 
Angell and Baulcombe (1997) EMBO J. 16:3675-3684, 
Angell and Baulcombe (1999) Plant J. 20:357-362, and U.S. 
Pat. No. 6,646,805, each of which is herein incorporated by 
reference. 
In additional embodiments of the present invention, the 
polynucleotide expressed by the expression cassette of the 
invention is catalytic RNA or has ribozyme activity specific 
for the messenger RNA of a cytochrome P450 polypeptide 
described herein. Thus, the polynucleotide causes the degra-
expression. 
The polynucleotide for use in antisense suppression may 
correspond to all or part of the complement of the sequence 
encoding the cytochrome P450 polypeptide, all or part of the 
complement of the 5' and/or 3' untranslated region of the 
cytochrome P450 polypeptide transcript, or all or part of the 
complement ofboth the coding sequence and the untranslated 
regions of a transcript encoding the cytochrome P450 
polypeptide. In addition, the antisense polynucleotide may be 
fully complementary (i.e., 100% identical to the complement 
of the target sequence) or partially complementary (i.e., less 
than 100% identical to the complement of the target 
sequence) to the target sequence. Antisense suppression may 
be used to inhibit the expression of multiple proteins in the 
same plant (e.g., U.S. Pat. No. 5,942,657). Furthermore, por-
tions of the antisense nucleotides may be used to disrupt the 
expression of the target gene. Generally, sequences of at least 
50 nucleotides, 100 nucleotides, 200 nucleotides, 300, 400, 
450, 500, 550, or greater may be used. Methods for using 
antisense suppression to inhibit the expression of endogenous 
genes in plants are described, for example, in Liu eta!. (2002) 
Plant Physiol. 129:1732-1743 and U.S. Pat. Nos. 5,759,829 
and 5,942,657, each of which is herein incorporated by ref-
erence. Efficiency of antisense suppression may be increased 
by including a poly-dT region in the expression cassette at a 
position 3' to the antisense sequence and 5' of the polyadeny-
lation signal. See, U.S. Patent Publication No. 20020048814, 
herein incorporated by reference. 
For dsRNA interference, a sense RNA molecule like that 
described above for cosuppression and an antisense RNA 
molecule that is fully or partially complementary to the sense 
RNA molecule are expressed in the same cell, resulting in 
inhibition of the expression of the corresponding endogenous 
messenger RNA. 
30 dation of the endogenous messenger RNA, resulting in 
reduced expression of the cytochrome P450 polypeptide. 
This method is described, for example, in U.S. Pat. No. 4,987, 
071, herein incorporated by reference. 
In further embodiments of the invention, inhibition of the 
35 expression of one or more cytochrome P450 polypeptides 
may be obtained by RNA interference (RNAi) by expression 
of a gene encoding a micro RNA (miRNA). miRNAs are 
regulatory agents consisting of about 22 ribonucleotides. 
miRNA are highly efficient at inhibiting the expression of 
40 endogenous genes. See, for example Javier et a!. (2003) 
Nature 425: 257-263, herein incorporated by reference. 
For miRNA interference, the expression cassette is 
designed to express an RNA molecule that is modeled on an 
endogenous miRNA gene. The miRNA gene encodes an 
45 RNA that forms a hairpin structure containing a 22-nucle-
otide sequence that is complementary to another endogenous 
gene (target sequence). For suppression of cytochrome P450 
polypeptide expression, the 22-nucleotide sequence is 
selected from a cytochrome P450 polypeptide transcript 
50 sequence and contains 22 nucleotides encoding this cyto-
chrome P450 polypeptide sequence in sense orientation and 
21 nucleotides of a corresponding antisense sequence that is 
complementary to the sense sequence. miRNA molecules are 
highly efficient at inhibiting the expression of endogenous 
55 genes, and the RNA interference they induce is inherited by 
subsequent generations of plants. 
In still other embodiments of the invention, inhibition of 
the expression of one or more cytochrome P450 polypeptides 
by RNAi may be obtained by hairpin RNA (hpRNA) inter-
60 ference or intron-containing hairpin RNA (ihpRNA) interfer-
ence. These methods are highly efficient at inhibiting the 
expression of endogenous genes. See, Waterhouse and Hel-
liwell (2003) Nat. Rev. Genet. 4:29-38 and the references 
cited therein. 
Expression of the sense and antisense molecules can be 
accomplished by designing the expression cassette to com-
prise both a sense sequence and an antisense sequence for the 
target cytochrome P450 sequence. Alternatively, separate 
expression cassettes may be used for the sense and antisense 65 
sequences. Multiple plant lines transformed with the dsRNA 
interference expression cassette or expression cassettes are 
For hpRNA interference, the expression cassette is 
designed to express an RNA molecule that hybridizes with 
itself to form a hairpin structure that comprises a single-
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stranded loop region and a base-paired stem. The base-paired 
stem region comprises a sense sequence corresponding to all 
or part of the endogenous messenger RNA encoding the gene 
product whose expression is to be inhibited, in this case, a 
cytochrome P450 polypeptide described herein, and an anti- 5 
sense sequence that is fully or partially complementary to the 
sense sequence. Alternatively, the base-paired stem region 
may correspond to a portion of a promoter sequence control-
ling expression of the gene encoding the cytochrome P450 
polypeptide to be inhibited. Thus, the base-paired stem region 10 
of the molecule generally determines the specificity of the 
RNA interference. hpRNA molecules are highly efficient at 
inhibiting the expression of endogenous genes, and the RNA 
interference they induce is inherited by subsequent genera-
tions of plants. See, for example, Chuang and Meyerowitz 15 
(2000) Proc. Nat!. Acad. Sci. USA 97:4985-4990; Stoutjes-
dijk et a!. (2002) Plant Physiol. 129:1723-1731; and Water-
house and Helliwell (2003) Nat. Rev. Genet. 4:29-38. Meth-
ods for using hpRNA interference to inhibit or silence the 
expression of genes are described, for example, in Chuang 20 
and Meyerowitz (2000) Proc. Nat!. Acad. Sci. USA 97:4985-
4990; Stoutjesdijk et a!. (2002) Plant Physiol. 129:1723-
1731; Waterhouse and Helliwell (2003) Nat. Rev. Genet. 
4:29-38; Pandolfini eta!. BMC Biotechnology 3:7, and U.S. 
Patent Publication No. 2003017 5965; each of which is herein 25 
incorporated by reference. A transient assay for the efficiency 
of hpRNA constructs to silence gene expression in vivo has 
been described by Panstruga et a!. (2003) Mol. Biol. Rep. 
30:135-140, herein incorporated by reference. 
For ihpRNA, the interfering molecules have the same gen- 30 
era! structure as for hpRNA, but the RNA molecule addition-
ally comprises an intron that is capable ofbeing spliced in the 
cell in which the ihpRNA is expressed. The use of an intron 
minimizes the size of the loop in the hairpin RNA molecule 
following splicing, and this increases the efficiency of inter- 35 
ference. See, for example, Smith et a!. (2000) Nature 407: 
319-320. In fact, Smith et a!. show 100% suppression of 
endogenous gene expression using ihpRNA-mediated inter-
ference. Methods for using ihpRNA interference to inhibit the 
expression of endogenous plant genes are described, for 40 
example, in Smith eta!. (2000) Nature 407:319-320; Wesley 
et a!. (2001) Plant J. 27:581-590; Wang and Waterhouse 
(2001) Curr. Opin. Plant Biol. 5:146-150; Waterhouse and 
Helliwell (2003) Nat. Rev. Genet. 4:29-38; Helliwell and 
Waterhouse (2003) Methods 30:289-295, and U.S. Patent 45 
Publication No. 20030180945, each of which is herein incor-
porated by reference. 
In one such embodiment, RNAi is accomplished by 
expressing an inhibitory sequence that comprises a first 
sequence of a cytochrome P450 polynucleotide of the inven- 50 
tion that is about 90 bp to about 110 bp in length, including 90, 
91,92,93,94,95,96,97,98,99,100, 101,102,103,104,105, 
106, 107, 108, 109, and 110 bp in length, and a second 
sequence that is complementary to all or a part of the first 
sequence. In another such embodiment, the inhibitory 55 
sequence comprises a first sequence of a cytochrome P450 
polynucleotide of the invention that is about 290 to about 310 
bp in length, including 290,291,292,293,294,295,296,297, 
298,299,300,301,302,303,304,305,306,307,308,309, 
and 310 bp in length, and a second sequence that is comple- 60 
mentary to all or a part of the fragment sequence. 
In other embodiments of the invention, RNAi is accom-
plished by expressing an inhibitory sequence that comprises 
a first polynucleotide sequence containing the nucleotides 
from about position 265 to about position 625 of a cyto- 65 
chrome P450 coding sequence disclosed herein and a second 
sequence that is fully or partially complementary thereto. In 
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some of these embodiments, the inhibitory sequence com-
prises as the first polynucleotide sequence the nucleotides 
corresponding to about position 297 to about position 594 of 
the P450 coding sequence set forth in SEQ ID N0:3 or SEQ 
ID N0:5 and the second sequence is the complement (i.e., 
antisense sequence) of this first sequence. The inhibitory 
sequence can optionally comprise an intron sequence linked 
between the first and second sequences. Any intron known to 
those of skill in the art can be used in this manner. In some 
embodiments, the intron is from the soybean omega-6 fatty 
acid desaturase (FAD) (see GenBank Accession No. 
DQ672337, and Example 7 herein below). In one such 
embodiment, the intron comprises about 151 nucleotides that 
comprise nucleotides 100-247 of the soybean omega-6 fatty 
acid desaturase polynucleotide shown in GenBankk Acces-
sion No. DQ672337. Examples of other introns include, but 
are not limited to, the intron nucleotide sequences of alcohol 
dehydrogenase (adh1) genes. Expression of this inhibitory 
sequence produces an intron-containing hairpin RNA that 
strongly interferes with expression of the cytochrome P450 
polypeptides disclosed herein. In this manner, Nicotiana 
plants that are normally converters of nicotine to nornicotine 
that are transformed with an expression cassette comprising 
such an inhibitory sequence advantageously have a nicotine 
to nomicotine conversion rate that, surprisingly, is even lower 
than that observed for Nicotiana plants that are nonconverters 
of nicotine to nornicotine. 
In yet other embodiments of the invention, RNAi is accom-
plished by expressing an inhibitory sequence that comprises 
a first polynucleotide sequence containing the nucleotides 
from about position 1420 to about position 1580 of a cyto-
chrome P450 coding sequence disclosed herein and a 
sequence that is fully or partially complementary thereto. In 
some of these embodiments, the inhibitory sequence com-
prises as the first polynucleotide sequence the nucleotides 
corresponding to about position 1453 to about position 1551 
of the P450 coding sequence set forth in SEQ ID NO: 1 and the 
second sequence is the complement (i.e., antisense sequence) 
of this first sequence. The inhibitory sequence can optionally 
comprise an intron sequence linked between the first and 
second sequences. Any intronknown to those of skill in the art 
can be used in this manner, as noted herein above. Expression 
of this inhibitory sequence produces a hairpin RNA (or 
intron-containing hairpin RNA when the intron is present) 
that also interferes with expression of the cytochrome P450 
polypeptides disclosed herein. 
The expression cassette for hpRNA interference may also 
be designed such that the sense sequence and the antisense 
sequence do not correspond to an endogenous RNA. In this 
embodiment, the sense and antisense sequence flank a loop 
sequence that comprises a nucleotide sequence correspond-
ing to all or part of the endogenous messenger RNA of the 
target gene. Thus, it is the loop region that determines the 
specificity of the RNA interference. See, for example, WO 
02/00904, herein incorporated by reference. 
Transcriptional gene silencing (TGS) may be accom-
plished through use of hpRNA constructs wherein the 
inverted repeat of the hairpin shares sequence identity with 
the promoter region of a gene to be silenced. Processing of the 
hpRNA into short RNAs that can interact with the homolo-
gous promoter region may trigger degradation or methylation 
to result in silencing (Aufsatz eta!. (2002) Proc. Nat!. A cad. 
Sci. 99 (Suppl. 4):16499-16506; Mette eta!. (2000) EMBOJ. 
19(19):5194-5201 ). 
In further embodiments, a polynucleotide may be utilized 
that encodes a zinc finger protein that binds to a gene encod-
ing a cytochrome P450 polypeptide, resulting in reduced 
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expression of the gene. In particular embodiments, the zinc 
finger protein binds to a regulatory region of a cytochrome 
P450 polypeptide gene. In other embodiments, the zinc finger 
protein binds to a messenger RNA encoding a cytochrome 
P450 polypeptide and prevents its translation. Methods of 5 
selecting sites for targeting by zinc finger proteins have been 
described, for example, in U.S. Pat. No. 6,453,242, and meth-
ods for using zinc finger proteins to inhibit the expression of 
genes in plants are described, for example, in U.S. Patent 
Publication No. 20030037355; each of which is herein incor- 10 
porated by reference. 
In other embodiments of the invention, the polynucleotide 
encodes an antibody that binds to at least one cytochrome 
P450 polypeptide, and reduces the activity of a cytochrome 
P450 polypeptide of the present invention. In another 15 
embodiment, the binding of the antibody results in increased 
turnover of the antibody-cytochrome P450 polypeptide com-
plex by cellular quality control mechanisms. The expression 
of antibodies in plant parts and the inhibition of molecular 
pathways by expression and binding of antibodies to proteins 20 
in plant parts are well known in the art. See, for example, 
Conrad and Sonnewald (2003) Nature Biotech. 21:35-36, 
incorporated herein by reference. 
In other embodiments, the activity of a cytochrome P450 
polypeptide of the present invention is reduced or eliminated 25 
by disrupting the gene encoding the cytochrome P450 
polypeptide. The gene encoding the cytochrome P450 
polypeptide may be disrupted by any method known in the 
art, for example, by transposon tagging or by mutagenizing 
plants using random or targeted mutagenesis and selecting for 30 
plants that have reduced cytochrome P450 activity. 
Transposon tagging may be used to reduce or eliminate the 
activity of one or more cytochrome P450 polypeptides of the 
present invention. Transposon tagging comprises inserting a 
transposon within an endogenous cytochrome P450 gene to 35 
reduce or eliminate expression of the cytochrome P450 
polypeptide. 
In this embodiment, the expression of one or more cyto-
chrome P450 polypeptides is reduced or eliminated by insert-
ing a transposon within a regulatory region or coding region 40 
of the gene encoding the cytochrome P450 polypeptide. A 
transposon that is within an exon, intron, 5' or 3' untranslated 
sequence, a promoter, or any other regulatory sequence of a 
cytochrome P450 polypeptide gene may be used to reduce or 
eliminate the expression and/or activity of the encoded cyto- 45 
chrome P450 polypeptide. 
Methods for the transposon tagging of specific genes in 
plants are well known in the art. See, for example, Maes eta!. 
(1999) Trends Plant Sci. 4:90-96; Dharmapuri and Santi 
(1999) FEMS Microbial. Lett. 179:53-59; Meissner et a!. 50 
(2000) Plant J. 22:265-274; Phogat et a!. (2000) J. Biosci. 
25:57-63; Walbot (2000) Curr. Opin. Plant Biol. 2:103-107; 
Gai eta!. (2000) Nucleic Acids Res. 28:94-96; Fitzmaurice et 
a!. (1999) Genetics 153:1919-1928). 
Additional methods for decreasing or eliminating the 55 
expression of endogenous genes in plants are also known in 
the art and can be similarly applied to the instant invention. 
These methods include other forms of mutagenesis, such as 
ethyl methanesulfonate-induced mutagenesis, deletion 
mutagenesis, and fast neutron deletion mutagenesis used in a 60 
reverse genetics sense (with PCR) to identify plant lines in 
which the endogenous gene has been deleted. For examples 
of these methods see Ohshima eta!. (1998) Virology 243:472-
481; Okubara eta!. (1994) Genetics 137:867-874; and Que-
sada eta!. (2000) Genetics 154:421-436; each of which is 65 
herein incorporated by reference. In addition, a fast and 
automatable method for screening for chemically induced 
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mutations, TILLING (Targeting Induced Local Lesions In 
Genomes ), using denaturing HPLC or selective endonuclease 
digestion of selected PCR products is also applicable to the 
instant invention. See McCallum eta!. (2000) Nat. Biotech-
no!. 18:455-457, herein incorporated by reference. 
Mutations that impact gene expression or that interfere 
with the function of the encoded cytochrome P450 protein 
can be determined using methods that are well known in the 
art. Insertional mutations in gene exons usually result in null-
mutants. Mutations in conserved residues can be particularly 
effective in inhibiting the metabolic function of the encoded 
protein. Conserved residues of plant cytochrome P450 
polypeptides suitable for mutagenesis with the goal to elimi-
nate activity of a cytochrome P450 polypeptide in converting 
nicotine to nornicotine in a Nicotiana plant or plant part have 
been described (See, for example, FIGS. 3 and 4). Such 
mutants can be isolated according to well-known procedures. 
In another embodiment of this invention, dominant 
mutants can be used to trigger RNA silencing due to gene 
inversion and recombination of a duplicated gene locus. See, 
for example, Kusaba eta!. (2003) Plant Cell15:1455-1467. 
While a number of sequences are recognized in the practice 
of the invention, in particular SEQ ID N0:3 and SEQ ID 
N0:5 find particular use. While not bound by any particular 
mechanisms of action, it is believed that these sequences 
encode a nicotine demethylase that catalyzes the oxidative 
N -demethy lation of nicotine to nornicotine. Thus, methods to 
specifically inhibit these coding sequences and not other 
P450 sequences may be beneficial to the recombinant plant. 
That is, strategies that would lead to inhibition of gene func-
tion of this individual locus may prove to be superior to those 
that inhibit the entire gene family. The P450 enzymes are 
involved in many mechanisms in the plant, the inhibition of 
which may prove deleterious or detrimental to the growth and 
development of the plant or may negatively impact factors 
such as the disease defense capabilities of the plant. Likewise, 
because the Nicotiana plant P450 enzymes have been impli-
cated in plant metabolites such as phenylpropanoid, alka-
loids, terpenoids, lipids, cyanogenic glycosides, glucosino-
lates, and a host of other chemical entities, disruption of p450 
activity may alter components involved in tobacco flavor, 
texture, or other properties that would impact the commercial 
usefulness of the plant. Therefore, the use of the methods 
discussed above to inhibit expression in a marmer that spe-
cifically targets the coding sequence of SEQ ID N0:3 or SEQ 
ID N0:5 may be preferred, including targeted mutational 
strategies, such as chimeraplasty. See, for example, Stewart et 
a!. (2000) Biotechniques 29(4): 838-843; Graham et a!. 
(2002) Biochim Biophys Acta 1587 (1 ): 1-6, herein incorpo-
rated by reference. 
The protein encoded by the eDNA designated 3D_ C12-1 0 
(SEQ ID N0:4) differs from 3D_C12-7 (SEQ ID N0:6) at 
only two amino acid residues immediately following the start 
methionine. The codons corresponding to these amino acids 
were contained within the PCR primer used to generate the 
3D_C12-7 eDNA. Thus, the original mRNA template from 
which 3D_C12-7 was amplified may be the same as that 
corresponding to the 3D_C12-10 gene, with the PCRprimer 
sequences mediating the changes observed in the second and 
third amino acid sequence. Regardless, the encoded protein 
products would function identically. The location of the two 
amino acids that differ between the predicted proteins is in the 
N-terminal signal sequence that merely serves to anchor the 
protein to the endoplasmic reticulum membrane and there-
fore would not be expected to influence the catalytic proper-
ties of the enzyme. 
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In another embodiment of the invention, the compositions 
of the invention find use in screening methods to identify 
nonconverter plants for use in breeding programs. In this 
manner, the nucleotide sequences of the invention can be used 
to screen native germplasms for nonconverter plants having a 5 
stable mutation in one or more p450 genes identified herein. 
These nonconverter plants identified by the methods of the 
invention can be used to develop breeding lines. 
In addition to the nucleotide sequences encoding P450 
coding sequences, compositions of the invention include an 10 
intron sequence in the 3D_C12-10 sequence that can be used 
in screening methods. While not bound by any mechanism of 
action, the 3D_C12-7/3D_C12-10 gene(s) may represent the 
only member(s) of the 3D_C12 family involved in the meta-
bolic conversion of nicotine to nornicotine (and as stated 15 
previously there is a good likelihood that the 3D_C12-7 and 
3D_C12-10 cDNAs originated from a single unique genetic 
locus). For certain applications it would be useful to have a 
means of diagnostically differentiating this specific member 
of the 3D_ C12 gene family from the rest of the closely related 20 
sequences within this family. For example, it is possible that 
within the naturally existing tobacco germplasm (or in 
mutagenized populations), accessions may exist in which this 
gene is naturally dysfunctional and may therefore may be 
valuable as a permanently nonconverter resource. A method 25 
to specifically assay for such genotypes (e.g. deletion 
mutants, rearrangements, and the like) could serve as a pow-
erful tool. To obtain such a tool, the sequence alignment 
shown in FIGS. 3A-3G was used to design PCR primers in 
regions possessing polymorphisms among the members. One 30 
primer combination (5' primer shown in SEQ ID N0:25 and 
3' primer shown in SEQ ID N0:26) using sequences specific 
to 3D_C12-10 yields two particularly useful results: (1) all 
PCR products amplified from tobacco genomic DNA gave 
that same unique product (as determined by DNA sequence 35 
analysis); and (2) the presence of a 992 bp intron was revealed 
that is located between the primer sequences (FIG. 7; intron 
shown in SEQ ID N0:24). 
When any eDNA corresponding to a member of the 
3D_C12 family is used as a hybridization probe in a Southern 40 
blotting assay of tobacco genomic DNA, a complex pattern is 
observed. This is expected, given that there are multiple, 
closely related members of this gene family. Because the 
intron regions of genes are typically less conserved than 
exons, it is predicted that the use of an intron-specific probe 45 
would reduce this complexity and better enable one to distin-
guish the gene(s) corresponding to the 3D_C12-7/3D_C12-
1 0 gene from the other members of the family. Indeed, the 
pro be corresponding to the sequence shown in FIG. 7 resulted 
in a Southern blotting pattern with greatly reduced complex- 50 
ity. The use of a 3D_C12-10 intron-specific probe, and/or the 
PCR primers used to generate the fragment shown in FIG. 7, 
therefore provide powerful tools in assays to determine 
whether any naturally occurring, or mutagenized, tobacco 
plants possess deletions or rearrangements that may render 55 
the gene inactive. Such a plant can then be used in breeding 
programs to create tobacco lines that are incapable of con-
verting. 
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duced into a plant or plant cell of interest. In some embodi-
ments the expression cassettes described herein are intro-
duced into a plant of interest, for example, a Nicotiana plant 
as noted herein below, using any suitable transformation 
methods known in the art including those described herein. 
The methods of the invention do not depend on a particular 
method for introducing a sequence into a plant or plant part, 
only that the desired sequence gains access to the interior of at 
least one cell of the plant or plant part. Methods for introduc-
ing polynucleotide sequences into plants are known in the art 
and include, but are not limited to, stable transformation 
methods, transient transformation methods, and virus-medi-
ated methods. 
Transformation protocols as well as protocols for introduc-
ing heterologous polynucleotide sequences into plants vary 
depending on the type of plant or plant cell targeted for 
transformation. Suitable methods of introducing polynucle-
otides into plant cells of the present invention include micro-
injection (Crossway eta!. (1986) Biotechniques 4:320-334), 
electroporation (Shillito eta!. (1987) Meth. Enzymol. 153: 
313-336; Riggs et a!. (1986) Proc. Nat!. Acad. Sci. USA 
83:5602-5606), Agrobacterium-mediated transformation 
(U.S. Pat. Nos. 5,104,310, 5,149,645, 5,177,010, 5,231,019, 
5,463,174, 5,464,763, 5,469,976, 4,762,785, 5,004,863, 
5,159,135, 5,563,055, and 5,981,840), direct gene transfer 
(Paszkowski eta!. (1984) EMBO J. 3:2717 -2722), and ballis-
tic particle acceleration (see, for example, U.S. Pat. Nos. 
4,945,050, 5,141,131, 5,886,244, 5,879,918, and 5,932,782; 
Tomes eta!. (1995) in Plant Cell, Tissue, and Organ Culture 
Fundamental Methods, ed. Gamborg and Phillips (Springer-
Verlag, Berlin); McCabe eta!. (1988) Biotechnology 6:923-
926). Also see Weissinger et a!. (1988) Ann. Rev. Genet. 
22:421-477; Christon eta!. (1988) Plant Physiol. 87:671-674 
(soybean); McCabe eta!. (1988) Bio/Technology 6:923-926 
(soybean); Finer and McMullen (1991) In Vitro Cell Dev. 
Biol. 27P: 175-182 (soybean); Singhet a!. (1998) Theor. Appl. 
Genet. 96:319-324 (soybean); De Wet eta!. (1985) in The 
Experimental Manipulation of Ovule Tissues, ed. Chapman et 
a!. (Longman, N.Y.), pp. 197-209 (pollen); Kaeppler eta!. 
(1990) Plant Cell Reports 9:415-418 and Kaeppler et a!. 
(1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated 
transformation); D'Halluin eta!. (1992) Plant Cell 4:1495-
1505 (electroporation); all of which are herein incorporated 
by reference. 
Any plant tissue that can be subsequently propagated using 
clonal methods, whether by organogenesis or embryogenesis, 
may be transformed with a recombinant construct comprising 
a cytochrome P450 inhibitory sequence, for example, an 
expression cassette of the present invention. By "organogen-
esis" in intended the process by which shoots and roots are 
developed sequentially from meristematic centers. By 
"embryogenesis" is intended the process by which shoots and 
roots develop together in a concerted fashion (not sequen-
tially), whether from somatic cells or gametes. Exemplary 
tissues that are suitable for various transformation protocols 
described herein include, but are not limited to, callus tissue, 
existing meristematic tissue (e.g., apical meristems, axillary 
buds, and root meristems) and induced meristem tissue (e.g., 
cotyledon meristem and hypocotyl meristem), hypocotyls, Transformed Plants, Plant Parts, and Products Having 
Reduced Nornicotine and NNN Content 60 cotyledons, leaf disks, pollen, embryos, and the like. 
The cytochrome P450 polynucleotides of the invention, 
and variants and fragments thereof, can be used in the meth-
ods of the present invention to inhibit expression or function 
of cytochrome P450s that are involved in the metabolic con-
version of nicotine to nornicotine in a plant. In this manner, 65 
inhibitory sequences that target expression or function of a 
cytochrome P450 polypeptide disclosed herein are intra-
As used herein, the term "stable transformation" is 
intended to mean that the nucleotide construct of interest 
introduced into a plant integrates into the genome of the plant 
and is capable of being inherited by the progeny thereof 
"Transient transformation" is intended to mean that a 
sequence is introduced into the plant and is only temporally 
expressed or is only transiently present in the plant. 
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techniques, such as cultivation in manure rich soil or without 
manure, bagging the flowers or no bagging, or topping or no 
topping. The harvested leaves and stems may be used in any 
traditional tobacco product including, but not limited to, pipe, 
cigar and cigarette tobacco, and chewing tobacco in any form 
including leaf tobacco, shredded tobacco, or cut tobacco. 
Thus the present invention provides a Nicotiana plant, 
particularly leaf tissues of these plants, comprising an expres-
sion cassette of the invention and a reduced amount of norni-
In specific embodiments, the inhibitory sequences of the 
invention can be provided to a plant using a variety of tran-
sient transformation methods. The inhibitory sequences of 
the invention can be transiently transformed into the plant 
using techniques known in the art. Such techniques include 
viral vector systems and the precipitation of the polynucle-
otide in a manner that precludes subsequent release of the 
DNA. Thus, the transcription from the particle-bound DNA 
can occur, but the frequency with which it is released to 
become integrated into the genome is greatly reduced. Such 
methods include the use of particles coated with polyethyen-
limine (PEl; Sigma #P3143). 
10 cotine and N'-nitrosonornicotine. As used herein, the term "a 
reduced amount" or "a reduced level" is intended to refer to an 
In other embodiments, the inhibitory sequence of the 
invention may be introduced into plants by contacting plants 
with a virus or viral nucleic acids. Generally, such methods 15 
involve incorporating an expression cassette of the invention 
within a viral DNA or RNA molecule. It is recognized that 
promoters for use in the expression cassettes of the invention 
also encompass promoters utilized for transcription by viral 
RNA polymerases. Methods for introducing polynucleotides 20 
into plants and expressing a protein encoded therein, involv-
ing viral DNA or RNA molecules, are known in the art. See, 
amount of nornicotine and/or N'-nitrosonornicotine in a 
treated or transgenic plant of the genus Nicotiana or a plant 
part or tobacco product thereof that is less than what would be 
found in a plant of the genus Nicotiana or a plant part or 
tobacco product from the same variety of tobacco, processed 
(i.e., cultured and harvested) in the same manner, that has not 
been treated or was not made transgenic for reduced norni-
cotine and/or N'-nitrosonornicotine. The amount of nornico-
tine may be reduced by about 10% to greater than about 90%, 
including greater than about 20%, about 30%, about 40%, 
about 50%, about 60%, about 70%, and about 80%. 
The term "tobacco products" as used herein include, but 
are not limited to, smoking materials (e.g., cigarettes, cigars, 
for example, U.S. Pat. Nos. 5,889,191, 5,889, 190, 5,866, 785, 
5,589,367, 5,316,931, and Porta eta!. (1996) Molecular Bio-
technology 5:209-221; herein incorporated by reference. 25 pipe tobacco), snuff, chewing tobacco, gum, and lozenges. 
Transformed cells may be grown into Nicotiana plants in 
accordance with conventional methods. See, for example, 
methods disclosed in Vasil and Hildebrandt (1965) Science 
150:889; Negaard and Hoffman (1989) Biotechniques 7(8): 
808-812. These plants may then be grown, and either polli- 30 
nated with the same transformed line or different lines, and 
the resulting progeny having expression of the desired phe-
notypic characteristic identified, i.e., reduced expression of 
one or more cytochrome P450s that are involved in the meta-
bolic conversion of nicotine to nornicotine, and thus reduced 35 
content of nornicotine, and a concomitant reduced content of 
its nitrosamine metabolite, NNN, in the plant, particularly in 
the leaf tissues. Two or more generations may be grown to 
ensure that expression of the desired phenotypic characteris-
tic is stably maintained and inherited and then seeds harvested 40 
to ensure expression of the desired phenotypic characteristic 
has been achieved. In this manner, the present invention pro-
vides transformed seed (also referred to as "transgenic seed") 
having a polynucleotide of the invention, for example, an 
expression cassette of the invention, stably incorporated into 45 
their genome. 
The present invention also encompasses a range of tobacco 
product blends that can be made by combining conventional 
tobacco with differing amounts of the low nornicotine and/or 
N'-nitrosonornicotine tobacco described herein. In further 
embodiments, the plant or plant part of the genus Nicotiana as 
described above is cured tobacco. 
In some embodiments of the present invention, the tobacco 
product reduces the carcinogenic potential of tobacco smoke 
that is inhaled directly with consumption of a tobacco product 
such as cigars, cigarettes, or pipe tobacco, or inhaled as sec-
ondary smoke (i.e., by an individual that inhales the tobacco 
smoke generated by an individual consuming a tobacco prod-
uct such as cigars, cigarettes, or pipe tobacco). The cured 
tobacco described herein can be used to prepare a tobacco 
product, particularly one that undergoes chemical changes 
due to heat, comprising a reduced amount of nornicotine 
and/or N'-nitrosonornicotine in the smoke stream that is 
inhaled directly or inhaled as secondary smoke. In the same 
manner, the tobacco products of the invention may be useful 
in the preparation of smokeless tobacco products such as 
chewing tobacco, snuff, and the like. 
The tobacco products obtained from the transgenic tobacco 
plants of the present invention thus find use in methods for 
reducing the carcinogenic potential of these tobacco prod-
ucts, and reducing the exposure of humans to the carcino-
genic nitrosamine NNN, particularly for individuals that are 
users of these tobacco products. 
The following examples are offered by way of illustration 
and not by way of limitation. 
EXPERIMENTAL 
The following materials and protocols were utilized in the 
experiments described herein below. 
The compositions and methods of the invention can be 
used to reduce the nornicotine content, particularly in the 
leaves and stems, of any plant of the genus Nicotiana includ-
ing, but not limited to, the following species: acuminata, 50 
ajfinis, alata, attenuate, bigelovii, clevelandii, excelsior, for-
getiana, glauca, glutinosa, langsdorjfii, longiflora, obtusifo-
lia, palmeri, paniculata, plumbaginifolia, qudrivalvis, 
repanda, rustica, suaveolens, sylvestris, tabacum, tomentosa, 
trigonophylla, and x sanderae. The present invention also 55 
encompasses the transformation of any varieties of a plant of 
the genus Nicotiana, including but not limited to Nicotiana 
acuminata multiflora, Nicotiana alata grand flora, Nicotiana 
bigelovii quadrivalvis, Nicotiana bigelovii wallacei, Nicoti-
ana obtusifolia obtusifolia, Nicotiana obtusifolia plameri, 
Nicotiana quadrivalvis bigelovii, Nicotiana quadrivalvis 
quadrivalvis, Nicotiana quadrivalvis wallacei, andNicotiana 
trigonophylla palmeri, as well as varieties commonly known 
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as flue or bright varieties, Burley varieties, dark varieties, and 
oriental/Turkish varieties. 
The transgenic plants of the genus Nicotiana as described 
herein are suitable for conventional growing and harvesting 
All plant materials utilized in these experiments were pro-
vided by Dr. Earl Wernsman, Department of Crop Science, 
North Carolina State University. DH 91-1307-46(NC) and 
DH91-1307-46(Con) are near-isogenic doubledhaploidBur-
65 ley lines (nonconverter and converter, respectively) recovered 
from the same maternal haploid plant. Burley lines DH 
98-326-3 (nonconverter) and DH 98-326-1 (converter), and 
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DH 98-325-5 (nonconverter) and DH 98-325-6 (converter) 
represent two additional pairs of near-isogenic lines. SC58 is 
40 
a flue-cured tobacco variety, nonconverter individuals of 
which are designated SC58(czer)· SC58(CzCr) is a near-
isogenic stable converter line that originated though the intra- 5 
gression of the single dominant converter locus (Cr) found in 
the tobacco progenitor species N. tomentosiformis into SC58 
(Mann eta!. (1964) Crop Sci. 4:349-353. After eight addi-
tional backcrosses to SC58, the near-isogenic SC58(CzCr) 
line was created and subsequently maintained via self-fertili- 10 
DSMO. The final DNA concentrations were estimated to be 
equal to or greater than 0.1 mg/ml. The DNAs were subse-
quently spotted onto amino silane-coated slides (Corning® 
GAPS II) using anAffymetrix GMS 417 array printer. DNAs 
were immobilized to the slide surface by UV crosslinking 
( -120 mJ/m2), followed by baking at 75° C. for two hours. 
Microarray Hybridization and Analysis 
The amino allyl dUTP-based indirect method of dye incor-
poration described by "The Institute of Genome Research" 
(http://pga.tigr.org/protocols.html) was used to label noncon-
verter and converter RNAs with Cy3 and Cy3 fluorescent zation. 
All plants were maintained in growth chambers or green-
houses using standard potting soil and fertilizer. For the 
microarray studies, the metabolism of nicotine to nornicotine 
was accelerated by excising individual leaves and inserting 
their petioles into a solution of0.1% ethephon or 1% sodium 
bicarbonate. The leaves were then placed in a growth cham-
ber (27° C.) for 5 to 7 hours to facilitate the entry of the 
ethephon or sodium bicarbonate solutions throughout the 
transpirational stream. The treated leaves were placed in 
small plastic storage bags after being lightly sprayed with 
water (to maintain high humidity) and cured for three days at 
30° C. in the dark. To enhance the nicotine to nornicotine 
dyes (Amersham Biosciences ). Briefly, 20 flg of total RNA 
was reverse transcribed in a 30 fll volume containing 400 units 
of SuperScript II RT (Invitrogen), 6 ng random hexamer 
15 primers, 0.5 mM each of dATP, dCTP, and dGTP, 0.3 mM 
dTTP, and 0.2 mM amino allyl dUTP (Sigma) in first strand 
synthesis buffer (Invitrogen). Reactions were incubuted for 6 
to 14 hours at 42° C., followed by hydrolysis of the RNA with 
NaOH. The resulting first strand eDNA molecules were col-
20 unm purified (Qiagen) and washed with phosphate buffer. 
Coupling reactions of the NHS-ester Cy3 or Cy5 fluorescent 
dyes to the eDNA occurred during incubation in 0.05 M 
sodium carbonate buffer (pH 9.0) and 25% DMSO at room 
conversion in the transgenic plants generated in this study, 
detached leaves were dipped into a solution of 0.2% ethep- 25 
hon, dried, and cured in plastic storage bags for seven days at 
room temperature in the dark. 
temperature for 1.5 hours. 
Microarray slides were prehybridized in a solution of 
5xSSC, 0.1% SDS, and 1% BSA at 42° C. for 45 minutes, 
rinsed gently with dH2 0 and isopropanol, and dried by low 
speed centrifugation. The Cy3- and Cy5-labeled cDNAs were 
column purified (Qiagen), combined, and hybridized to the 
eDNA Libraries and Expressed Sequence Tags 
Total cellular RNA was isolated from senescing leaf tissue 
of Burley lines DH 91-1307-46(NC) and DH 91-1307-46 
(Con) using the TRizol® reagent according to the manufac-
turer's protocol (Invitrogen). PolyA+RNA was isolated from 
total RNA using the MessageMaker system (Invitrogen), and 
eDNA was subsequently synthesized and cloned into the 
lambda ZAP II phage vector using the ZAP-eDNA Synthesis 
and Gigapack III Gold Cloning Kit (Stratagene ). Aliquots of 
the phage libraries were converted to pB!uescript-based plas-
mid libraries following the mass excision protocol outlined 
by Stratagene. 
30 DNA slides in a solution containing 5xSSC, 0.5% SDS, 
5xDenhardt's, 0.45 flg/fll Poly ARNA, 0.45 flg/fll calf thymus 
DNA, and 50% formamide. The slides were incubated with 
the hybridization solution for 14 to 16 hours at 42° C. Post-
hybridization washes consisted of sequential 4-minute incu-
35 bations with the following solutions: 1xSSC, 0.2% SDS; 
0.1xSSC, 0.2% SDS; 0.1xSSC, and a final 10 second rinse 
with 0.01xSSC. 
Thousands of colonies from both the converter and non- 40 
The microarrays were subsequently scanned using Sca-
nArray 2.1 (GSI Lumonics) or ScanArray Express (Perki-
nElmer). Sequential scanning for Cy5 and Cy3 fluorescence 
was performed at a maximal resolution of 10 grn/pixel, and converter libraries were grown on selective solid media and 
picked into 384-well plates containing Luria broth (with 
ampicillin) in 10% glycerol to facilitate long term storage of 
the clones at -80° C. Over 11,000 clones from each library 
were transferred from the 384-well plates to 96-well growth 
blocks and grown in selective media. Plasmids were isolated 
in 96-well format using the R.E.A.L. Preparation Kit 
(Qiagen) with the aid of a BioRobot 3000 Workstation 
(Qiagen). To generate the ESTs, the plasmid clones were 
sequenced using the T3 primer (Qiagen) and BigDye® Ter-
minator system (Applied Biosystems) according to the Big-
Dye® cycle sequencing protocol. Performa® DTR 96-well 
plates (Edge Biosystems) were used to remove the unincor-
porated dye from the sequencing reactions prior to loading 
the samples onto a Perkin Elmer Prism 3700 96-Capillary 
Automated DNA Sequencer. 
Preparation of DNA Chips 
To obtain DNAs suitable for spotting onto glass slides, the 
M13 forward and reverse sequencing primers (Qiagen) were 
used as PCR primers to amplifY eDNA inserts from the plas-
mids containing cDNAs represented in the EST databases. 
Plasmid clones were subjected to PCR in 96-well format 
using an Applied Biosystems Gene Amp 9700 model ther-
mocycler. The resulting PCR products were processed 
through Millipore Multiscreen™ PCR or Montage™ 
PCRf196 purification systems. The resulting products were 
transferred into 384-well plates containing equal volumes of 
laser power and PMT gain adjusted to provide reliable and 
equivalent signal strengths. The acquired array images were 
quantified for signal intensity with QuantArray™ analysis 
45 software (PerkinElmer), using the histogram-based method. 
Total intensities were used as quantification output fields, and 
the acquired data sets were saved as Unicode, tab-delimited 
text files. Importation of the text files into Microsoft Excel 
enabled the subsequent calculation ofCy5/Cy3 and Cy3/Cy5 
50 ratios, the statistic we employed for the identification of can-
didate genes. 
Cloning Full-Length andAdditional Members of the 3D_ C 12 
Gene Family 
To clone the entire coding region of3D_C12 and 7D_A06 
55 a modified 5'-RACE strategy was employed using a pB!ue-
script II vector-specific forward primer (BlueSK; 
5'-CGCTCTAGAACTAGTGATC-3'; SEQ ID NO: 17) and a 
set of gene-specific reverse primers. Two 3D_C12-specific 
reverse primers were designed, one of which is complemen-
60 tary to the downstream portion of the 3' nntranslated region 
(5'-TTTTTGGGACAATCAGTCAA-3'; SEQ ID NO: 18) and 
the other complementary to a sequence within the coding 
region (5'-GTTAGATTTATCGTACTCGAATT-3'; SEQ ID 
N0:19). For the former primer, the first five Ts are comple-
65 mentary to the poly A tail of the transcript. A 7D _A06-specific 
reverse primer ( 5'-TTCATTTCAAATTATTTTATGCACCA-
3'; SEQ ID N0:20) was also designed, and is complementary 
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to a segment in the 3' untranslated region of this gene. PCR 
reactions contained 10 ng of converter tobacco leaf eDNA 
library (within the pB!uescript vector) as template, 2 f.LM 
concentration of each primer, 350 f.LM of each dNTP, and 1.5 
mM MgC12 in a final reaction volume of 50 f.LL. Amplification 5 
was initiated by the addition of 2.5 units of UniPol enzyme 
mix using conditions described by the manufacturer (Roche). 
After an initial denaturation step at 94 o C. for 4 minutes, the 
samples were subjected to 30 cycles of denaturation at 94 o C. 
for 15 seconds, annealing at 57° C. for 30 seconds, and 10 
extension at 72° C. for 90 seconds. A final extension step at 
72o C. for 10 minutes was includedattheendofthe 30 cycles. 
The amplicons were ligated into the pGEM Easy T/A vector 
(Promega), and 10 randomly selected clones from each 
15 
amplification were subjected to DNA sequence analysis. 
Nucleic acid and predicted protein sequences of the various 
members of the 3D_C12 gene family were analyzed and 
compared using the BLASTX (Altschul eta!. (1997) Nucleic 
Acids Res. 25:3389-3402), ClustalW (Higgins eta!. (1994) 20 
Nucleic Acids Res. 22:4673-4680) and GAP (University of 
Wisconsin Genetic Computing Group software package) 
algorithms. 
The above described strategy was effective in identifying 
full-length sequence information for 3D_C12 and 7D_A06. 25 
In addition, PCR amplifications using the PCR primer inter-
nal to the 3D_ C 12 coding region gave rise to partial-sequence 
information for the unique 3D_ C12-15 eDNA. In an attempt 
to obtain full-length sequence information for 3D_ C 12-15, a 
gene-specific primer complementary to the 5' terminus of its 30 
coding region ( 5'-ATGGTTTTTCCCATAGAAGCC-3'; SEQ 
ID N0:21) was used in conjunction with a pB!uescript-spe-
cific reverse primer (5'-TCGAGGTCGACGGTATC-3'; SEQ 
ID N0:22). Although a full-length 3D_C12-15 eDNA was 
35 
not recovered, this amplification resulted in the isolation of 
3D_ C12-7, which proved to be another unique member of the 
3D_C12 gene family. 
Transgenic Plant Analysis 
The RNAi-based gene silencing constructs were 40 
assembled in a version of the pKYL80 cloning vector 
(Schardl eta!. (1987) Gene 61:1-11) that was engineered to 
contain a 151-bp fragment of the soybean FAD3 gene intron 
between the Xhol and Sad restriction sites of the poly linker 
(pKYLX80I). To create a construct in which the FAD3 intron 45 
was flanked by a sense and antisense fragment of3D_C12, a 
99-bp region located immediately upstream of the stop codon 
ofthe3D_C12 eDNA (FIGS. 3A-3G)was cloned between the 
Hindiii-Xhol and Sacl-Xbal restriction sites of pKYLX80I in 
its sense and antisense orientation, respectively. The resulting 50 
Hindiii-Xbal fragment containing the 3D_C12 sense arm, 
FAD3 intron, and 3D_C12 antisense arm was subcloned into 
the pKYLX71 plant binary expression vector (Maiti et a!. 
(1993) Proc. Nat!. Acad. Sci. USA 90:6110-6114) between 
the 35S CaMV promoter and a rubisco small subunit termi- 55 
nat or. 
Overexpression constructs were created by replacing the 
3-glucuronidase ORF of the plant binary expression vector 
pBI121 (Clontech) with the full-length coding regions of the 
3D_C12, 7D_A06, and 3D_C12-7 cDNAs. This placed the 60 
tobacco P450s under the transcriptional control of the 35S 
CaMV promoter. The pBI121- and pKYLX71-based con-
structs were transformed into Agrobacterium tumefaciens 
strain LBA 4404 and introduced into tobacco cultivars Petite 
Havana and DH98-325-6 (converter), respectively, using 65 
established protocols (Horsch eta!. (1985) Science 227:1229-
1231). 
42 
Northern Blot Analysis 
Total cellular RNAs were isolated from tobacco leaves 
using the TRIZOL® method as described by the manufac-
turer (Invitrogen). Five to ten micrograms of RNA were size 
fractionated on a 1.2% agarose gel prepared in TBE buffer. 
RNA immobilization, probe labeling, and signal detection 
were carried out using the DIG nucleic acid labeling and 
detection kits according to the manufacturer's instructions 
(Roche). Alternatively, probes were synthesized using 32P-
dCTP according to protocols accompanying the Random 
Primed DNA Labeling kit (Roche). 
Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
65° C. for 2 days.A 100mg sample of crushed, dried leaf was 
addedto0.5 ml of2 NNaOHina20mL scintillation vial. The 
sample was mixed and allowed to incubate for 15 minutes at 
room temperature. Alkaloids were extracted by the addition 
of 5 mL of extraction solution [0.04% quinoline (wt/vol) 
dissolved in methyl-t-butyl ether] and gently rotated on a 
linear shaker for 3 hours. Following phase separation, an 
aliquot of the organic phase was transferred to a sample vial. 
Samples were analyzed using a PerkinElmer Auto system XL 
gas chromatograph equipped with a flame ionization detector, 
a 4 mm split/splitless glass liner, and a 30 mx0.53 mm ID 
DB-5 colunm. Chromatographic conditions were as follows: 
detector temperature: 250° C.; injector temperature: 250° C.; 
helium flow rate at 120° C.: 20 mL/min; injection volume: 2 
f.LL; column conditions: 120° C., hold 1 minute, 120-280° C. 
at 30° C./minute ramping rate, hold at 280° C. for 2 minutes. 
Alkaloid composition was determined by the TotalChrome 
Navigator software using a calibration curve. 
Example 1 
Generation of EST Databases 
RNAs isolated from senescing leaves of the converter 
genotype DH 91-1307-46(Con) and its near-isogenic non-
converter counterpart DH 91-1307 -46(NC) were used to gen-
erate eDNA libraries. High-throughput automated DNA 
sequencers were initially used to generate single-run 
sequence information (ESTs) for 11,136 randomly chosen 
cDNAs from the converter library. The local alignment search 
tool BLASTX (Altschul eta!. (1990) J. Mol. Biol. 215:403-
410) was used to compare the predicted protein sequence of 
each tobacco eDNA with the nonredundant protein database 
curated by the National Center for Biotechnology Informa-
tion of the National Library of Medicine and National Insti-
tutes of Health. Subsequently, a similar annotated EST data-
base was generated by conducting sequencing runs on 11,904 
cDNAs selected from the nonconverter library. 
Example 2 
Microarray Analyses of Converter CDNA Library 
Methods 
Upon completion of the EST database generated from the 
converter eDNA library, the inserts from 4992 clones were 
amplified by PCR and spotted onto glass slides. Given the 
possibility that the nicotine demethylase enzyme may be 
catalyzed by an enzyme of the P450 class of oxidative 
enzymes, special attention was given to library entries that 
were predicted by BLASTX analysis to encode P450s. 
From visual inspection of the BLASTX results, it was 
estimated that 31 unique P450 genes were represented in the 
database. When selecting specific 96-well plates to be 
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included on the microarray, care was taken to ensure that all 
unique P450 genes would be included among the 4992 
cDNAs selected. 
RNAs isolated from the near-isogenic Burley genotypes 
DH 98-326-3 (nonconverter) and DH 98-326-1 (converter), 5 
and DH 98-325-5 (nonconverter) and DH 98-325-6 (con-
verter) were used to generate Cy3- and Cy5-labeled cDNAs. 
44 
3D_C12, 7D_A06, 27C_C12, 33A_D06, and 34D_F06. 
BLASTX analysis of the partial sequence information for 
3D_C12 and 7D_A06 found in our EST database predicted 
that the cDNAs encode two closely related P450 enzymes. 
27C_C12 and 33A_D06 were predicted to encode glycine-
rich cell wall proteins, displaying over 90% sequence identity 
to small tobacco glycine-rich proteins found in GenBank 
(e.g., Accession No. AAK57546). Clone 34D_F06 was found 
to contain a double eDNA insert, one insert showing homol-
To maximize the metabolic conversion of nicotine to norni-
cotine in converter genotypes, detached leaves were treated 
with sodium bicarbonate or ethephon prior to curing, treat-
ments that have been shown to accelerate nomicotine produc-
tion in converter plants while having no effect in nonconverter 
individuals (Fannin and Bush (1992) Med. Sci. Res. 20:867-
868; Shi eta!. (2003) J. Agric. Food Chern. 51:7679-7683). 
10 ogy to serine/threonine protein kinases, and the other show-
ing high sequence identity to the same glycine-rich cell wall 
proteins as the 27C_C12 and 33A D06 cDNAs. 
To minimize the variability inherent with microarray 15 
experiments, reciprocal experiments were conducted simul-
taneously. In this manner, DH 98-325-5 RNA was labeled 
with Cy5 and DH 98-325-6 RNA was labeled with Cy3, and 
then in a reciprocal experiment DH 98-325-5 RNA was 
labeled with Cy3 and DH 98-325-6 RNA was labeled with 20 
Cy5 (collectively referred to as Exp. 2.1). Similarly, DH 
98-326-3 and DH 98-326-1 RNAs were labeled with Cy3 and 
Cy5, respectively, in one experiment, and then the same 
RNAs were labeled with Cy5 and Cy3, respectively, in a 
reciprocal experiment (collectively referred to as Exp. 2.2). 25 
Even when conducted reciprocally, the results of any given 
microarray experiment are likely to include "false positives," 
representing genes that are differentially regulated between a 
specific genotypic pair and/or uniquely in response to a spe-
cific treatment, as opposed to differences directly associated 30 
with the conversion phenomenon. To define the set of candi-
date genes that are most likely to be upregulated due to the 
conversion process, cDNAs were identified that met the fol-
lowing criteria: for any set of reciprocal experiments (i.e., 
Exp. 2.1, or Exp. 2.2), the hybridization intensity of a given 35 
eDNA had to be at least 2-fold higher with the converter probe 
than nonconverter probe in at least one of the hybridizations, 
and not less than 1.5-fold higher in the reciprocal experiment. 
Example 3 
Microarray Analysis ofCDNA Non-Converter 
Library 
Upon completion of the EST database from the noncon-
verter library (generated from senescing leaves of genotype 
DH 91-1307-46 (NC) ), another set of microarray experiments 
was initiated. For this next generation of microarrays, the goal 
was to produce glass slides containing the complete nonre-
dundant set of genes represented in both libraries. 
To obtain an estimate of the number of unique genes that 
are represented in the database, clustering analysis was con-
ducted to identifY ESTs predicted to be represented multiple 
times in the database ( contigs) versus those predicted to be 
represented only once (singletons) (Huang and Madan (1999) 
Genome Res. 9:868-877). Due to the nature of the clustering 
algorithms, sequences showing high, but imperfect, sequence 
identities are clustered into the same contig. The total set of 
predicted unique genes, or unigenes, within a database is 
calculated as the sum of the contigs and singletons. Clustering 
analysis of the combined converter and nonconverter data-
bases predicted 2246 contigs and 4 717 singletons for a total of 
6,963 unigenes. Inserts from all singletons and an individual 
from each contig were amplified by PCR and spotted onto 
glass slides, resulting in a gene chip containing the complete 
6,963 unigene set. 
In addition to creating a new DNA chip, the genetic mate-
rials used to generate hybridization probes also differed from 
those used in Example 2. SC58 is a flue-cured tobacco variety, 
nonconverter individuals of which are designated SC58 
Experiment 2.1-Leaves from near-isogenic lines DH 
98-325-5 and DH 98-325-6 were treated with ethephon and 40 
cured for 3 days at 30° C. Alkaloid analysis revealed that 
virtually all of the nicotine had been metabolized to nomico-
tine in the DH 98-325-6leaf during this period while minimal 
nomicotine was observed in the DH 98-325-5 leaf. RNAs 
from the DH 98-325-5 nonconverter plant were labeled with 
the Cy3 fluorescent dye, and RNAs extracted from a DH 
98-325-6 (converter) leaf were labeled with Cy5. The Cy3-
and Cy5-labeledcDNAs were incubated together on the same 
DNA chip and allowed to hybridize overnight. 
45 (crer)· SC58(CrCr) is a near-isogenic stable converter line 
that originated though the introgression of the single domi-
nant converter locus (Cr) found in the tobacco progenitor 
species N. tomentosiformis into SC58 (Mann eta!. (1964) 
Crop Sci. 4:349-353). After eight additional backcrosses to 
Experiment 2.2-Amicroarray analysis similar to Exp. 2.1 
was conducted using the DH 98-326-3 (nonconverter) and 
DH 98-326-1 (converter) near-isogenic lines. In these experi-
ments, leaves from each genotype were treated with 1% 
sodium bicarbonate and cured for 3 days at 30° C. At the end 
50 SC58, the near-isogenic SC58(CrCr) line was created and 
subsequently maintained via self-fertilization. The conver-
sion phenotype of SC58(CrCr) plants is unique with respect 
to standard converter tobacco lines in that the metabolism of 
of the treatment period, nicotine was the predominant alka- 55 
laid in the DH 98-326-3 leaf, while nearly all of the alkaloid 
nicotine to nornicotine in the leaf does not require senescence 
or curing. Plants possessing the Cr converter locus from N. 
tomentosiformis contain nomicotine as the predominant alka-
in the DH 98-326-1 leaf was nornicotine. As described for 
Exp. 2.1, these experiments were reciprocally conducted. 
Results 
In both Experiment 2.1 and Experiment 2.2, the great 
majority of the 4992 cDNAs spotted on the glass slides 
showed no substantial differences in their hybridization 
intensities to the competing Cy3- and Cy5-labeled probes. 
Of the 4992 cDNAs spotted on the glass slides, only five 
showed at least 2-fold higher expression in one hybridization 
and not less than 1.5-fold in the reciprocal hybridization for 
both Exp. 2.1 and Exp. 2.2. These entries were designated 
loid even in green leaf tissue (Wemsman and Matzinger 
(1968) Tab. Sci. 12:226-228). 
RNAs isolated from green leaf tissue of SC58( CrCr) and 
60 SC58(CrCr) were labeled with Cy3 and Cy5, respectively, 
and simultaneously hybridized to a DNA chip containing the 
entire 6,963 unigene set of cDNAs. The fluorescent dyes were 
reversed to produce the probes for a reciprocal experiment as 
described in Exps. 2.1 and 2.2 of Example 2. 
65 Results 
Results were evaluated using the same criteria as in 
Example 2, i.e., individual cDNAs were identified that 
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showed at least 2-fold enhanced hybridization to the labeled 
SC58(CzCr) versus SC58(czer) cDNAs in one experiment 
and at least 1.5-fold enhancement in the reciprocal assay. 
Results were compared to those from Exp. 2.1 and Exp. 2.2 
in Example 2 above. Enhanced hybridization of converter 
RNAs to cDNAs encoding members of the same closely 
related P450 family was the only result shared by all three 
microarray experiments using the defined criteria. 131 
A_A02 is the name of the eDNA that was spotted onto the 
6963-member unigene chip that is representative of the 10 
closely-related P450 gene family that includes 3D_C12 and 
7D_A06 (3D_C12 and 7D_A06 themselves were not spotted 
on the unigene slide). No other cDNAs on the array in 
Example 3, which included representatives of the contigs 
containing the glycine-rich protein-encoding 27C_C12 and 15 
33A_D06 and 34D_F06 cDNAs, scored positive by the 
defined criteria and also scored positive in Exp. 2.1 or Exp. 
2.2 of Example 2 above, regardless of whether the results 
were compared individually or collectively. 
TABLE 1 
Microarray results of members oftbe 3D_C12 gene family 
46 
sequenced when generating the EST database described else-
where herein (and spotted onto the microarrays) were not 
full-length cDNAs. To obtain a full-length sequence, primers 
were generated corresponding to regions in the 3' flanking 
region and in the interior of the coding regions that were 
sufficiently polymorphic to distinguish between 7D _A06 and 
3D_C12. These gene-specific primers were used in combina-
tion with primers specific to the cloning site of pB!uescript II 
to amplifY cDNAs from the converter eDNA library in an 
attempt to obtain sequence that would include the complete 5' 
ends of the 3D_C12 and 7D_A06 reading frames. 
This strategy led to the determination of the DNA sequence 
corresponding to the complete coding regions of3D_C12 (nt 
1-1551 of SEQ ID N0:1; predicted amino acid sequence 
shown in SEQ ID N0:2) and 7D_A06 (nt 1-1554 of SEQ ID 
N0:7; predicted amino acid sequence shown in SEQ ID 
NO:S) (FIGS. 3A-3G and 4). GAP analyses of the 3D_C12 
and 7D_A06 DNA and predicted protein sequences showed 
that they share 93.4% DNA sequence identity and 92.3% 
Experiment 2.1 Experiment 2.1 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 Cy5/Cy3 
eDNA reading reading ratio reading reading ratio 
3D C12 15514.14 25928.95 1.67 19355.85 9507.87 2.04 
7D _A06 15238.23 37196.19 2.44 13651.03 8121.04 1.68 
Experiment 2.2 Experiment 2.2 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 Cy5/Cy3 
reading reading ratio reading reading ratio 
3D C12 12756.43 28669.28 2.25 32198.81 16166.13 1.99 
7D _A06 7571.06 19180.94 2.53 42408.85 18440.17 2.30 
Example 3 Example 3 (reciprocal) 
Cy3 Cy5 Cy5/Cy3 Cy3 Cy5 
reading reading ratio reading reading 
131A_A02 11138.96 19638.82 1.76 36963.45 10085.25 
Combined Results 
The combined results of micro array experiments described 
above defined members of a closely related P450 gene family, 
hereafter referred to as the 3D_C12 family, to be the best 
candidates for playing a direct role in the metabolic conver-
sion of nicotine to nornicotine in converter tobacco plants. 
The hybridization results of the members of this P450 family 
in each of the three microarray experiments are shown in 
Table 1. The results of the microarrays were independently 
confirmed using Northern blotting assays. As shown in FIG. 
2, an approximately 2-fold higher signal was observed in 
senescing, cured converter leaves compared to their noncon-
verter counterparts when RNA blots were incubated with a 
radiolabeled 7D_A06 hybridization probe. 
Example 4 
Sequence Analysis of the 3D_C12 Gene Family 
Once microarray experiments defined 3D_C12 and 
7D _A06 as potentially being involved in the conversion pro-
cess, obtaining complete DNA sequence information for 
these genes became the next step in their characterization. 
The original 3D_C12 and 7D_A06 clones that were 
Cy5/Cy3 
ratio 
3.67 
identity at the protein level (Tables 2 and 3). Initial BLASTX 
45 analysis against the nonredundant GenBank database 
revealed that 3D_C12 and 7D_A06 share greatest sequence 
homology to CYP82E1, a tobacco P450 gene of unknown 
function that is upregulated in response to fungal elicitors 
(Takemoto eta!. (1999) Plant Cell Physiol. 40:1232-1242). 
50 The CYP82E1 protein is 66.9% and 67.5% identical to the 
predicted amino acid sequences of3D_C12 (SEQ ID N0:2) 
and 7D_A06 (SEQ ID NO:S), respectively, and the CYP82E1 
DNA sequence is 72.1% and 73.5% identical to the respective 
coding sequences for 3D_C12 (nt 1-1551 of SEQ ID N0:1) 
55 and 7D_A06 (nt 1-1554 of SEQ ID N0:7). 
60 
TABLE2 
Nucleotide sequence identities between members oftbe 3D_C12 gene 
famil. 
7D_A06 
3D_C12-7 
3D C12 7D_A06 
3D_C12- 3D C12- 3D_C12-
7 10 15* 
65 3D_C12-10 
93.4** 
93.7 
93.7 
95.5 
94.0 
94.4 
92.6 
99.7 
93.1 3D_C12- 92.8 
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TABLE 2-continued 
Nucleotide sequence identities between members oftbe 3D_C12 gene 
famil. 
48 
(SEQ ID N0:5) (FIGS. 3A-3G), and at only two amino acids 
positions from the predicted 3D_ C 12-7 protein product (SEQ 
ID N0:6) (FIG. 4). 
With the completion of the nonconverter EST database, 
3D C12- 3D C12- 3D C12- 5 another member of the 3D_C12 gene family was revealed. 
15* 
131A_A02* 
3D_C12 7D_A06 
98.0 94.0 
7 
93.4 
10 
93.1 
15* 
93.1 
The partial DNA sequence of 131A_A02 (SEQ ID NO: 11; 
predicted amino acid sequence set forth in SEQ ID N0:12) 
that is found in this database is 98.0% identical to the corre-
sponding sequence of 3D_C12, and 94.0% identical to the 
*partial sequences 
**numbers indicate percentages 
TABLE3 
10 same region of 7D_A06 (FIGS. 3A-3G and Table 2). As 
described in the previous section, 131A_A02 is a member of 
the 3D_C12 gene family that was represented on the compre-
hensive unigene chip used in microarray assays as described 
elsewhere herein. 
Predicted amino acid sequence identities between full-lengtb members of 15 
tbe 3D C12 gene family. 
3D C12 
7D_A06 
3D C12-7 
3D C12-10 
**numbers indicate percentages 
92.3* 
92.8 
92.5 
7D_A06 
94.8 
94.4 
3D C12-7 
99.6 
20 
In addition to enabling the acqmsJtJon of full-length 
sequence information for the 3D_C12 and 7D_A06 cDNAs, 25 
the above described PCR amplifications yielded additional 
products that were closely related to, yet clearly distinct from, 
the 3D_C12 and 7D_A06 eDNA sequences. Using a primer 
directed against a sequence interior to the 3D_C12 eDNA, in 
combination with a primer specific to pB!uescript II, a unique 30 
sequence designated 3D_C12-15 (FIGS. 3A-3G; SEQ ID 
N0:9; predicted amino acid sequence shown in SEQ ID 
N0:10) was amplified in addition to the expected 3D_C12 
product. 3D_C12-15 is 95.5% identical to the corresponding 
DNA sequence of3D_C12 and 92.6% identical to the same 35 
region of7D_A06 (Table 2). 
Because the 3D_C12-15 fragment represented an addi-
tional, distinct member of the 3D_C12 gene family, an 
attempt was made to obtain a full-length eDNA sequence of 
this gene. A PCR primer specific to the first seven codons of 
40 
the 3D_C12-15 reading frame was used in combination with 
a pB!uescript II-specific primer in an amplification reaction 
using our converter eDNA library as template. Sequence 
analysis of several independent amplification products failed 45 
to reveal a full-length 3D_C12-15 gene. Instead, a new mem-
ber of this family was recovered, designated 3D_C12-7 
(FIGS. 3A-3G; coding sequence set forthasnt 1-1551 of SEQ 
ID N0:5). Across the full-length nucleotide sequence shown 
in SEQ ID N0:5, 3D_C12-7 shares 93.7% nucleotide 50 
sequence identity with 3D_C12 (across SEQ ID N0:1), 
94.0% nucleotide sequence identity with 7D_A06 (across 
SEQ ID N0:7), and 93.1% identity over the corresponding 
region of fragment 3D_C12-15 (SEQ ID N0:9) (Table 2). 
The predicted amino acid sequence of 3D_C12-7 (SEQ ID 55 
N0:6) is 92.8% identical to the 3D_C12 protein (SEQ ID 
N0:2), and 94.8% identical to the 7D_A06 protein (SEQ ID 
N0:8) (Table 3). 
Two additional members of the 3D_C12 family were also 
identified. A gene designated 3D_C12-10 (FIGS. 3A-3G; 60 
coding sequence set forth as nt 1-1551 of SEQ ID N0:3; 
predicted amino acid sequence set forth in SEQ ID N0:4) was 
recovered from an amplification reaction using a PCR primer 
complementary to a sequence in the 3' flanking region of 
3D_ C 12 together with a Bluescript II -specific primer (and the 65 
converter library as template). 3D_C12-10 differs at only five 
nucleotide positions from the 3D_ C12-7 nucleotide sequence 
Example 5 
Transgenic Plant Analysis of Members ofthe 
3D_C12 Gene Family 
To determine whether members of the 3D_C12 family of 
cytochrome P450 genes are involved in the metabolic con-
version of nicotine to nomicotine, transgenic plants were 
generated using constructs designed to either enhance or 
inhibit gene expression. To test the effects of down-regulating 
gene activity, an RNA interference (RNAi) strategy was 
employed. A 99-bp region of 3D_C12 located immediately 
upstream of the stop codon (FIGS. 3A-3G), was used to create 
a construct that would form a dsRNA hairpin within the plant 
cell. Such dsRNA structures are known to activate an RNAi 
silencing complex that leads to the degradation of both trans-
gene RNAs and endogenous RNAs that are identical or highly 
homologous to the sequence found in the dsRNA (Wesley et 
a!. (2001) Plant J. 27: 581-590; Waterhouse & Helliwell 
(2002) Nat. Gen. Rev. 4: 29-38). 
Given that each member of the 3D_C12 characterized as 
described herein shares over 90% DNA sequence identity, an 
RNAi construct synthesized against one member was 
expected to silence the entire gene family. Specifically, the 
RNAi construct generated against the 3D_C12 sequence 
shares sequence identities of 90/99 and 91/99 with the 
7D_A06 and 3D_C12-7 cDNAs, respectively, over this 
region (FIGS. 3A-3G). The 3D_C12/RNAi construct (also 
referred to in Example 7 as the 3D_Cl2Ri99 construct) was 
cloned downstream of the constitutive 35S promoter of cau-
liflower mosiac virus (CaMV) and introduced into the strong 
converter Burley tobacco line DH 98-325-6 using Agrobac-
terium-mediated transformation. 
A hallmark of RNAi-mediated silencing is the marked 
reduction in steady-state transcript accumulation of the gene 
whose activity has been down-regulated. To confirm that gene 
silencing of the 3D_C12 gene family had occurred in the 
plants showing low nomicotine phenotypes, a Northern blot 
analysis was conducted using RNAs isolated from three of the 
transgenic plants possessing 3D_C12/RNAi constructs and 
displaying low nomicotine phenotypes, two individuals 
transformed with the 3D_C12/RNAi construct yet still show-
ing high levels of nomicotine, and one of the vector-only 
control plants. 
To assess the affects of overexpression of gene activity, the 
cDNAs from the three members of the 3D_C12 gene family 
for which we first obtained full-length sequence information 
(3D_C12, 7D_A06, and 3D_C12-7) were cloned in their 
sense orientations downstream of the 35S CaMV promoter. 
These constructs were subsequently introduced into N. 
tabacum cultivar Petite Havana using Agrobacterium-medi-
ated transformation. The Petite Havana line is commonly 
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used by researchers because of its shorter stature and abbre-
viated generation time in relation to commercial tobacco 
cultivars. The converter/nonconverter status of the Petite 
Havana cultivar is unknown, but the alkaloid assays of the 
present application clearly showed that the plants in our pos-
session were strong converters. 
Although the host plants in these experiments were con-
verters, the present strategy was to conduct alkaloid assays on 
green, non-cured tissue, where minimal nornicotine accumu-
lates in converter and nonconverter plants alike (and the 3 5 S 
CaMV promoter is very active). In fact, a nonconverter line 
was purposely chosen because tissue culturing, as required 
when conducting Agrobacterium-mediated transformation, 
is known to enhance the frequency of genetic conversion and 
would thus potentially complicate interpretation of results 
(e.g., assessing whether a novel phenotype was solely attrib-
utable to the transgene as opposed to being the result of the 
plant having undergone genetic conversion). 
Results 
Given the high degree of variability typically observed 
among independent transgenic plants transformed with the 
same transgene construct, 10 independently transformed 
individuals were selected to assess the effects of the 3D_C12/ 
RNAi construct on the metabolic conversion of nicotine to 
nomicotine. Leaves from each of the 10 3D_C12/RNAi indi-
viduals, in addition to two control plants transformed with the 
pBI121 vector alone, were treated with ethephon and cured 
for seven days. Alkaloid analysis of these materials is shown 
in Table 4. 
TABLE4 
50 
struct displayed minimal nicotine to nornicotine conversion, 
with conversion percentages ranging from 2.8 to 7.0 percent. 
The other three 3D_C12/RNAi lines displayed alkaloid con-
tents similar to the vector-only control plants. Concentrations 
of the minor alkaloids anabasine and anatabine did not appear 
to be significantly influenced by the presence or absence of 
the 3D_C12/RNAi transgene (Table 4). 
Although the eDNA insert of the 3D_C12-7 gene was used 
as the specific hybridization probe, at the hybridization and 
10 wash conditions used in this experiment, cross-hybridization 
to the entire 3D_C12 gene family would be expected. As 
shown in FIG. 5, a strong hybridization signal was detected in 
each plant showing a high nomicotine phenotype, and mini-
mal hybridization was detected in the plants transformed with 
15 
the 3D_C12/RNAi construct that showed a low nornicotine 
phenotype. We thus conclude that the effective silencing of 
the 3D_C12 gene family inhibits the metabolic conversion of 
nicotine to nomicotine in tobacco. 
Alkaloid analysis of the Petite Havana transgenic plants is 
shown in Table 5. Four independently transformed plants 
20 containing the 35S:3D_C12 and 35S:3D_C12-7 constructs 
were tested along with seven independent 35S:7D_A06 indi-
viduals and three plants independently transformed with the 
pBI121 control vector. As expected, the green, non-cured 
leaves of the three vector-only control plants contained mini-
25 mal amounts of nomicotine. Likewise, all plants transformed 
with the 35S:3D_C12 and 35S:7D_A06 constructs showed 
minimal metabolic conversion of nicotine to nomicotine. A 
very different phenotype, however, was observed with plants 
Alkaloid analysis ofDH 98-325-6 plants independently transformed with the 3D_C12/RNAi 
construct (and pBI121 vector control). Leaves were treated with ethephon and cured for 
seven da s. 
% % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* 
3D_C12 RNAi (1) 3.149 0.100 0.012 0.159 
3D_C12 RNAi (2) 2.569 0.193 0.009 0.110 
3D_C12 RNAi (3) 2.175 0.064 0.007 0.080 
3D_C12 RNAi (4) 3.517 0.125 0.012 0.139 
3D_C12 RNAi (5) 1.085 0.868 0.009 0.119 
3D_C12 RNAi (6) 0.025 2.260 0.011 0.122 
3D_C12 RNAi (7) 0.027 1.867 0.011 0.122 
3D_C12 RNAi (8) 2.268 0.128 0.009 0.102 
3D_C12 RNAi (9) 2.197 0.133 0.008 0.099 
3D C12RNAi 2.434 0.112 0.009 0.110 -
(10) 
vector control (3) 1.811 1.1735 O.G18 0.170 
vector control (11) 0.290 2.090 0.013 0.143 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
Typical ofline DH 98-325-6, ethephon treatment and cur-
ing resulted in substantial nomicotine production in the two 
control plants ( 48.9% and 87.8% conversion of nicotine to 
nomicotine). In dramatic contrast, seven of the ten indepen-
dent transgenic plants possessing the 3D_C12/RNAi con-
50 
% 
Conversion** 
2.8 
7.0 
2.9 
3.4 
44.4 
98.9 
98.6 
5.3 
5.7 
4.4 
48.9 
87.8 
transformed with 35S:3D_C12-7. All four plants indepen-
dently transformed with this construct contained nornicotine 
as the predominant alkaloid in the green, nontreated leaf; 
nicotine to nomicotine conversion percentages ranged from 
94.6 to 98.6. 
TABLES 
Alkaloid analysis of individual Petite Havana plants transformed with 3D_C12, 3D_C12-7, 
7D_A06 constructs or the pBI121 vector control. Green leaves were harvested and analyzed 
without treatment or curing. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
vector control (2) 0.673 0.018 0.006 O.G18 2.6 
vector control (8) 0.605 0.014 0.005 0.016 2.3 
vector control (10) 0.694 0.017 0.004 O.G18 2.4 
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TABLE 5-continued 
Alkaloid analysis of individual Petite Havana plants transformed with 3D_C12, 3D_C12-7, 
7D_A06 constructs or the pBI121 vector control. Green leaves were harvested and analyzed 
without treatment or curing. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
35S:3D_C12 (1) 0.706 0.005 0.006 0.020 0.7 
35S:3D_C12 (2) 0.814 0.022 0.007 0.017 2.6 
35S:3D_C12 (3) 0.630 0.010 0.003 0.012 1.6 
35S:3D_C12 (4) 0.647 0.010 0.004 0.011 1.5 
35S:3D_C12-7 (1) 0.005 0.347 0.002 0.012 98.6 
35S:3D_C12-7 (2) 0.006 0.255 0.002 0.009 97.4 
35S:3D_C12-7 (3) 0.017 0.300 0.002 0.010 94.6 
35S:3D_C12-7 (4) 0.010 0.384 0.002 O.G15 97.5 
35S:7D_A06 (1) 0.761 0.011 0.005 O.G18 1.4 
35S:7D_A06 (2) 0.507 0.009 0.003 0.007 1.7 
35S:7D_A06 (4) 0.653 0.015 0.006 O.G15 2.2 
35S:7D_A06 (5) 0.643 0.013 0.004 O.G18 2.0 
35S:7D_A06 (6) 0.521 0.007 0.004 0.014 1.3 
35S:7D_A06 (7) 0.716 0.015 0.005 0.020 2.1 
35S:7D_A06 (8) 0.701 0.027 0.004 O.G18 3.7 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
Example 6 35S:3D_C12 (1) and two vector-only control plants. As 
Cosuppression of the 3D_C12 Gene Family 
25 shown in Table 6, ethephon treatment and curing resulted in 
over 97% nicotine to nomicotine conversion in the two con-
trol plants whereas similarly treated 35S:3D_C12 (1) leaves 
displayed negligible conversion (0.6%). Leaves from five 
other plants expressing either35S:3D_C12 and35S:7D_A06 
transgenes were also subjected to ethephon treatment and 
In addition to the major conclusion that the 3D_C12-7 gene 
30 
was capable of mediating nicotine to nornicotine conversion, 
one additional observation stood out in the alkaloid analyses 
of the Petite Havana transgenic plants. The alkaloid results 
reported in Table 5 together with additional alkaloid assays 
curing. In each case a high nomicotine phenotype was 
observed, similar to the vector-only control plants (data not 
shown). 
TABLE6 
Alkaloid analysis of35S:3D_C12 (1) and pBI121 vector controls plants. Leaves were 
treated with ethephon cured for seven days. 
% % % % % 
Sample Nicotine* Nornicotine* Anabasine* Anatabine* Conversion** 
vector control (8) 0.009 0.425 n.d. 0.011 97.9 
vector control (10) 0.008 0.560 n.d. 0.025 98.6 
35S:3D_C12 (1) 1.185 0.007 n.d. 0.020 0.6 
*percentage of leaf dry weight 
**[% nornicotine/(% nicotine+ nornicotine)] x 100 
n.d., not detected 
conducted independently (data not shown) consistently 
showed one of the plants transformed with the 35S:3D_C12 
construct (35S:3D_C12(1)) as having less nornicotine in the 
green, nontreated leaf than any other plant in this study. This 
may be the result of co suppression of the 3D_C12 gene fam-
Finally, Northern blot assays were conducted on select 
50 plants representing each of the Petite Havana transgenic 
genotypes (FIG. 6). Using a 3D_C12-7 eDNA as a hybrid-
ization probe, minimal signal was detected with RNAs iso-
lated from green, nontreated leaves of the vector-only control 
ily in this specific plant, a phenomenon frequently observed 55 plant. In contrast, hybridization was easily detected in RNA 
in transgenic plants even when a trans gene is expressed in its 
sense orientation (Fagard and Vaucheret (2000) Annu. Rev. 
Plant Physiol. Plant Mol. Biol. 51: 167-194). 
If plant 35S:3D_C12 (1) was truly displaying a co suppres-
sion phenotype, this phenotype would be expected to be 
maintained even upon ethephon treatment and curing of the 
leaves, similar to the low nornicotine phenotypes conferred 
samples from all four independent transgenic plants possess-
ing the 35S:3D_C12-7 construct. A strong hybridization sig-
nal was similarly observed using RNAs from all other trans-
60 genic plants tested that were transformed with the 35S: 
3D_C12 and 35S:7D_A06 constructs, with the exception of 
the low nomicotine containing plant 35S:3D_C12 (1). 
by the 3D_ C 12/RNAi construct in the converter genotype D H 
65 
Overall results of the Northern blotting assays show that 
the 35S CaMV promoter was generally effective in mediating 
a high level of gene expression for each of the three members 
of the 3D_C12 gene family tested in this study. Failure to 98-325-6 as described above. To test this prediction, alkaloid 
profiles were determined on ethephon treated, cured leaves of detect a hybridization signal in plant 35S:3D_C12 (1) is con-
US 9,187,759 B2 
53 
sistent with the interpretation that the 3D_C12 gene family 
has been silenced via co suppression in this individual. 
Example 7 
Additional Characterization and Suppression of 
Additional3D_C12 Genes 
A second RNAi construct was prepared using polynucle-
otide sequences from the 3D_C12-7 sequence. The assembly 
of the 3D_C12-7/RNAi expression cassette followed the 
same basic steps as those outlined for 3D_C12/RNAi above. 
Briefly, a 298-bp sense and antisense strand of the 3D_C12-7 
eDNA (SEQ ID N0:5) corresponding to the region between 
nucleotide positions 297 and 594 of the coding sequence 
(positions 1-1551 of SEQ ID N0:5) were ligated into the 
pKYLX801 vector downstream and upstream of the 151-bp 
soybean omega-6 fatty acid desaturase intron (see GenBank 
Accession No. DQ6n337), respectively. The primers 
(E4SFwd and E4SRev) used for the isolation of the 298-bp 
region by sense and antisense arms were 
5'-AAGCTTTGACGCCATTTTTTCCAATCG-3' (SEQ ID 
N0:27), and 5'-CTCGAGTTTTCCAGCGATCATCT-
TCAC-3' (SEQ ID N0:28), respectively. The RNAi cassette 
was excised from pKYL801 and placed between a strong 
CaMV35S2 promoter and a rubisco small subunit terminator 
of the binary plant expression vector, pKYLX71 (see FIG. 8). 
In the discussions below, this RNAi construct is referred to as 
the 3D_C12-7-Ri298 construct. 
Transgenic tobacco plants were generated via Agrobacte-
rium-mediated transformation following the procedures pro-
vided above. Briefly, transformed burley tobacco plants were 
regenerated from calli on Murashige-Skoog (MS) medium 
supplemented with 100 mg/L kanamycin and plant hormones 
in a growth room maintained at 25° C. under a 16 hr/8 hr 
light/dark cycle. Calli were transferred to fresh selection 
media every 2-3 weeks until shoots appeared. Small shoots 
were transferred to rooting media to allow root development 
for 2 weeks. Fully regenerated plants were transferred to a 
greenhouse and grown under standard conditions. 
SYBR® Green I Chemistry 
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a-tubulin gene was used as an internal standard. 3D_C12-7 
eDNA concentration was determined from the transcript-
specific calibration curve and normalized to the internal stan-
dard. Fold-induction was calculated by dividing the normal-
s ized fluorescence values of the converter by the nonconverter 
samples. Melting-curve analysis was used to confirm the 
purity of PCR products as described in Ririe eta!. (1997) 
Anal. Biochem. 245:154-160. Two plants were sampled per 
treatment and amplifications were repeated three times. 
10 TaqMan® Chemistry 
Total RNA was isolated from tobacco lines using TRizol 
reagent. Purified RNA was treated with RNase-free DNase 
(TURBO DNA-free™). First strand eDNA was synthesized 
using 10 flg of total RNA and the High Capacity eDNA 
15 Archive Kit (Applied Biosystems, Foster City, Calif.). The 
RT-PCR mixture contained 1xTaqMan® Universal PCR 
Master Mix (Applied Biosystems, Foster City, Calif.), 400 
nM of each primer (E4TmFwd and E4TmRev), 250 nM Taq-
Man® minor groove binder (MGB) probe (E4MGB), 2 ng of 
20 eDNA, and nuclease-free water (Afonina eta!. (2002) Rio-
techniques 32:940-949). The primer and probe sequences 
were 5'-CGGTAATCGGCCATCTTTTC-3' (E4TmFwd 
(SEQ ID N0:31)), 5'-CCGAGTTTTCGAGCTAATGGA-3' 
(E4TmRev(SEQ ID N0:32)), and 5'-CAATGACGAACG-
25 GCGACAG-3' (MGB probe(SEQ ID N0:33)). RT-PCR was 
performed in anABI 7500 Real-Time System (Applied Bio-
systems, Foster City, Calif.) set to the following protocol: 50° 
C. for 2 min; 95° C. for 10 min; 40 cycles of95° C. for 15 sec, 
60° C. for 1 min. Glyceraldehyde-3-phosphate dehydroge-
30 nase (G3PDH) was used as the endogenous control to nor-
malize the amount of eDNA template in the reactions. Fold-
change was determined by dividing the normalized 
fluorescence values of each sample by those obtained from a 
nonconverter or uncured control sample. For each treatment, 
35 RNA was isolated from three independent plants and ampli-
fications were repeated 3 times per RNA sample. 
Northern and Southern Blot Analyses 
Total RNA was isolated from cured tobacco leaves using 
the TRizol reagent according to the manufacturer's instruc-
40 tions (Invitrogen, Life Technologies). Total RNA samples 
were separated on 1.2% TBE agarose gel, and transferred to 
positively charged nylon membranes by electro blotting with 
2xTBE buffer. Membranes were UV crosslinked and washed 
Total RNA was isolated from cured leaves of converter and 
nonconverter burley tobacco plants using the TRizol® 
reagent (Invitrogen, Life Technologies, Carlsbad, Calif.). 
Purified RNA was treated with RNase-free DNase (TURBO 45 
DNA-free™, Ambion, Austin, Tex.). First strand eDNA was 
synthesized using 5 flg of total RNA and the StrataScript® 
First-Strand Synthesis System (Stratagene, Cedar Creek, 
Tex.). Relative quantitative RT-PCR was employed for deter-
miningthe abundanceofthe3D_C12-7 eDNA using SYBR® so 
Green I fluorescence chemistry Morrison et a!. (1998) Bio-
techniques 24:954-962. 
in 2xSSC for 5 min. Northern blot hybridization, washing, 
and detection were carried out using the digoxigenin (DIG) 
System as described by the manufacturer (Roche Diagnostics 
Corp., Indianapolis, Ind.). The 1.8 kb full-length ORF of the 
3D_C12-7 eDNA was labeled with DIG and used as a probe. 
Genomic DNA was extracted with DNAzol® (Invitrogen, 
Life Technologies) from green tobacco leaves according to 
manufacturer's protocol. After incubation with FcoR1 or 
Nco! restriction enzymes overnight, 15 flg of the digested 
DNA was separated on 0.7% TBE agarose gel, depurinated 
with 0.25 M HCI for 10 min, and denaturated with 0.5 N 
A calibration curve was generated with a serial dilution of 
the 3D_ C 12-7 eDNA cloned into the pGEM®-T Easy vector 
(Promega Corporation, Madison, Wis.). The RT-PCRmixture 55 
contained 2.5 mM MgCI2 , 125 f.LM each dNTP, 0.5 f.LM each 
primer, 0.5xSYBR® Green I, 0.5 flg eDNA (or 1 fll reference 
plasmid), and 1.25 U Platinum Taq polymerase (Invitrogen 
Life Technologies). The sequences of the allele-specific 
3D_C12-7 primers (E4SyFwdandE4SyRev)were 5'-ACGT- 60 
GATCCTAAACTCTGGTCTG-3' (E4SyFwd (SEQ ID 
N0:29)) and 5'-GCCTGCACCTTCCTTCATG-3' (E4SyRev 
(SEQ ID N0:30)). RT-PCR was performed in a BioRad iCy-
cler thermocycler (BioRad Laboratories, Hercules, Calif.) set 
to the following protocol: 95° C. for 2 min; 35 cycles of 95° 65 
C. for 30 sec, 55° C. for 30 sec no C. for 50 sec, followed by 
final extension at no C. for 5 min. A 165-bp fragment of the 
NaOH for 30 minutes. DNA was blotted overnight by capil-
lary transfer onto positively charged nylon membranes 
(Roche Diagnostics Corp.) and hybridized at 65° C. overnight 
with a 515-bp DIG-labeled fragment of the neomycin phos-
photransferase II (NPT II) gene. Hybridization, washing, and 
detection were performed according to the protocols supplied 
with the DIG System. The primers used for the amplifications 
of the Northern and Southern hybridization probes were 
E4FIFwsd (5'-ATGGTTTTTCCCATAGAAGCC-3' (SEQ ID 
N0:34)), E4FIRev (5'-TTTTTGGGACAATCAGTCAAT-3' 
(SEQ ID N0:35)), KanFwd (5'-TGAATGAACTGCAG-
GACGAG-3' (SEQ ID N0:36)), and KanRev (5'-AATAT-
CACGGGTAGCCAACG-3' (SEQ ID N0:37)). 
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Alkaloid Analysis 
Tobacco leaves were harvested and air dried in an oven at 
50° C. for 2 days. A 100 mg sample of crushed, dried leaf is 
added to 0.5 ml of2 N NaOH in a 20 ml scintillation vial. The 
sample was mixed and allowed to incubate for 15 minutes at 
room temperature. Alkaloids were extracted by the addition 
56 
chemistry revealed an 80-fold increase in the levels of the 
3D_C12-7 transcript in the cured leaves of converter versus 
nonconverter tobacco. A single peak melting curve and gel 
electrophoretic analyses of the amplicons confirmed the 
homogeneity of the PCR products. 
In the TaqMan® chemistry-based RT-PCR experiment, 
3D_C12-7 transcript levels were quantified in untreated and 
ethephon-treated converter and nonconverter tobacco leaves 
that were cured for 0, 1 or 5 days. Low levels of3D_C12-7 
of 5 ml of extraction solution [0.04% quinoline (wt/vol) dis-
solved in methyl-t-butyl ether] and gently rotated on a linear 
shaker for 3 hours. Following phase separation, an aliquot of 
the organic phase was transferred to a sample vial. Samples 
were analyzed using a PerkinElmer Autosystem XL (Perki-
nElmer, Boston, Mass.) gas chromatograph equipped with a 
flame ionization detector, a 4 mm split/splitless glass liner and 
10 transcripts were detected in the uncured leaves or following a 
1-day curing period regardless of conversion type or ethep-
hon treatment. Similarly, base line levels of3D_C12-7 tran-
scription were observed in converter or nonconverter leaves 
that were cured for 5 days without ethephon treatment. In a 30 mx0.53 mm ID DB-5 column. Chromatographic condi-
tions were as follows: detector temperature: 250° C.; injector 
temperature: 250° C.; helium flow at 120° C.: 20 ml/min; 
injection volume: 2 fll; colunm conditions: 120°, hold 1 min, 
20-280° C. at 30° C./min ramping rate, hold at 280° C. for 2 
min. Alkaloid composition was determined by the Total-
Chrome Navigator software using a calibration curve. Means 20 
of the alkaloid measurements were separated according to 
Fisher's Protected LSD (PROC MIXED). 
15 contrast, a 7.5-fold increase in 3D_C12-7 transcript accumu-
lation was detected in the cured leaves of converter versus 
Plants 
Double haploid burley tobacco lines DH 98-325-5 (325-5; 
nonconverter) and DH98-325-6 (325-6; converter) described 25 
above were used in all experiments, except for the fluorogenic 
5' nuclease (TaqMan®) chemistry-based RT-PCR assays 
where the isogenic DH 91-1307-46 (nonconverter) and DH 
91-1307-46 (converter) lines were used. All plants were 
grown in a controlled environment greenhouse equipped with 30 
supplemental lighting providing, a 14 hr/10 hr light/dark 
cycle. 
For curing, tobacco leaves were collected from converter 
and nonconverter plants about 1 month before flowering and 
treated by dipping each leaf twice for 10 sec, into 2% ethep- 35 
hon and dried for 2 hours. Leaves were cured for up to two 
weeks in plastic bags, under dark conditions, until they turned 
yellow. Cured leaves were used for the Northern and alkaloid 
analyses. Samples of cured leaves subjected to GC analysis 
were dried at 50° C. for 2 days. For Southern analysis, green 40 
tobacco leaves of adult plants were used. To produce T 1 
generation transgenic plants, primary transformants (T0 ) 
were self-pollinated, and the harvested T 1 seed was screened 
by germinating seedlings on MS-agar plates containing 100 
mg/L kanamycin for 6 weeks. Survivors were transplanted to 
soil and grown in a greenhouse as described above. Plants 
were fertilized with Peter's Professional All Purpose Plant 
Food (20-20-20; Spectrum Brands Inc., Madison, Wis.) once 
a week. 
RT-PCR Analysis of3 D _ C 12-7 Expression in Converter and 
Nonconverter Tobacco 
To further characterize the role of 3D_C12-7 in nicotine 
N-demethylation, experiments were performed to demon-
strate that the regulation of3D_C12-7 expression is consis-
tent with the levels of nicotine N-demethylation activity 
observed in converter versus nonconverter tobacco. 
To determine the rate of3D_C12-7 mRNA accumulation 
in converter and nonconverter tobacco, an allele-specific real-
time RT-PCR strategy was employed. Because RT-PCR 
involves the detection and measurement of the amplification 
products of a PCR template, the use of allele-specific primers 
allows the quantification of a single isoform among a group of 
highly homologous sequences. For accurate quantification of 
the 3D_ C 12-7 transcript, two different segments of the 
3D_C12-7 coding region were amplified and both SYBR® 
Green and TaqMan® chemistries were used to generate fluo-
rescence signals. RT-PCR analysis using the SYBR® Green I 
45 
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nonconverter tobacco, and a 70-fold increase was observed in 
the uncured versus cured leaves of a converter tobacco variety 
when ethephon treatment preceded the 5-day curing period. 
While not intending to be limited by any particular theory, 
these results suggest that 3D_C12-7 is a major contributor to 
nicotine N-demethylation and is strongly inducible by ethyl-
ene in senescing tobacco leaves. 
Suppression of Nicotine to Nornicotine Conversion by the 
3D_C12-Ri99 and 3D_C12-7-Ri298 Constructs 
To compare the extent to which 3D_C12 and 3D_C12-7 
mediate the suppression of nornicotine production, converter 
and nonconverter burley tobacco plants were transformed 
with the two gene silencing vectors. Ten (10) transgenic 
plants were regenerated per RNAi construct. About 80% of 
tobacco plants overexpressing either the 99-bp or 298-bp 
inverted repeat showed reduced nornicotine levels compared 
to the empty vector controls (Tables 7 and 8). In the noncon-
verter genotype, 3D_C12-Ri99 and 3D_C12-7-Ri298 
expression reduced nicotine to nornicotine conversion by 
about 1.8-fold (2.0%) and 3.0-fold (1.2%), respectively, in 
comparison to the rate of conversion detected in the vector 
controls (3 .6%) (Table 7). Among the silenced nonconverter 
plants, the lowest conversion level of 0.9% was achieved 
using the 3D_C12-7-Ri298 construct (Table 7). 
TABLE 7 
Alkaloid analysis ofnonconvertor burley tobacco plants transformed witb 
tbe 3D C12-Ri99 or 3D C12-7-Ri298 construct. 
Linec % Nicotined % Nornicotined % Conversione 
3D-C12-Ri99 
1.693 0.034 2.0 
2 1.435 0.031 2.1 
2.095 0.043 2.0 
4 2.868 0.053 1.8 
0.947 0.025 2.6 
2.357 0.043 1.8 
7 2.599 0.043 1.6 
0.796 0.020 2.4 
9 2.178 0.039 1.8 
10 3.162 0.061 1.9 
MEAN 2.013 0.039 2.0a 
STE 0.748 0.012 0.3 
3D C12-7-Ri298 
1.806 0.020 1.1 
4 1.948 0.207 1.4 
2.061 0.020 1.0 
2.704 0.040 1.5 
2.652 0.023 0.9 
9 1.074 O.G15 1.3 
MEAN 2.041 0.024 1.2b 
STE 0.550 0.008 0.2 
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TABLE 7 -continued 
Alkaloid analysis ofnonconvertor burley tobacco plants transformed witb 
tbe 3D C12-Ri99 or 3D C12-7-Ri298 construct. 
% Nicotined % Nornicotined % Conversione 
Vector Controlg 
1.206 0.052 4.2 
2 1.265 0.038 2.9 
1.752 0.058 3.2 
4 1.230 0.072 5.6 
1.777 0.060 3.3 
1.536 0.044 2.8 
MEAN 1.461 0.054 3.6c 
STE 0.240 0.011 1.0 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
bOf the plants transformed with an RNAi construct, only silenced individuals are shown. 
Alkaloid data represent the means of 2 measurements. 
'Numbers represent independently transformed individuals. 
«'percentage of leaf dry weight. 
10 
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TABLE 8-continued 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
Linec % Nicotined % Nornicotined % Conversione 
0.060 1.419 95.9 
4 0.114 1.267 91.7 
0.119 1.303 91.6 
MEAN 0.150 1.628 92.1c 
STE 0.093 0.498 2.3 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
bOfthe plants transformed with an RNAi construct, only silenced individuals are shown. 
15 <Numbers represent independently transformed individuals. 
dPercentage of leaf dry weight. 
e[% nornicotine/(% nicotine+% nornicotine )] x 1 00; values followed by different letters are 
significantly different according to Fisher's Protected LSD (0.05). 
fsTE, standard error 
e[% nornicotine/(% nicotine+% nornicotine )] x 1 00; values followed by different letters are 
J~f~~~~~Jar~~:~;t according to Fisher's Protected LSD (0.05). 
20 
gTobacco plants transformed with onlypKYLX71 vector were used as controls. 
8Tobacco plants transformed with only pKYLX71 vector were used as controls. To test the heritability of nornicotine suppression in the 
3D_C12-7-Ri298-transformed plants, a set of 3D_C12-7-
Ri298-transformed converter and nonconverter lines that dis-
played the lowest levels of nicotine conversion were 
advanced to the T 1 generation (Table 9). Because segregation 
of the transgene( s) occurs in the T 1 progeny, transgenic indi-
viduals were identified by selecting seedlings capable of 
growing on kanamycin-containing media. Nine kanamycin-
Relative to nonconverter tobacco, nornicotine accumula-
tion was suppressed even more dramatically in the silenced 
individuals of the strong converter plants (Table 8). Using 25 
3D_C12-Ri99 constructs, nicotine conversion was reduced to 
levels as low as 4.5% in 3D_C12-Ri 99-transformed 325-6 
tobacco plants in sharp contrast to the 325-6 control plants 
exhibiting about 98% conversion rates; Table 8). However, 
using the 3D_ C 12-7-Ri298 construct even greater reductions 30 resistant progenies of each selected T0 -generation 3D_C12-
7 -Ri298 transformant and four kanamycin-resistant individu-
als from each selected vector control line were analyzed for 
alkaloid content. The rate of nicotine conversion did not differ 
significantly between the primary 3D_C12-7-Ri298 transfor-
in nicotine conversion were obtained (Table 8). Four 
3D_C12-7-Ri298-transformed individuals converted as low 
as 0.8% of their nicotine to nornicotine, and the arithmetic 
mean across the 9 silenced transformants was 0.9% conver-
sion. All silenced plants were morphologically indistinguish-
able from both the empty vector and wild-type controls (data 
not shown). 
TABLES 
Alkaloid analysis of convertor burley tobacco plants transformed witb tbe 
3D C12-Ri99 or 3D C12-7-Ri298 construct. 
% Nicotined % Nornicotined % Conversione 
3D C12-Ri99 
3.419 0.100 2.8 
2 2.569 0.193 7.0 
2.175 0.064 2.9 
4 3.517 0.125 3.4 
2.268 0.128 5.3 
9 2.197 0.133 5.7 
10 2.434 0.112 4.4 
MEAN 2.654 0.122 4.5a 
STF 0.573 0.039 1.6 
3D C12-7-Ri298b 
2.043 0.020 1.0 
2 3.427 0.026 0.8 
2.603 0.020 0.8 
2.427 0.030 1.2 
2.106 0.021 1.0 
7 1.412 O.G15 1.1 
3.328 0.028 0.8 
9 1.493 O.G15 1.0 
10 2.065 O.G18 0.8 
MEAN 2.323 0.021 0.9b 
STE 0.669 0.005 0.1 
Vector Controlh,i 
0.126 1.550 92.5 
2 0.330 2.604 88.8 
35 mants and their T 1 progeny, indicating high heritability of the 
nornicotine suppression trait (see Tables 7, 8, and 9). How-
ever, advancing the "nonconverter" vector control line by a 
single generation increased the nicotine to nornicotine con-
version rate from 4.2% to an average value of 11.6%, illus-
40 trating the high degree of instability of the conversion locus in 
transgenic plants lacking the 3D_C12-7-Ri298-specific 
RNAi construct (Tables 7 and 9). Overall, these results show 
that RNAi-mediated silencing of the 3D_C12 gene subfamily 
45 
is a highly effective means of lowering nornicotine produc-
tion in bothnonconverter and strong converter tobacco plants. 
TABLE9 
Alkaloid analysis ofT,-generation 3D C12-7-Ri298 transformants. 
50 
Line % Nicotinec % Nornicotinec % Conversiond 
DH98-325-5 (nonconverter) 
3D _Cl2-7-Ri298#3 
55 
Mean 1.764 0.024 1.4a 
STE 0.456 0.004 0.3 
3D C12-7-Ri298#5 
Mean 1.500 0.020 1.3a 
60 
STE 0.306 0.006 0.3 
3D C12-7-Ri298#8 
Mean 1.772 0.020 1.2a 
STE 0.409 0.003 0.3 
Vector Control#! e 
65 Mean 1.466 0.203 11.6b 
STE 0.713 0.161 9.7 
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TABLE 9-continued 
Alkaloid analysis ofT,-generation 3D C12-7-Ri298 transformants. 
Line % Nicotinec % Nornicotinec % Conversiond 
DH98-325-6 (converter) 
3D C12-7-Ri298#2 
Mean 1.970 0.019 l.Oa 
STE 0.536 0.004 0.3 
3D C12-7-Ri298#8 
Mean 1.623 0.022 1.3a 
STE 0.300 0.002 0.2 
3D C12-7-
Ri298#10 
Mean 1.419 0.017 1.3a 
STE 0.515 0.004 0.3 
Vector Control#2e 
Mean 0.028 1.170 97.6c 
STE 0.006 0.234 0.5 
aTobacco leaves were treated with ethephon and cured for 2 weeks at 25° C. 
~eans and standard errors (STE) represent 9 and 4 T1 progenies of the 3D_Cl2-7-Ri298 
construct and empty vector-transformed (vector control) lines, respectively. 
"Percentage of leaf dry weight. 
d[% nornicotine/(%nicotine +% nornicotine)] x 1 00; values followed by different letters are 
significantly different according to Fisher's Protected LSD (0.015). 
eTobacco plants transformed with only pKYLX71 vector were used as controls. 
Furthermore, transforming tobacco with the 3D_C12-7-
298 construct conferred a 3.6-fold reduction in nicotine con-
version relative to typical nonconverter control plants without 
affecting plant growth and development. 
10 
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expression of this P450 family in converter tobacco lines 
inhibited the metabolism of nicotine to nornicotine to levels 
similar to that observed in nonconverter plants. Furthermore, 
sense expression of several individuals of this closely related 
gene family identified one member, designated 3D_ C12-7, as 
playing a direct role in the metabolic conversion of nicotine to 
nornicotine. Overexpression of 3D_C12-7 using a strong 
constitutive promoter caused a dramatic increase in nornico-
tine production and accumulation in non-cured green leaves 
of transgenic tobacco plants, a tissue where nicotine is nor-
mally the predominant alkaloid in converter and nonconverter 
plants alike. Given that the cytochrome P450 family member 
designated 3D_C12-10 differs from 3D_C12-7 at only two 
amino acid residues immediately following the start methion-
ine and within theN-terminal signal sequence, it is predicted 
that these encoded products function identically. 
The contrast in alkaloid phenotypes between the 35S: 
3D_C12 (1) plant and vector-only control plants was most 
dramatic in leaves that had been ethephon treated and cured 
(0.6% conversion versus >97% conversion; Table 6). How-
ever, it is noteworthy that the nornicotine content of the co-
suppressed 35 S :3D_ C 12 (1) plant was reduced even in green, 
nontreated leaves where the high nornicotine phenotype is 
typically not manifest in converter or nonconverter tobacco 
25 lines. The green, nontreated leaves of line 35S:3D_C12 (1) 
showed only 0.7% nicotine to nornicotine conversion, 
whereas every other plant in this experiment showed conver-
sion percentages ranging from 1.3 to 3.7 (Table 5). This result 
suggests that the inhibition of gene expression of the 3D_ C 12 
30 family may prove to be effective in the further lowering of 
nornicotine levels even in tobacco lines where genetic con-
version isn't typically a major problem (such as flue-cured 
tobaccos) or in the nonconverter individuals in lines that are 
To demonstrate that the down-regulation of nornicotine 
production in 3D_C12-7-298-transformed tobacco was con-
comitant with a reduction of the 3D_C12 gene subfamily 
transcripts, a 3D_C12-7 eDNA probe was hybridized to the 35 
total RNA isolated from cured leaves of nonconverter and 
prone to genetic conversion (such as Burley tobaccos). 
Southern blotting assays using members of the 3D_C12 
gene family as hybridization probes gives very complex 
banding patterns, suggesting that more members of this gene 
family may exist even beyond those that have been identified 
and characterized herein (data not shown). The hypothesis 
converter plants. A weak hybridization signal was generated 
by the RNA isolated from 3D_C12-7-Ri298 transformants 
displaying low nornicotine content in contrast to the strong 
signal produced by the RNA extracted from plasmid control 
or wild-type plants. These results indicate that the down-
regulation of nicotine conversion was a result of RNAi -me-
diated gene silencing of the nicotine N -demethylase gene(s ). 
Determination ofTransgene Copy Number 
To determine whether the integration of multiple 3D_ C12-
7-Ri298 copies were required for producing transplants dis-
playing very low nicotine N-demethylase activity, Southern 
analysis was performed on selected individuals exhibiting 
<1.5% nornicotine accumulation. The number of transgenes 
varied widely among these plants including individuals con-
taining 1 copy (325-5, lines 5 & 8; 325-6, lines 2 & 8), 5 
copies (325-6, line 1 0), and 6 copies (325-5, line 6) of the 
3D_C12-7-Ri298 construct using Southern blot analysis of 
genomic DNA digested with the EcoRI restriction enzyme. 
Trans gene copy number was confirmed using Nco I digested 
DNA (data not shown). These results indicate that the inte-
gration of a single 3D_C12-7-Ri298 construct into the 
genome of a strong converter tobacco is sufficient for sup-
pressing nornicotine production to very low levels. 
General Conclusions 
40 that the 3D_ C12 gene family is comprised of additional mem-
bers is further supported by the recent publication of 75 
full-length tobacco P450 cDNAs of unknown function (U.S. 
Patent Application Publication 20040162420). Within this 
list of P450s are additional cDNAs that would, based on the 
45 work described herein, be placed within the 3D_C12 family 
in view of their display of over 90% amino acid sequence 
identity to the protein sequences shown in FIG. 4. 
With respect to the specific molecular function of the 
3D_C12-7 gene or the nearly identical family member 
50 3D_C12-10, it is possible that it encodes the actual nicotine 
demethylase enzyme which catalyzes the oxidative N-dem-
ethylation of nicotine to nornicotine (FIG. 1). Alternatively, 
the 3D_C12-7 encoded enzyme or nearly identical3D_C12-
1 0 encoded enzyme may produce a product that leads to the 
55 up-regulation of the nicotine demethylase activity of the leaf, 
as opposed to directly catalyzing the N-demethylation reac-
tion. 
In addition, an allele-specific RT-PCR was employed to 
compare 3D-C12-7 expression between converter and non-
60 converter plants (Example 7). An approximately 80-fold 
increase in 3D-C12-7 expression in converter versus noncon-
verter plants was identified using the SYBR® Green-chem-
istry RT-PCR assay. A 7.5-fold up-regulation was identified 
The analyses outlined in Examples 1-6 above resulted in 
the discovery of a closely related P450 gene family, desig-
nated the 3D_C12 family, whose collective steady-state tran-
script levels were significantly elevated in converter tobacco 
plants that were actively metabolizing nicotine to nornicotine 65 
in comparison to their nonconverter counterparts. Transgenic 
plant analysis demonstrated that the suppression of gene 
by the TaqMan® chemistry-based RT-PCR experiment. 
While the DH 91-1307-46 tobacco variety used in the Taq-
Man® chemistry-based RT-PCR experiment exhibits low to 
moderate levels of nicotine conversion, the DH98-325-5 non-
US 9,187,759 B2 
61 62 
converter plants used in the SYBR® Green-based RT-PCR 
assay consistently convert a very low percentage of their 
nicotine to nomicotine. Expression of the 3D-C 12-7 gene was 
induced at least 7-fold by ethylene in senescing leaves of 
converter tobacco plants. 
An additional RNAi construct, 3D_ C12-7-Ri298, was pre-
pared based on a region of the 3D_ C12-7 polynucleotide that 
corresponds to nucleotide positions 297 through 594 of SEQ 
ID N0:5. Expression of this RNAi construct allows for the 
suppression of nomicotine production in a strong converter 
tobacco line below the levels normally found in nonconverter 
plants. The expression cassette of the 3D_C12-7-Ri298 con-
struct encoded an intron-spliced hairpin RNA in which the 
stem region was engineered from this 298-bp fragment of the 
3D_C12-7 eDNA inserted as an inverted repeat. The loop of 
the hairpin was created by placing a 151-bp intronofthe FAD 
gene between the two sides of the palindromic sequences. An 
arm length of 298-bp was used for the inverted repeats. 
expression cassette enabled the production of tobacco with a 
conversion rate as low as 0.8%, which is below the 3-5% rate 
detected in burley lines used by seed producers. Such dra-
matic reduction in nomicotine production by targeting this 
particular region of the 3D_C12-7 polynucleotide is an unex-
pected result. Also, suppression of nornicotine production 
showed a high degree of heritability in the T 1 progeny of the 
primary transformants (Table 9). Suppression of nornicotine 
production in these transgenic plants yielded no obvious dif-
3D_C12-7-Ri298-transformed plants accumulated less 
nomicotine than those harboring the 3D_C12-Ri99 construct 
(Tables 7 and 8). No correlation was found between the num-
ber of copies of the 3D_C12-7-Ri298 construct and nomico-
tine production (Tables 7 and 8). The 3D_C12-7-Ri298 
<160> NUMBER OF SEQ ID NOS, 37 
<210> SEQ ID NO 1 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
10 ferences in growth and development when compared to wild-
type plants. 
All publications and patent applications mentioned in the 
specification are indicative of the level of those skilled in the 
art to which this invention pertains. All publications and 
15 patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli-
cation was specifically and individually indicated to be incor-
porated by reference. 
Although the foregoing invention has been described in 
20 some detail by way of illustration and example for purposes 
of clarity of understanding, it will be obvious that certain 
changes and modifications may be practiced within the scope 
of the appended claims. 
atg gtt ttt ccc ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa ccc 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 6 0 
gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg ega aaa aat cgt aaa tta gtc att cag gaa gtt etc tct 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
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-continued 
get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att caa 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act ega att aat gga aat tcg agt acg 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
ata aat eta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt tta tea atg 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
gaa ttt gta tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggt cat att aag gca atg aaa agg aca ttt aag gat ata 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aac tgg tta gag gaa cat att aat aaa aga gaa 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt ggt gca gaa ggg aat gaa caa gat ttc att gat gtg 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa ttg agt aaa gaa tat ctt gat gaa ggt tac tct cgt 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca aca gtt ttt agt ttg gtc ttg gat gca gca 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg aca tta ttg ata aac 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
aat caa aat gee ttg atg aaa gca caa gaa gag ata gac aca aaa gtt 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gat aga tgg gta gaa gag agt gat att aag gat tta gta tac 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa aag gtg tta ega tta tat cca cca gga cct 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cat gaa aat gta aag gat tgt gtt gtt agt gga tat 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa gag act aga tta ttc gca aac gtc atg aaa ctg cag 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgc gat cct aaa etc ttg tea aat cct gat aag ttc gat cca gag aga 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
ttc ate get ggt gat att gac ttc cgt ggt cac cac tat gag ttt ate 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
cca ttt ggt tct gga aga ega tct tgt ccg ggg atg act tat gca ttg 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
64 
480 
528 
576 
624 
672 
720 
768 
816 
864 
912 
960 
1008 
1056 
1104 
1152 
1200 
1248 
1296 
1344 
1392 
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-continued 
caa gtg gaa cac eta aca atg gca cat tta ate cag ggt ttc aat tac 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aaa act cca aat gac gag gee ttg gat atg aag gaa ggt gca ggc ata 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
ace ata cgt aag gta aat cca gtg gaa ttg ata ata acg cct cgc ttg 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
gca cct gag ctt tac taaaacctaa gatctttcat cttggttgat cattgtttaa 
Ala Pro Glu Leu Tyr 
515 
tactcctaga tgggtattca tttacctttt ttcaattaat tgcatgtacg agctttttta 
atttggtata tttgtaacaa taagtaaaga atgattgtgc taatatataa agatttgcag 
aagataattg actgattgtc cc 
<210> SEQ ID NO 2 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 2 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Ile Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
66 
1440 
1488 
1536 
1591 
1651 
1711 
1733 
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-continued 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Gly Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Leu Ser Lys Glu Tyr Leu Asp Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Thr Leu Leu Ile Asn 
325 330 335 
Asn Gln Asn Ala Leu Met Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Lys Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Lys Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Glu Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Leu Ser Asn Pro Asp Lys Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Gly Asp Ile Asp Phe Arg Gly His His Tyr Glu Phe Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Lys Thr Pro Asn Asp Glu Ala Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Thr Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 3 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
<400> SEQUENCE, 3 
atg ctt tct ccc ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc ccc gtt ttc act ttt egg eta ggc ctt 240 
68 
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69 
-continued 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg ega aaa aat ega aaa tta gtt att cag gaa gtt etc tee 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act ega att gat gga aat tcg agt acg 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aaa gca acg gtg ttt agt ttg gtc ttg gat gca gca 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta ega tta tat cca cca gga cct 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
70 
288 
336 
384 
432 
480 
528 
576 
624 
672 
720 
768 
816 
864 
912 
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1056 
1104 
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-continued 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga ega tct tgt cca ggg atg act tat gca ttg 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag ccc ttg gat atg aag gaa ggt gca ggc ata 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 
aagataattg actgattgtc cc 
<210> SEQ ID NO 4 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 4 
Met Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
72 
1200 
1248 
1296 
1344 
1392 
1440 
1488 
1536 
1591 
1651 
1711 
1733 
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-continued 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 5 
<211> LENGTH, 1733 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1551) 
74 
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75 76 
-continued 
<400> SEQUENCE, 5 
atg gtt ttt ccc ata gaa gee att gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc ttc ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc 96 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat gac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac ggc ccc gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtc tta gtt gta age agt tac gaa get gta aaa gac tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttt tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gat tac ctt ggc tac aat aat gee atg eta ttt ttg gee aat tac gga 384 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
cct tac tgg ega aaa aat ega aaa tta gtt att cag gaa gtt etc tee 432 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttt gca aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
gcg age att aag aat tta tat act ega att gat gga aat tcg agt acg 528 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aag atg ate get gga aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 768 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aat aaa aga gaa 816 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
aaa atg gag gtt aat gca gaa ggg aat gaa caa gat ttc att gat gtg 864 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
gtg ctt tea aaa atg agt aat gaa tat ctt ggt gaa ggt tac tct cgt 912 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
gat act gtc att aag gca acg gtg ttt agt ttg gtc ttg gat gca gca 960 
US 9,187,759 B2 
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-continued 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
gac aca gtt get ctt cac ata aat tgg gga atg gca tta ttg ata aac 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
aat caa aag gee ttg acg aaa gca caa gaa gag ata gac aca aaa gtt 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
ggt aag gac aga tgg gta gaa gag agt gat att aag gat ttg gta tac 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
etc caa get att gtt aaa gaa gtg tta ega tta tat cca cca gga cct 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga tat 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
cac att cct aaa ggg aca aga tta ttc gca aac gtc atg aaa ctg caa 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
cgt gat cct aaa etc tgg tct gat cct gat act ttc gat cca gag aga 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
ttc att get act gat att gac ttt cgt ggt cag tac tat aag tat ate 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
ccg ttt ggt tct gga aga ega tct tgt cca ggg atg act tat gca ttg 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
caa gtg gaa cac tta aca atg gca cat ttg ate caa ggt ttc aat tac 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
aga act cca aat gac gag ccc ttg gac atg aag gaa ggt gca ggc ata 
Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
act ata cgt aag gta aat cct gtg gaa ctg ata ata gcg cct cgc ctg 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
gca cct gag ctt tat taaaacctaa gatctttcat cttggttgat cattgtataa 
Ala Pro Glu Leu Tyr 
515 
tactcctaaa tggatattca tttacctttt atcaattaat tgtcagtacg agtttttcta 
atttggtaca tttgtaataa taagtaaaga ataattgtgc taatatataa aggtttgtag 
aagatgattg actgattgtc cc 
<210> SEQ ID NO 6 
<211> LENGTH, 517 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Phe Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
78 
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1056 
1104 
1152 
1200 
1248 
1296 
1344 
1392 
1440 
1488 
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1591 
1651 
1711 
1733 
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50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Val Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Asp Tyr Leu Gly Tyr Asn Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Ala Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Asn Lys Arg Glu 
260 265 270 
Lys Met Glu Val Asn Ala Glu Gly Asn Glu Gln Asp Phe Ile Asp Val 
275 280 285 
Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser Arg 
290 295 300 
Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala Ala 
305 310 315 320 
Asp Thr Val Ala Leu His Ile Asn Trp Gly Met Ala Leu Leu Ile Asn 
325 330 335 
Asn Gln Lys Ala Leu Thr Lys Ala Gln Glu Glu Ile Asp Thr Lys Val 
340 345 350 
Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val Tyr 
355 360 365 
Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly Pro 
370 375 380 
Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly Tyr 
385 390 395 400 
His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu Gln 
405 410 415 
Arg Asp Pro Lys Leu Trp Ser Asp Pro Asp Thr Phe Asp Pro Glu Arg 
420 425 430 
Phe Ile Ala Thr Asp Ile Asp Phe Arg Gly Gln Tyr Tyr Lys Tyr Ile 
435 440 445 
Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala Leu 
450 455 460 
Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn Tyr 
465 470 475 480 
80 
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Arg Thr Pro Asn Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly Ile 
485 490 495 
Thr Ile Arg Lys Val Asn Pro Val Glu Leu Ile Ile Ala Pro Arg Leu 
500 505 510 
Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 7 
<211> LENGTH, 1727 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (1554) 
<400> SEQUENCE, 7 
atg gtt ttt ccg gta gaa gee att gta ggg eta gtg ace ttc aca ttt 48 
Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc ttc tac ttc eta tgg aca aaa aaa tct caa aaa cct tea aaa ccc 96 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
tta cca ccg aaa ate ccg gga gga tgg ccg gta ate ggc cat ctt ttc 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
tac ttc gat gac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gac aaa tac gga ccc gtt ttc act ttt egg eta ggc ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtg tta gtt gta age agt tac gaa get ata aaa gat tgt ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac aaa aat gee atg eta ttt ttg gca aat tac gga 384 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
tct tac tgg ega aaa aat cgt aaa tta att att cag gaa gtt etc tct 432 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
get agt cgt etc gaa aaa ttc aaa cac gtg aga ttc gee aga att caa 480 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
acg age att aag aat tta tac act ega att gat gga aat tcg agt acg 528 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
ata aat tta act gat tgg tta gaa gaa ttg aat ttt ggt ctg ate gtg 576 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa caa 624 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
gtg gag aga ttt aag aaa gcg ttt aag gat ttt atg att tta tea atg 672 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
gag ttt gtg tta tgg gat gca ttt cca att cca tta ttt aaa tgg gtg 720 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
82 
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225 230 235 240 
gat ttt caa ggg cat gtt aag get atg aaa agg act ttt aaa gat ata 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
gat tct gtt ttt cag aat tgg tta gag gaa cat att aag aaa aga gaa 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
aaa ata atg gag gtt ggt aca gaa ggg aat gaa caa gat ttt ata gat 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
gtg gtg ctt tea aaa atg agt aat gaa tat ctt ggc gaa ggt tac tct 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
cgc gat act gtc ata aaa gca aca gta ttt agt ttg gtc ttg gat gca 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
gca gac aca gtt get ctt cac ata aat tgc gga atg gca tta ttg ata 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
aac aat caa aat gee ttg aag aaa gca caa gaa gag ata gac aca aaa 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
gtt ggt aag gat aga tgg gta gaa gag agt gat att aag gat ttg gta 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
tac etc caa get att gtt aaa gaa gtg tta ega tta tat cca ccg gga 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
370 375 380 
cct ttg tta gta cca cac gaa aat gta gaa gat tgt gtt gtt agt gga 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
tat cac att cct aaa gga act aga eta ttc gca aat gta atg aaa eta 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
caa cgt gat cct aaa etc tgg tea aat cct gat aag ttc aat cca gag 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
aga ttc ate get cgt gat att gac ttt cat ggt cag cac tat gag tat 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
ate ccg ttt ggt tct gga aga cgc tct tgt ccg ggg atg act tat gca 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
ttg caa gtg gaa cac eta aca atg gca cat ttg ate cag ggt ttc aat 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
tac aga act cca act gat gag ccc ttg gat atg aaa gaa ggt gca ggc 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
ata act ata cgt aag gta aat cct gtg aaa gtg ata att acg cct cgc 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
ttg gca cct gag ctt tat taaaatctaa gatgtttcat cttggttgat 
Leu Ala Pro Glu Leu Tyr 
515 
cattgtttaa tactcctaga tgggtattca tctacctttt ttcaattagt tgtcggtacg 
tattttttta atttggtaag tttgtaataa taagtaaaga aggattgtgc taatatataa 
tggtgcataa aataattgaa atg 
84 
768 
816 
864 
912 
960 
1008 
1056 
1104 
1152 
1200 
1248 
1296 
1344 
1392 
1440 
1488 
1536 
1584 
1644 
1704 
1727 
<210> SEQ ID NO 8 
<211> LENGTH, 518 
<212> TYPE, PRT 
85 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 8 
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Met Val Phe Pro Val Glu Ala Ile Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Phe Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Pro Ser Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
Tyr Phe Asp Asp Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Lys Asn Ala Met Leu Phe Leu Ala Asn Tyr Gly 
115 120 125 
Ser Tyr Trp Arg Lys Asn Arg Lys Leu Ile Ile Gln Glu Val Leu Ser 
130 135 140 
Ala Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe Ala Arg Ile Gln 
145 150 155 160 
Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asp Gly Asn Ser Ser Thr 
165 170 175 
Ile Asn Leu Thr Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile Val 
180 185 190 
Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu Gln 
195 200 205 
Val Glu Arg Phe Lys Lys Ala Phe Lys Asp Phe Met Ile Leu Ser Met 
210 215 220 
Glu Phe Val Leu Trp Asp Ala Phe Pro Ile Pro Leu Phe Lys Trp Val 
225 230 235 240 
Asp Phe Gln Gly His Val Lys Ala Met Lys Arg Thr Phe Lys Asp Ile 
245 250 255 
Asp Ser Val Phe Gln Asn Trp Leu Glu Glu His Ile Lys Lys Arg Glu 
260 265 270 
Lys Ile Met Glu Val Gly Thr Glu Gly Asn Glu Gln Asp Phe Ile Asp 
275 280 285 
Val Val Leu Ser Lys Met Ser Asn Glu Tyr Leu Gly Glu Gly Tyr Ser 
290 295 300 
Arg Asp Thr Val Ile Lys Ala Thr Val Phe Ser Leu Val Leu Asp Ala 
305 310 315 320 
Ala Asp Thr Val Ala Leu His Ile Asn Cys Gly Met Ala Leu Leu Ile 
325 330 335 
Asn Asn Gln Asn Ala Leu Lys Lys Ala Gln Glu Glu Ile Asp Thr Lys 
340 345 350 
Val Gly Lys Asp Arg Trp Val Glu Glu Ser Asp Ile Lys Asp Leu Val 
355 360 365 
Tyr Leu Gln Ala Ile Val Lys Glu Val Leu Arg Leu Tyr Pro Pro Gly 
86 
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370 375 380 
Pro Leu Leu Val Pro His Glu Asn Val Glu Asp Cys Val Val Ser Gly 
385 390 395 400 
Tyr His Ile Pro Lys Gly Thr Arg Leu Phe Ala Asn Val Met Lys Leu 
405 410 415 
Gln Arg Asp Pro Lys Leu Trp Ser Asn Pro Asp Lys Phe Asn Pro Glu 
420 425 430 
Arg Phe Ile Ala Arg Asp Ile Asp Phe His Gly Gln His Tyr Glu Tyr 
435 440 445 
Ile Pro Phe Gly Ser Gly Arg Arg Ser Cys Pro Gly Met Thr Tyr Ala 
450 455 460 
Leu Gln Val Glu His Leu Thr Met Ala His Leu Ile Gln Gly Phe Asn 
465 470 475 480 
Tyr Arg Thr Pro Thr Asp Glu Pro Leu Asp Met Lys Glu Gly Ala Gly 
485 490 495 
Ile Thr Ile Arg Lys Val Asn Pro Val Lys Val Ile Ile Thr Pro Arg 
500 505 510 
Leu Ala Pro Glu Leu Tyr 
515 
<210> SEQ ID NO 9 
<211> LENGTH, 539 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (539) 
<400> SEQUENCE, 9 
atg gtt ttt ccc ata gaa gee ttt gta gga eta gta ace ttc aca ttt 48 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
etc tta tac ttc eta tgg aca aaa aaa tct caa aaa ctt cca aaa ccc 96 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
tta cca ccg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt ttt 144 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
cac ttc aat aac gac ggc gac gac cgt cca tta get ega aaa etc gga 192 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt ctt 240 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc ttc 288 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
tct aca aat gat gee att ttc tee aat cgt cca get ttt ctt tat ggc 336 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
gaa tac ctt ggc tac agt aat gee atg eta ttt tga caa aat acg gac 384 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp 
115 120 125 
ctt act ggc gaa aaa ata gaa aat tag tea ttc agg aag ttc tct gtg 432 
Leu Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val 
130 135 140 
eta gtc gtc tcg aaa aat tga age acg tga gat ttg gtg aaa ttc aga 480 
Leu Val Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg 
145 150 155 
88 
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ega gca tta aga att tat aca etc gaa ttg atg gaa att ega gta ega 528 
Arg Ala Leu Arg Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg 
160 165 170 
taa ate taa ca 53 9 
Ile 
<210> SEQ ID NO 10 
<211> LENGTH, 173 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 10 
Met Val Phe Pro Ile Glu Ala Phe Val Gly Leu Val Thr Phe Thr Phe 
1 5 10 15 
Leu Leu Tyr Phe Leu Trp Thr Lys Lys Ser Gln Lys Leu Pro Lys Pro 
20 25 30 
Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu Phe 
35 40 45 
His Phe Asn Asn Asp Gly Asp Asp Arg Pro Leu Ala Arg Lys Leu Gly 
50 55 60 
Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly Leu 
65 70 75 80 
Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys Phe 
85 90 95 
Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr Gly 
100 105 110 
Glu Tyr Leu Gly Tyr Ser Asn Ala Met Leu Phe Gln Asn Thr Asp Leu 
115 120 125 
Thr Gly Glu Lys Ile Glu Asn Ser Phe Arg Lys Phe Ser Val Leu Val 
130 135 140 
Val Ser Lys Asn Ser Thr Asp Leu Val Lys Phe Arg Arg Ala Leu Arg 
145 150 155 160 
Ile Tyr Thr Leu Glu Leu Met Glu Ile Arg Val Arg Ile 
165 170 
<210> SEQ ID NO 11 
<211> LENGTH, 666 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (1) ... (666) 
<400> SEQUENCE, 11 
atg gtt ttt ccc ata gaa gee att gta gga gca gta ace eta att aca 48 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr 
1 5 10 15 
ttt etc tta tac ttc eta tgt aca aaa aaa tct caa aaa cat tea aag 96 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys 
20 25 30 
ccc tta cca acg aaa ate ccc gga gga tgg ccg gta ate ggc cat ctt 144 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
ttc cac ttc aat aac gac ggc gac gac cgt cca ttt get ega aaa etc 192 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
gga gac tta get gat aaa tac ggc ccc gtt ttc act ttt egg eta ggt 240 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
90 
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ctt ccc ctt gtg eta gtt gta age agt tac gaa get ata aaa gat tgc 288 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
ttc tct aca aat gac gee att ttc tee aat cgt cca get ttt ctt tac 336 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
ggc gaa tac ctt ggc tac aat aat aca atg ctt ttt eta gca aat tac 384 
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
gga cct tac tgg ega aaa aat cgt aaa tta gtc att cag gaa gtt etc 432 
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
tct get agt cgt etc gaa aaa ttc aaa caa gtg aga ttc ace aga att 480 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
caa acg age att aag aat tta tac act ega att aat gga aat tcg agt 528 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser 
165 170 175 
acg ata aat eta agt gat tgg tta gaa gaa ttg aat ttt ggt ctg ate 576 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
180 185 190 
gtg aaa atg ate get ggg aaa aat tat gaa tee ggt aaa gga gat gaa 624 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu 
195 200 205 
caa gtg gaa aga ttt aag aat gcg ttt aag gat ttt atg gtt 666 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 12 
<211> LENGTH, 222 
<212> TYPE, PRT 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 12 
Met Val Phe Pro Ile Glu Ala Ile Val Gly Ala Val Thr Leu Ile Thr 
1 5 10 15 
Phe Leu Leu Tyr Phe Leu Cys Thr Lys Lys Ser Gln Lys His Ser Lys 
20 25 30 
Pro Leu Pro Thr Lys Ile Pro Gly Gly Trp Pro Val Ile Gly His Leu 
35 40 45 
Phe His Phe Asn Asn Asp Gly Asp Asp Arg Pro Phe Ala Arg Lys Leu 
50 55 60 
Gly Asp Leu Ala Asp Lys Tyr Gly Pro Val Phe Thr Phe Arg Leu Gly 
65 70 75 80 
Leu Pro Leu Val Leu Val Val Ser Ser Tyr Glu Ala Ile Lys Asp Cys 
85 90 95 
Phe Ser Thr Asn Asp Ala Ile Phe Ser Asn Arg Pro Ala Phe Leu Tyr 
100 105 110 
Gly Glu Tyr Leu Gly Tyr Asn Asn Thr Met Leu Phe Leu Ala Asn Tyr 
115 120 125 
Gly Pro Tyr Trp Arg Lys Asn Arg Lys Leu Val Ile Gln Glu Val Leu 
130 135 140 
Ser Ala Ser Arg Leu Glu Lys Phe Lys Gln Val Arg Phe Thr Arg Ile 
145 150 155 160 
Gln Thr Ser Ile Lys Asn Leu Tyr Thr Arg Ile Asn Gly Asn Ser Ser 
165 170 175 
Thr Ile Asn Leu Ser Asp Trp Leu Glu Glu Leu Asn Phe Gly Leu Ile 
92 
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180 185 190 
Val Lys Met Ile Ala Gly Lys Asn Tyr Glu Ser Gly Lys Gly Asp Glu 
195 200 205 
Gln Val Glu Arg Phe Lys Asn Ala Phe Lys Asp Phe Met Val 
210 215 220 
<210> SEQ ID NO 13 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from 
SEQ ID N0,1 
<400> SEQUENCE, 13 
gacgaggcct tggatatgaa ggaaggtgca ggcataacca tacgtaaggt aaatccagtg 60 
gaattgataa taacgcctcg cttggcacct gagctttac 99 
<210> SEQ ID NO 14 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from 
SEQ ID N0,3 
<400> SEQUENCE, 14 
gacgagccct tggatatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 15 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from 
SEQ ID N0,5 
<400> SEQUENCE, 15 
gacgagccct tggacatgaa ggaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
gaactgataa tagcgcctcg cctggcacct gagctttat 99 
<210> SEQ ID NO 16 
<211> LENGTH, 99 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Partial coding sequence selected from 
SEQ ID N0,7 
<400> SEQUENCE, 16 
gatgagccct tggatatgaa agaaggtgca ggcataacta tacgtaaggt aaatcctgtg 60 
aaagtgataa ttacgcctcg cttggcacct gagctttat 99 
<210> SEQ ID NO 17 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 17 
cgctctagaa ctagtgatc 19 
94 
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, DNA 
95 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 18 
tttttgggac aatcagtcaa 
<210> SEQ ID NO 19 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 19 
gttagattta tcgtactcga att 
<210> SEQ ID NO 20 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 20 
ttcatttcaa attattttat gcacca 
<210> SEQ ID NO 21 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 21 
atggtttttc ccatagaagc c 
<210> SEQ ID NO 22 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer 
<400> SEQUENCE, 22 
tcgaggtcga cggtatc 
<210> SEQ ID NO 23 
<211> LENGTH, 1118 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 23 
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20 
23 
26 
21 
17 
ctgtcattaa agcaacggtg tttgtaagtt catctgtcat ttttcattta ttcactttta 60 
ttttgaggag cagacatgtt aataataatt tggagcaact gtaaagttat ctatgtgtac 120 
aggttcgagc ctcaggtgca accactaatg cttgtattag attatgttgt ctgcatcata 180 
cccctaattg gagtgtggct cttcccgaac cctgcaatgc tggatgctgg atgctttatg 240 
tatcagactg acctttttgt taaactatct aaatactaag gatgatttaa taaaaatata 300 
96 
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gaatggtaaa cagaaaaaga tgagattatt tttggggcta tatggattcg cccgggcttt 360 
gggaggtaaa acggtatcta ccagttgaga ctttactcca gaactttatc tcgagagctc 420 
tgaataaaaa tgaaatagta tttaccactc caaaatcttt gatggtaaaa agatgagata 480 
taacctctta taattgattg aaccacgttg atagaataaa acttctttac tcccattcag 540 
cataagaaaa atgaaaccaa acggaattct tctctttttt agggggaaat tccttaattg 600 
cttgttgaat atagattcat gtcgttattc tatttttaat aatgatgaaa atcaatatag 660 
tcaaagttaa tacttatgtc atttggtttg cggacaagtt atattggaac tatataatac 720 
gtctattata gaatagtgat tatttagagg atatacattt tttttggata aatatttgat 780 
ttattggatt aaaaatagaa tatacaggta aggtctaaaa cgtgtgtttg cttttacact 840 
aaataaactt gacctcgtac aattctaaga aaatatttga aataaatgaa ttattttatt 900 
gttaatcaat taaaaaaatc atagtataga tgagatgtgt gcatacttgg caataactat 960 
actaactaaa acaaggtatg tgaataattg atattccttt tttaattatt cttttttcca 1020 
gagtttggtc ttggatgcag cagacacagt tgctcttcac ataaattggg gaatggcatt 1080 
attgataaac aatcaaaagg ccttgacgaa agcacaag 1118 
<210> SEQ ID NO 24 
<211> LENGTH, 998 
<212> TYPE, DNA 
<213> ORGANISM, Nicotiana sp. 
<400> SEQUENCE, 24 
gtaagttcat ctgtcatttt tcatttattc acttttattt tgaggagcag acatgttaat 60 
aataatttgg agcaactgta aagttatcta tgtgtacagg ttcgagcctc aggtgcaacc 120 
actaatgctt gtattagatt atgttgtctg catcataccc ctaattggag tgtggctctt 180 
cccgaaccct gcaatgctgg atgctggatg ctttatgtat cagactgacc tttttgttaa 240 
actatctaaa tactaaggat gatttaataa aaatatagaa tggtaaacag aaaaagatga 300 
gattattttt ggggctatat ggattcgccc gggctttggg aggtaaaacg gtatctacca 360 
gttgagactt tactccagaa ctttatctcg agagctctga ataaaaatga aatagtattt 420 
accactccaa aatctttgat ggtaaaaaga tgagatataa cctcttataa ttgattgaac 480 
cacgttgata gaataaaact tctttactcc cattcagcat aagaaaaatg aaaccaaacg 540 
gaattcttct cttttttagg gggaaattcc ttaattgctt gttgaatata gattcatgtc 600 
gttattctat ttttaataat gatgaaaatc aatatagtca aagttaatac ttatgtcatt 660 
tggtttgcgg acaagttata ttggaactat ataatacgtc tattatagaa tagtgattat 720 
ttagaggata tacatttttt ttggataaat atttgattta ttggattaaa aatagaatat 780 
acaggtaagg tctaaaacgt gtgtttgctt ttacactaaa taaacttgac ctcgtacaat 840 
tctaagaaaa tatttgaaat aaatgaatta ttttattgtt aatcaattaa aaaaatcata 900 
gtatagatga gatgtgtgca tacttggcaa taactatact aactaaaaca aggtatgtga 960 
ataattgata ttcctttttt aattattctt ttttccag 998 
<210> SEQ ID NO 25 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR Primer 
<400> SEQUENCE, 25 
ctgtcattaa agcaacggtg 
<210> SEQ ID NO 26 
<211> LENGTH, 20 
<212> TYPE, DNA 
99 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR Primer 
<400> SEQUENCE, 26 
ggccttgacg aaagcacaag 
<210> SEQ ID NO 27 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 27 
aagctttgac gccatttttt ccaatcg 
<210> SEQ ID NO 28 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 28 
ctcgagtttt ccagcgatca tcttcac 
<210> SEQ ID NO 29 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 29 
acgtgatcct aaactctggt ctg 
<210> SEQ ID NO 30 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 30 
gcctgcacct tccttcatg 
<210> SEQ ID NO 31 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 31 
cggtaatcgg ccatcttttc 
<210> SEQ ID NO 32 
<211> LENGTH, 21 
<212> TYPE, DNA 
100 
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-continued 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 32 
ccgagttttc gagctaatgg a 
<210> SEQ ID NO 33 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 33 
caatgacgaa cggcgacag 
<210> SEQ ID NO 34 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 34 
atggtttttc ccatagaagc c 
<210> SEQ ID NO 35 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 35 
tttttgggac aatcagtcaa t 
<210> SEQ ID NO 36 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 36 
tgaatgaact gcaggacgag 
<210> SEQ ID NO 37 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide primer 
<400> SEQUENCE, 37 
aatatcacgg gtagccaacg 
What is claimed is: 
21 
19 
21 
21 
20 
20 
or N-nitrosonomicotine in said cured tobacco material is 
60 reduced by greater than about 10% compared to cured 
tobacco material made from a control tobacco plant compris-
ing said wild type allele; and wherein said tobacco plant is a 
Nicotiana tabacum plant. 
1. Cured tobacco material or a tobacco product comprising 
said cured tobacco material, wherein said cured tobacco 
material is made from a tobacco plant comprising a stable 
mutation in a wild type allele encoding a nicotine demethy-
lase having an amino acid sequence of SEQ ID N0:4 or a 
sequence having 98% identity to SEQ ID N0:4, wherein said 65 
mutation reduces or eliminates the expression or activity of 
said nicotine demethylase, wherein the amount of nornicotine 
2. The tobacco product according to claim 1. 
3. The tobacco product according to claim 2, wherein said 
tobacco plant is homozygous for said mutation. 
US 9,187,759 B2 
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4. The tobacco product according to claim 2, wherein said 
tobacco material is made by a curing process selected from 
the group consisting of flue curing, air curing, and fire curing. 
5. The tobacco product according to claim 2, wherein said 
tobacco product is selected from the group consisting of a 
cigar, a cigarette, pipe tobacco, a cigarillo, a non-ventilated or 
vented recess filter cigarette, a dissolving strip, a gum, a 
tablet, snuff, and chewing tobacco. 
6. The tobacco product according to claim 2, wherein said 
tobacco plant has a non-converter phenotype and reduced 
10 
nicotine demethylase activity from said nicotine demethy-
lase. 
7. The tobacco product according to claim 2, wherein said 
tobacco plant has a non-converter phenotype and comprises 
less than 5% nicotine demethylation. 
8. The tobacco product according to claim 2, wherein said 15 
tobacco plant is a hybrid. 
9. The tobacco product according to claim 2, wherein said 
tobacco plant is selected from the group consisting of a Bur-
ley type, a dark type, a flue-cured type, and an Oriental type. 
10. The tobacco product according to claim 2, wherein said 20 
mutation is selected from the group consisting of a point 
mutation, a deletion, an insertion, and an inversion. 
11. The tobacco product according to claim 2, wherein said 
mutation is a nonsense or missense mutation, said missense 
mutation resulting in an abolished or reduced nicotine dem- 25 
ethylase activity compared to said wild type allele. 
12. The tobacco product according to claim 2, wherein said 
wild type allele encodes SEQ ID N0:4. 
13. The tobacco product according to claim 2, wherein said 
stable mutation results in a substitution of the isoleucine at 30 
position 27 4 or the tryptophan at position 329 of said SEQ ID 
N0:4. 
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14. The cured tobacco material or tobacco product accord-
ing to claim 1, wherein the amount of nornicotine or N-ni-
trosonornicotine in said cured tobacco material is reduced by 
greater than about 20% compared to cured tobacco material 
made from a control tobacco plant comprising said wild type 
allele. 
15. The cured tobacco material or tobacco product accord-
ing to claim 1, wherein the amount of nornicotine or N-ni-
trosonornicotine in said cured tobacco material is reduced by 
greater than about 40% compared to cured tobacco material 
made from a control tobacco plant comprising said wild type 
allele. 
16. The cured tobacco material or tobacco product accord-
ing to claim 1, wherein the amount of nornicotine or N-ni-
trosonornicotine in said cured tobacco material is reduced by 
greater than about 60% compared to cured tobacco material 
made from a control tobacco plant comprising said wild type 
allele. 
17. The cured tobacco material or tobacco product accord-
ing to claim 1, wherein the amount of nornicotine or N-ni-
trosonornicotine in said cured tobacco material is reduced by 
greater than about 80% compared to cured tobacco material 
made from a control tobacco plant comprising said wild type 
allele. 
18. The cured tobacco material or tobacco product accord-
ing to claim 1, wherein the amount of nornicotine or N-ni-
trosonornicotine in said cured tobacco material is reduced by 
greater than about 90% compared to cured tobacco material 
made from a control tobacco plant comprising said wild type 
allele. 
* * * * * 
